WO1995030673A1 - Anti-cancer compounds containing cyclopentaquinazoline ring - Google Patents

Anti-cancer compounds containing cyclopentaquinazoline ring Download PDF

Info

Publication number
WO1995030673A1
WO1995030673A1 PCT/GB1995/001016 GB9501016W WO9530673A1 WO 1995030673 A1 WO1995030673 A1 WO 1995030673A1 GB 9501016 W GB9501016 W GB 9501016W WO 9530673 A1 WO9530673 A1 WO 9530673A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
cyclopenta
group
quinazolin
Prior art date
Application number
PCT/GB1995/001016
Other languages
French (fr)
Inventor
Vassilios Bavetsias
Francis Thomas Boyle
Laurent François André HENNEQUIN
Jonathan Hugh Marriott
Original Assignee
British Technology Group Limited
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Limited, Zeneca Limited filed Critical British Technology Group Limited
Priority to US08/732,273 priority Critical patent/US5747499A/en
Priority to CA002187449A priority patent/CA2187449C/en
Priority to JP52877095A priority patent/JP4173911B2/en
Priority to DK95917433T priority patent/DK0758328T3/en
Priority to DE69531296T priority patent/DE69531296T2/en
Priority to EP95917433A priority patent/EP0758328B1/en
Priority to AT95917433T priority patent/ATE245154T1/en
Publication of WO1995030673A1 publication Critical patent/WO1995030673A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to novel anti-cancer agents and more particularly it relates to cyclopentaquinazoline derivatives which possess anti-cancer activity.
  • One group of anti-cancer agents comprises antimetabolites having anti-folate activity, such as aminopterin and methotrexate.
  • a newer compound of this type which showed considerable promise in clinical trials is known as CB3717 and is described and claimed in United Kingdom Patent No. 2 065 653B.
  • CB3717 shows symptoms of toxicity in humans, particularly in relation to the liver and kidneys (Cancer Treatment Reports, 1986, 70, 1335).
  • Such adverse side effects are reduced in compounds in which the 2-amino substituent of CB3717 is either missing or is replaced by one of various alternative substituents as described and claimed respectively in United Kingdom Patents Nos. 2 175 903 and 2 188 319.
  • Compounds of this type are believed to act as anti-cancer agents by inhibiting the enzyme thymidylate synthase which catalyses the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA synthesis.
  • the anti-cancer activity of CB3717 and like compounds may be assessed in vitro by determining their inhibitory effect on that enzyme, and in cell cultures by their inhibitory effect on cancer cell lines such as the mouse leukaemia cell line LI 210, the mouse lymphoma cell line L5178Y TK-/- and the human breast cancer cell line MCF-7.
  • Antimetabolites such as aminopterin and methotrexate which are inhibitors of enzymes which utilise folic acid derivatives have also shown promise in the treatment of various allergic diseases such as allergic rhinitis, atopic dermatitis and psoriasis.
  • Antimetabolites such as methotrexate have also shown promise in the treatment of various inflammatory diseases such as inflammation of the joints, especially rheumatoid arthritis, osteoarthritis and gout, and inflammation of the gastrointestinal tract, especially inflammatory bowel disease, ulcerative colitis and gastritis (New England J. Med., 1985, 312, 818).
  • inflammatory diseases such as inflammation of the joints, especially rheumatoid arthritis, osteoarthritis and gout
  • inflammation of the gastrointestinal tract especially inflammatory bowel disease, ulcerative colitis and gastritis (New England J. Med., 1985, 312, 818).
  • certain cyclopentaquinazoline derivatives show a good level of activity both as regards their ability to inhibit thymidylate synthase and also as regards their anti-cancer activity against various cell lines.
  • the present invention comprises a cyclopentaquinazoline of formula (I):-
  • R* is hydrogen, amino, C j _4 alkyl, C j _4 alkoxy, C j _4 hydroxyalkyl or j _4 fluoroalkyl; wherein R ⁇ is hydrogen, C j .4 alkyl, C3.4 alkenyl, C3.4 alkynyl, C 2 _4 hydroxyalkyl, C 2 _4 halogenoalkyl or C 1.4 cyanoalkyl;
  • Ar* is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C j _4 alkyl and C j _4 alkoxy; and wherein R ⁇ is a group of the formula:- -A ⁇ Ar ⁇ -Y 1 in which A Ms a bond between the ⁇ -carbon atom of the group -CONHCH(C ⁇ 2H)- and
  • Ar ⁇ is phenylene, tetrazoldiyl, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C j _4 alkyl and C j _4 alkoxy;
  • a ⁇ is a C ] _3 alkylene or C 2 _3 alkenylene group
  • Y* is carboxy, tetrazol-5-yl, N-(C ⁇ _4 alkylsulphonyl)carbamoyl,
  • N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C j _4 alkyl and C j _4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or ⁇ l is a group of the formula:-
  • R is hydrogen, C ⁇ _4 alkyl, C3.4 alkenyl or C3.4 alkynyl;
  • Y 2 is carboxy, tetrazol-5-yl, N-(C j _4 alkylsulphonyl)carbamoyl, N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C j _4 alkyl and
  • Y 3 is the residue of a naturally occurring amino acid NH 2 CH(CO 2 H)Y 3 ;
  • Y 3 is a group of the formula:- -A 4 -CO 2 H in which A 4 is a C 2 .g alkylene group other than ethylene; wherein R 3 is a group of the formula:-
  • a ⁇ is a C j . ⁇ alkylene group and R is as defined above;
  • Y 4 is carboxy, tetrazol-5-yl, N-(C ⁇ .4 alkylsulphonyl)carbamoyl,
  • N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C j .4 alkyl and
  • Y-> is the residue of a naturally occurring amino acid NH 2 CH(CO 2 H)Y provided that when R is hydrogen and Y 4 is carboxy it is not the residue of glutamic acid; or
  • Y ⁇ is a group of the formula:-
  • Y ⁇ is a group of the formula:- -A 6 -Ar 3 -A 7 -Y 6 in which A ⁇ is a bond between the ⁇ -carbon atom of the group -A ⁇ -CON(R)CH(Y 4 )- and Ar J or is a C ⁇ 2 alkylene group;
  • Ar 3 is phenylene, tetrazoldiyl, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C1.4 alkyl and C ⁇ _4 alkoxy;
  • A' is a Cj_3 alkylene or C2.3 alkenylene group;
  • Y° is carboxy, tetrazol-5-yI, N-(C ⁇ _4 alkylsulphonyl)carbamoyl,
  • N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C1.4 alkyl and C j _4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or wherein R 3 is a group of the formula:-
  • A° is a C j .4 alkylene group
  • X is sulphinyl, sulphonyl or methylene; and Ar 4 is 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl or, except when X is methylene, tetrazol-5-yl; the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester.
  • alkyl, alkenyl, alkynyl and alkylene include both straight and branched chain groups but references to individual alkyl or alkylene groups, such as "propyl", are specific for the straight chain group only.
  • An analogous convention applies to other generic terms.
  • the numbering system used for the cyclopenta(g)quinazoline nucleus is the conventional one as shown below.
  • ⁇ -glutamyl denotes the radical H 2 NCH(C0 2 H)CH 2 CH CO- or -NHCH(C0 2 H)CH 2 CH CO- according to the context, the carbon atoms in these radicals being numbered from the carbon atom of the ⁇ -carboxy group as position 1.
  • a cyclopentaquinazoline of the invention contains at least two asymmetric carbon atoms [present at the point of attachment of the group -N(R 2 )- to the tri cyclic ring system and at the ⁇ -carbon atom of the group -CONHCH(CO 2 H)-] and can therefore exist in racemic and optically active forms.
  • this invention encompasses both racemic and optically active forms of the physiologically active cyclopentaquinazolines, it being a matter of common general knowledge how such optically active forms may be obtained by stereospecific synthesis or by separation of a mixture of isomeric compounds. It will be appreciated that one isomer may be of more interest than another due to the nature of the activity which it exhibits or due to superior physical properties, for example aqueous solubility.
  • a cyclopentaquinazoline of the formula (I) may exhibit the phenomenon of tautomerism and that the formulae shown in this specification represent only one of the possible tautomeric forms.
  • Y', Y 2 , Y 4 or Y" is a tetrazol-5-yl group
  • that group may be in the form of a lH-tetrazol-5-yl group or a 2H-tetrazol-5-yl group. It is to be understood therefore that the invention is not limited merely to any one tautomeric form which is illustrated.
  • cyclopentaquinazolines of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms.
  • C-l-4 alkyl is, for example, methyl, ethyl, propyl or isopropyl.
  • a suitable value for R ⁇ when it is C 1.4 alkoxy or for a Cj_4 alkoxy substituent which may be present on Ar 1 , Ar 2 or Ar 3 or on a phenyl-containing group Y 1 , Y 2 , Y 4 or ⁇ 6 is, for example, methoxy, ethoxy, propoxy, isopropoxy or butoxy.
  • a suitable value for a halogeno substituent which may be present on Ar Ar 2 or Ar 3 or on a phenyl-containing group Y*, Y 2 , Y 4 or Y 6 is, for example, fluoro, chloro or bromo.
  • a suitable value for R ⁇ when it is C j _4 hydroxyalkyl is, for example, hydroxymethyl, 1 -hydroxyethyl, 2-hydroxy ethyl or 3-hydroxypropyl; and when it is C ] _4 fluoroalkyl is, for example, fluoromethyl, difluoromethyl, trifluoromethyl or 2-fluoroethyl.
  • R 3 when it is alkenyl is, for example, prop-2-enyl, but-2-enyl, but-3-enyl or 2-methylprop-2-enyl; and when R 2 or R is C3.4 alkynyl is, for example, prop-2-ynyl or but-3-ynyl.
  • a suitable value for R 2 when it is C 2 _4 hydroxyalkyl is, for example, 2-hydroxyethyl or 3-hydroxypropyl; when it is C _4 halogenoalkyl is, for example, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 3-fluoropropyl, 3-chloropropyl or 3-bromopropyl; and when it is C j _4 cyanoalkyl is, for example, cyanomethyl, 2-cyanoethyl or 3-cyanopropyl.
  • a suitable value for Ar*, Ar 2 or Ar 3 when it is phenylene is, for example, 1,3- or 1 ,4-phenylene, especially 1 ,4-phenylene.
  • a suitable value for Ar* , Ar 2 or Ar 3 when it is thiophenediyl is, for example, thiophene-2,4-diyl or thiophene-2,5-diyl; when it is thiazolediyl is, for example thiazole-2,4-diyl or thiazole-2,5-diyl; when it is pyridinediyl is, for example, pyridine-2,4-diyl, pyridine-2,5-diyl, pyridine-2,6-diyl or pyridine-3,5-diyl; and when it is pyrimidinediyl is, for example, pyrimidine-2,4-diyl, pyrimidine-2,5-diyl or pyrimidine-4,6-diyl.
  • Ar* and a phenylene group Ar 2 or Ar 3 or a phenyl group in Y may carry one or two substituents.
  • a preferred level of substitution in Ar ⁇ , where substitution is present, is either two substituents or especially one substituent; and the one or two substituents may conveniently be at positions adjacent to the atom bonded to the group -CONHCH(C0 H)-R 3 , halogeno substituents such as fluoro being preferred.
  • a preferred level of substitution on a phenylene group Ar 2 or Ar 3 or on a phenyl group in Y ⁇ where substitution is present, is one substituent.
  • R 3 is a group of the formula
  • a suitable value for A* when it is a C j _ 2 alkylene group is, for example methylene or ethylene and for A 2 when it is a C 1.3 alkylene group is, for example, methylene, ethylene or trimethylene.
  • a preferred value for both A* , when it is not a bond, and for A 2 is methylene or ethylene.
  • Suitable values for Ar 2 include those which have been discussed hereinbefore, such as thiophenediyl or most especially phenylene, or additionally tetrazol-l,5-diyl or tetrazol-2,5-diyl.
  • a suitable value for Y* or for Y 2 in a group Y* of formula -CON(R)CH(Y 2 )Y 3 when it is N-(C 1 . alkylsulphonyl)carbamoyl is, for example, N-methylsulphonylcarbamoyl, N-ethylsulphonylcarbamoyl or N-propy lsulphony 1 carbamoy 1.
  • a suitable value for A 4 when Y 3 is a group of the formula -A 4 -CO 2 H is trimethylene, pentamethylene or hexamethylene, A 4 preferably being a C3.6 alkylene group with especially suitable values for Y 3 being -(CH 2 ) n CO 2 H where n is 3, 4 or 5.
  • a preferred value for Y or for Y 2 , Y 4 and Y is tetrazol-5-yl or especially carboxy.
  • R 3 is a group of the formula
  • a suitable value for A 5 is, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene or hexamethylene and a suitable value for R is as described hereinbefore.
  • a suitable value for Y 4 when it is N-(C j _4 alkylsulphonyl)- carbamoyl is, for example, N-methylsulphonylcarbamoyl, N-ethylsulphonylcarbamoyl or N-propylsulphonylcarbamoyl.
  • Y 5 is a group of the formula -A 4 -CO 2 H
  • suitable values for A 4 and Y* are as described hereinbefore in relation to a group Y 3 of the formula -A 4 -C0 2 H.
  • a suitable value for A" in a group Y ⁇ of the formula -A°-Ar 3 -A'-Y" is as described hereinbefore for A' and for A' is as described for A 2 .
  • a suitable value for Ar 3 is as described hereinbefore for Ar 2 .
  • a suitable value for Y" in such a group Y ⁇ when it is N-(C j _4 alkylsulphonyl)carbamoyl is, for example, N-methylsulphonyl ⁇ carbamoyl, N-ethylsulphonylcarbamoyl or N-propylsulphonylcarbamoyl.
  • R 3 is a group of the formula
  • a 8 is, for example, methylene, ethylene, trimethylene or tetramethylene.
  • Groups R 3 of particular value have the formula -A ⁇ -Ar 2 -A 2 -Y', especially when ⁇ l is a group not of the formula -CON(R)CH(Y 2 )Y 3 , such as carboxy or tetrazol-5-yl.
  • Specific examples of such groups R 3 are groups -A*-Ar 2 -A 2 - ⁇ l in which A* is a bond or methylene or ethylene, Ar 2 is phenylene, thiophenediyl or tetrazoldiyl, A 2 is methylene, ethylene or trimethylene and Y* is carboxy or tetrazol-5-yl.
  • R 3 of particular value have the formula -A 5 -CON(R)CH(Y 4 )Y 5 , especially when Y ⁇ is a group of the formula -A°-Ar 3 -A'-Y° in which Ar 3 is phenylene, thiophenediyl or tetrazoldiyl.
  • R ⁇ are groups -A 5 -CON(R)CH(Y 4 )-A 6 -Ar 3 -A 7 -Y 6 in which A 5 is methylene or ethylene, R is hydrogen or methyl, Y 4 is carboxy or tetrazol-5-yl, A ⁇ is a bond or is methylene or ethylene, Ar 3 is phenylene, thiophenediyl or tetrazoldiyl, A 7 is methylene, ethylene or trimethylene and Y° is carboxy or tetrazol-5-yl.
  • a suitable pharmaceutically-acceptable salt form of a cyclopentaquinazoline of the invention is, for example, an acid addition salt with an inorganic or organic acid, for example hydrochloric, hydrobromic, trifluoroacetic or maleic acid; or an alkali metal, for example sodium, an alkaline earth metal, for example calcium, or ammonium, for example tetra(2-hydroxyethyl)ammonium, salt.
  • an inorganic or organic acid for example hydrochloric, hydrobromic, trifluoroacetic or maleic acid
  • an alkali metal for example sodium, an alkaline earth metal, for example calcium, or ammonium, for example tetra(2-hydroxyethyl)ammonium, salt.
  • a suitable pharmaceutically-acceptable ester form of a cyclopentaquinazoline of the invention is, for example, an ester with an aliphatic alcohol of up to 6 carbon atoms, for example a methyl, ethyl or tert-butyl ester.
  • R 3 may contain several carboxy groups in addition to the carboxy group in the grouping -CONHCH(C ⁇ 2H)-.
  • a salt or ester may be mono-acid-mono-salt or -ester, di-salt or di-ester and when, for example, three carboxy groups are present a salt or ester may be mono-acid-di-salt or -ester, di-acid-mono-salt or -ester or even tri-salt or -ester.
  • Particularly preferred values for the various symbols R* , R 2 and Ar * individually are as expressed for the preferred cyclopentaquinazolines described hereinafter.
  • a preferred cyclopentaquinazoline of the invention has the formula (I) wherein Ri is hydrogen, amino, hydroxymethyl or especially methyl; wherein R 2 is hydrogen, methyl, ethyl, propyl, prop-2-enyl, prop-2-ynyl, 2-hydroxyethyl, 2-fluoroethyl, 2-bromoethyl or 2-cyanoethyl; wherein Ar ⁇ is 1 ,4-phenylene which may optionally bear one or two substituents selected from the group consisting of chloro and especially fluoro, thiophene-2,5-diyl, thiazole-2,5-diyl or pyridine-2,5-diyl; wherein R 3 is a group of the formula -A'-Ar 2 -A 2 -Yl in which A Ms a bond or is methylene or ethylene, Ar 2 is phenylene, thiophenediyl or tetrazoldiyl, A 2
  • A" is a bond or is methylene or ethylene
  • Ar 3 is phenylene, thiophenediyl or tetrazoldiyl
  • a ' is methylene, ethylene or trimethylene
  • Y" is carboxy or tetrazol-5-yl.
  • a further preferred cyclopentaquinazoline of the invention has the formula (I) wherein R' is amino, hydroxymethyl or methyl; wherein R 2 is methyl, ethyl or prop-2-ynyl; and wherein Ar* is 1 ,4-phenylene or 1 ,4-phenylene having a 2-fluoro substituent as in
  • An especially preferred cyclopentaquinazoline of the invention has the formula (I) wherein R* is methyl; wherein R 2 is ethyl or preferably methyl or prop-2-ynyl; wherein Ar ⁇ is 1 ,4-phenylene or 2-fluoro-l,4-phenylene; and wherein R 3 is p-carboxymethylphenyl, 2-(l-carboxymethyltetrazol-5-yl)ethyl,
  • cyclopentaquinazolines of the invention correspond firstly to those listed above but with a p-carboxymethylphenyl or 2-(N.-[p-carboxymethyl-a-carboxybenzyl]carbamoyl)ethyl group in place of the 2-(l- or 2-carboxymethyltetrazol-5-yl)ethyl group R 3 thereof and secondly to those listed above but with a 2-(N- 1 ,3-dicarboxypropyl-]__-rnethylcarbamoyl)ethyl,
  • the compounds of the present invention can exist as a mixture of stereoisomers it is preferred that they are resolved into one optically active isomeric form. Such a requirement complicates the synthesis of the compounds and it is preferred therefore that they contain as few asymmetric carbon atoms as possible consistent with achieving the desired activity.
  • the cyclopentaquinazolines of the present invention contain at least two asymmetric carbon atoms.
  • that at the 6 position of the ring system preferably has the 6S orientation rather than the 6R orientation, whilst the alpha carbon atom of the group -CONHCH(C0 H)- preferably has the L rather than the D configuration.
  • the preferred compounds (I) described hereinbefore thus preferably have such a configuration at these two asymmetric carbon atoms or less preferably are a racemic mixture in which one or both of these asymmetric carbon atoms is unresolved.
  • the asymmetric carbon atom of a residue R 3 of the form -A 1 -Ar 2 -A 2 -CON(R)CH(Y 2 )Y 3 or -A 5 -CON(R)CH(Y 4 )Y 5 may be of the L- or D-configuration but the amide bond will be stabilised in vivo when it is of the D-configuration as it will also be when R is other than hydrogen.
  • Y 3 or Y ⁇ is the residue of a naturally occurring amino acid, however, the amino acid intermediate for the synthesis of the cyclopentaquinazoline will of course be more readily available when this asymmetric carbon atom is of the L-configuration.
  • a cyclopentaquinazoline of the invention may be prepared by any process known to be applicable to the preparation of chemically-related compounds.
  • the particularly preferred process (a) for the manufacture of a cyclopenta ⁇ quinazoline of the invention comprises the reaction of an acid of the formula (II):-
  • R 3 and Ar* is protected by a conventional protecting group, and any amino group in R* , any hydroxy group in R , R 2 , R 3 and Ar' and the carboxy group or groups in
  • NH CH(CO 2 H)-R 3 may be protected by a conventional protecting group or alternatively such an amino, hydroxy or carboxy group need not be protected; and wherein R 4 is hydrogen or a protecting group which can be removed to replace -NR 4 - by -NH-; whereafter any undesired protecting group including any protecting group R 4 is removed, for example by conventional means.
  • the reactants i.e. the compound NH CH(CO 2 H)-R 3 and the cyclopentaquinazoline acid (II) in the case of the first process, conveniently have the stereochemical configuration at the asymmetric carbon atoms therein which is desired in the final cyclopentaquinazoline of formula (I).
  • a suitable reactive derivative of an acid of the formula (II) may be, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid (II) and a phenol such as pentafluorophenol or an alcohol such as
  • N-hydroxybenzotriazole the product of the reaction of the acid and a carbodiimide, for example dicyclohexylcarbodiimide; or particularly an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide or an acyl phosphonate, for example an acyl phosphonate formed by the reaction of the acid and a phosphonate such as diethylcyano phosphonate or ( 1 H- 1 ,2,3-benzotriazol- 1 - yloxy)-tris(pyrrolidino)-phosphonium hexafluorophosphate.
  • acyl azide for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide or an acyl phosphonate, for example an acyl phosphonate formed by the reaction of the acid and a phosphonate such as diethylcyano phosphonate or ( 1 H-
  • a suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group, especially a (C1.4 alkyl)carbonyl group such as acetyl, an alkoxycarbonyl group, especially a (C ] _4 alkoxy)carbonyl group such as methoxy carbonyl, ethoxycarbonyl or tert-butoxycarbonyl, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid, for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions will vary with the choice of protecting group.
  • an acyl or aroyl group may be removed, for example, by hydrolysis with a suitable base, such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • An arylmethyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, thereby avoiding the possibility of racemization which can arise with groups removable by base.
  • An alternative esterifying group is, for example, a benzyl group which can be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a further alternative protecting group for a carboxy group is, for example, an allyl group which may be removed, for example, using catalytic amounts of tetrakis triphenylphosphine palladium(O) in the presence of an excess of pyrrolidine.
  • group R 4 is a protecting group rather than hydrogen this may for example be one of the various forms of conventional protecting group such as are described hereinbefore as being generally suitable as a protecting group for an amino group, for example an alkoxycarbonyl group such as tert-butoxycarbonyl.
  • an alkyloxymethyl group such as methyloxymethyl removable, for example, with a suitable acid such as the Lewis acid boron tribormide
  • an aralkyloxymethyl group such as benzyloxymethyl removable, for example, by palladium-catalysed hydrogenolysis
  • an arylmethyl group such as a 4-methoxy- or 3,4- or 2,4-dimethoxy-benzyl removable, for example, with a suitable acid such as trifluoracetic acid
  • a trialkylsilyl group such as tri-isopropyl- or tert-butyldimethyl- silyl removable, for example, with a suitable acid such as hydrochloric acid or with a fluoride salt such as tetra-n-butylammonium fluoride, and especially (e) an alkanoyloxymethyl group such as pivaloyloxymethyl group such as pivaloyloxymethyl group
  • a suitable acid such as the Lewis acid boron tribormide
  • the protecting groups for the various carboxy groups in R 3 may be esterifying groups such as permit the product after removal of any undesired protecting group in R*, R 2 , R 3 and Ar ⁇ and of any protecting group R 4 to fall within the definition of a cyclopentaquinazoline of the invention.
  • the esterified carboxy groups in R 3 may if desired be retained in the final product.
  • either such a protecting group or a different protecting group used in R 3 will be removed.
  • the reaction of the acid (II) and the compound NH 2 CH(CO 2 H)-R 3 is preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride or an organometallic base such as an alkyl-lithium, for example n-butyl-lithium, or a dialkylamino-lithium, for example lithium di-isopropylamide, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene.
  • a suitable base such as, for example, an alkali or alkaline
  • the reaction is also preferably carried out in a suitable inert solvent or diluent, for example tetrahydrofuran, 1,2-dimethoxyethane, M,N-dimethylformamide, N ⁇ N-dimethylacetamide, N_-methylpyrrolidin-2-one, dimethylsulphoxide or acetone, and at a temperature in the range, for example, of -78° to 150 ⁇ C, conveniently at or near ambient temperature.
  • a suitable inert solvent or diluent for example tetrahydrofuran, 1,2-dimethoxyethane, M,N-dimethylformamide, N ⁇ N-dimethylacetamide, N_-methylpyrrolidin-2-one, dimethylsulphoxide or acetone
  • a suitable inert solvent or diluent for example tetrahydrofuran, 1,2-dimethoxyethane, M,N-dimethylformamide, N ⁇ N-dimethylace
  • the amide bond is produced by reaction of the appropriate two amino acids in solution, the amino group of one acid and the carboxy group of the other acid being protected, for example by protecting groups as described hereinbefore, particularly suitable groups being a benzyloxycarbonyl or trityl group and a tert-butyl or methyl esterifying group, respectively.
  • the cyclopentaquinazoline acid (II) used as starting material may, for example, be obtained by the reaction of a compound of the formula (III):-
  • a suitable value for the displaceable group Z is, for example, a halogeno or sulphonyloxy group, particularly a chloro, bromo, methanesulphonyloxy (mesyloxy) or 4-toluenesulphonyloxy group.
  • a group W is the group -CO2R ⁇ wherein R ⁇ is a protecting group which can be removed from -CO2R ⁇ to provide a carboxy group, the reactant then having the formula
  • R ⁇ is, for example, an alkyl group such as a methyl or an ethyl group which may be removed by hydrolysis with a base, for example sodium hydroxide, or alternatively a tert-butyl group which may be removed by cleavage with an acid, for example an organic acid such as trifluoroacetic acid.
  • the protecting group for the carboxy group provided by R* is preferably an esterifying group which can be removed while the protecting group for any amino, hydroxy and carboxy group in R , R 2 and Ar' is retained.
  • a second particular example of a group W is the group -CONR"R ' wherein R ⁇ and R 7 are each separately hydrogen or a group such that -CONR"R 7 is convertible to a carboxy group, preferably while the protecting group for any amino, hydroxy and carboxy group in R ⁇ , R 2 and Ar I is retained, the reactant then having the formula
  • R° is, for example, hydrogen or an alkyl group such as methyl, ethyl, propyl or butyl and for R 7 is, for example, hydrogen, a group -CH(C ⁇ 2H)(CH 2 ) 2 CO 2 H or an alkyl group such as methyl, ethyl, propyl or butyl.
  • R° is hydrogen and R 7 is a group
  • carboxypeptidase G2 enzyme may conveniently be used to remove the L-glutamic acid residue from a compound of formula (I) but in which R 3 is instead -(CH 2 ) 2 CO H thereby generating a carboxy group.
  • Such an L-glutamic acid compound may itself be prepared from a compound of formula (III) by reaction with a compound of the formula NH(R 2 )-Ar l -CONHCH(C0 2 H)-R 3 in which R 3 is instead a group -(CH ) 2 CO2H using the process (b), including the protection procedures, described hereinafter.
  • conversion of the group -CONR"R 7 to a carboxy group may be effected by any suitable procedure for hydrolysing amides.
  • an alkali metal hydroxide such as potassium hydroxide or an alkali metal peroxide such as sodium peroxide may be used to effect direct conversion of the group to a carboxy group
  • milder conditions is preferred to minimise unwanted reactions elsewhere in the molecule, for example a two stage procedure may be used involving N-acylation with a reagent such as ⁇ -acetoxypivaloyl chloride or di-tert-butyl dicarbonate followed by hydrolysis of the acylated product with a reagent such as lithium hydroxide.
  • Lewis acid such as titanium (IN) chloride or titanium (IV) isopropoxide, a mineral acid such as hydrobromic acid or a carboxylic acid such as acetic acid, in a suitable inert solvent or diluent, for example 1,2-dimethoxy ethane.
  • the reaction is conveniently effected at a temperature in the range of, for example 60-100°C, and preferably at or near 80°C, preferably at the reflux temperature of the inert solvent or diluent and in the presence of molecular sieve beads to aid the removal of the water formed during the condensation of the compound (IIIA) and the amino compound.
  • a suitable reducing agent is used to reduce the product of the condensation in a suitable inert solvent or diluent and at a suitable temperature depending upon the reducing agent used.
  • Reducing agents include, by way of example, an alkali metal borohydride such as sodium cyanoborohydride, hydrogen in the presence of a catalyst such as platinum or tris (triphenylphosphine) rhodium (I) chloride and formic acid and the complex of borane with a suitable amine such as pyridine.
  • the reduction is conveniently effected with sodium cyanoborohydride or other alkali metal borohydride in an inert solvent such as 1 ,2-dimethoxyethane and at a temperature in the range of, for example 10 to 30°C, preferably at or near ambient temperature.
  • an inert solvent such as 1 ,2-dimethoxyethane
  • the compounds of formula (IIIA) are useful intermediates for the preparation of the compounds (I) and as novel compounds are included within the scope of the present invention.
  • Such compounds may, for example, be obtained by the oxidation with a suitable oxidising agent of the corresponding cyclopentaquinazoline lacking any substituent at the 6 position in a suitable inert solvent or diluent and at a suitable temperature depending upon the oxidising agent used.
  • Oxidising agent systems may comprise, by way of example, various compounds containing chromium in oxidation state (VI) such as (a) chromium (VI) oxide in acetic acid, (b) pyridinium chlorochromate in benzene, (c) chromium (VI) oxide-70%- tert-butyl hydroperoxide in dichloromethane, (d) pyridinium dichromate -70% tert-butyl hydroperoxide in benzene and (e) bistriphenylsilyl chromate -70% tert-butyl hydroperoxide in dichloromethane, as well as compounds of a different type such as (f) 2,3-dichloro-5,6-dicyano-l ,4-benzoquinone (DDQ) in aqueous acetic acid.
  • DDQ 2,3-dichloro-5,6-dicyano-l ,4-benzoquinone
  • the systems (a), (c), (d), (e) may conveniently be used at a temperature in the range of 10 to 30°C and preferably at or near ambient temperature whilst the systems (b) and (f) may conveniently be used at or about the reflux temperature of the solvent.
  • An alternative process (b) for the manufacture of a cyclopentaquinazoline of the invention comprises the reaction of a compound of the formula (III) or the reductive amination of a compound of the formula (IIIA) with a compound of the formula:-
  • any amino group in R 3 and Ar' is protected by a conventional protecting group, for example as described hereinbefore, the carboxy group or groups in NH(R )-Ar -CONHCH(C0 2 H)-R 3 are protected by a conventional protecting group, for example as described hereinbefore, and any amino group in R ⁇ and any hydroxy group in R', R 2 , R 3 and Ar' may be protected by a conventional protecting group, for example as described hereinbefore, or alternatively such an amino or hydroxy group need not be protected; whereafter any undesired protecting group including any protecting group R 4 is removed, for example by conventional means as described above
  • the reaction is preferably carried out in the presence of a suitable base, for example as described hereinbefore in relation to the process (a), in a suitable inert solvent or diluent, for example as described hereinbefore in relation to the process (a), and at a temperature in the range of, for example, 25° to 150°C, conveniently at or near 90 ⁇ C.
  • the reductive animation is preferably carried out as described previously for the reaction of a compound (IIIA) with a compound of the formula HNR 2 -Ar ] -W.
  • a further alternative process (c) for the manufacture of a cyclopentaquinazoline of the invention in which R 2 is not hydrogen comprises the alkylation of an amine of the formula (IV):-
  • R 2 -Z wherein R* , R 2 , R 3 , R 4 , Ar I and Z have the meanings stated hereinbefore and any amino group in R*, R 3 and Ar ⁇ is protected by a conventional protecting group, for example as described hereinbefore.
  • the reaction is conveniently carried out in the presence of a suitable base, for example as described hereinbefore in relation to process (a), in a suitable inert solvent or diluent, for example as described hereinbefore in relation to process (a), and at a temperature in the range of, for example 25° to 150°C, preferably at or near 100°C.
  • a suitable base for example as described hereinbefore in relation to process (a)
  • a suitable inert solvent or diluent for example as described hereinbefore in relation to process (a)
  • the compounds of formula (IV) do of course correspond to compounds of formula (I) in which R 2 is hydrogen with optional protection at the 3-position and may be obtained by the use of a process (a) or particularly a process (b) as described hereinbefore to provide such a compound of formula (I).
  • a further alternative process (d) for the manufacture of a cyclopentaquinazoline of the invention in which R 2 is a group whose attachment to the nitrogen atom to which it is bonded is through a methylene group comprises the reductive amination with an amine of the formula (IV) as described hereinbefore of a compound of the formula:
  • R 8 -CHO wherein R° is a group which corresponds to the group R 2 lacking that methylene group, i.e. R°-CH 2 corresponds to R 2 .
  • the reaction is conveniently performed in the presence of a suitable reducing agent, for example an alkali metal borohydride or cyanoborohydride such as sodium cyanoborohydride, in the presence of a suitable inert solvent or diluent, for example methanol, ethanol or acetic acid, and at a temperature in the range, for example, 10° to 60 °C, preferably at or near ambient temperature.
  • a suitable reducing agent for example an alkali metal borohydride or cyanoborohydride such as sodium cyanoborohydride
  • a suitable inert solvent or diluent for example methanol, ethanol or acetic acid
  • a pharmaceutically acceptable salt of a novel compound of the formula (I) When a pharmaceutically acceptable salt of a novel compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure.
  • a pharmaceutically acceptable ester of a novel compound of the formula (I) When a pharmaceutically acceptable ester of a novel compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or alcohol using a conventional procedure.
  • an optically active form of a compound of the formula (I) When an optically active form of a compound of the formula (I) is required, it may preferably be obtained by carrying out one of the aforesaid processes using an optically active starting material, or alternatively by resolution of a racemic form of said compound using a conventional procedure.
  • One example of a procedure for obtaining an optically active starting material is the controlled use of carboxypeptidase G2 enzyme on a compound of formula (I) having the 6RS configuration but in which R 3 is instead -(CH 2 ) 2 C0 2 H, as described hereinbefore to produce a separable mixture of the same compound of the 6S configuration and of the corresponding compound of formula (II) having the 6R configuration in which the L-glutamic acid residue has been removed.
  • a second example is the use of a reducing agent such as the complex of borane with an optically active amino alcohol, for example (R)-(+)-2-amino-3 -methyl- 1 , 1 -diphenylbutan- 1 -ol, in the second stage of the reaction of a compound (IIIA) with an amino compound HNR 2 -Ar!-W, for example HNR 2 -Ar 1 -CO 2 R 5 or HN(R 2 )-Ar 1 -CONHCH(CO 2 H)-R 3 , as described hereinbefore, to effect reduction of the intermediate to produce a product enriched in the 6S isomer.
  • a reducing agent such as the complex of borane with an optically active amino alcohol, for example (R)-(+)-2-amino-3 -methyl- 1 , 1 -diphenylbutan- 1 -ol
  • cyclopentaquinazolines of the present invention are believed to function as anti-cancer agents at least in part due to their ability to inhibit the enzyme thymidylate synthase.
  • This anti-cancer activity may be assessed, for example, using one or more of the procedures set out below:-
  • Thymidylate synthase may be obtained in partially purified form from L1210 mouse leukaemia cells and utilised in the assay using the procedures described by Jackman et al (Cancer Res., 1986, 46, 2810) and Sikora et al. (Biochem. Pharmacol., 1988, 37, 4047);
  • test compound (b) An assay which determines the ability of a test compound to inhibit the growth of the leukaemia cell line LI 210 in cell culture.
  • the test may be similar to that described in UK Patent Specification No. 2065653B and has been described by Jones et al. (J. Med. Chem., 1985, 28, 1468);
  • lymphoma cell line L5178Y TK-/- An assay which determines the ability of a test compound to be cytotoxic to the lymphoma cell line L5178Y TK-/- in vitro.
  • the lymphoma cell line L5178Y TK-/- is deficient in the enzyme thymidine kinase which phosphorylates thymidine and thus operates to generate a pool of thymidylate when de novo synthesis of thymidylate is prevented by the presence of an effective amount of an inhibitor of thymidylate synthase.
  • the L5178Y TK-/- cell line is thereby more sensitive to the presence of an inhibitor of thymidylate synthase.
  • the title cyclopentaquinazolines of Examples 8 and 10 to 19 hereinafter have IC 50 values in test (a) of 0.0076, 0.0088, 0.0148, 0.0040, 0.00142, 0.00184, 0.00108, 0.0034, 0.00158, 0.00108 and 0.00184 ⁇ M, respectively, and the title cyclopentaquinazolines of Examples 10 to 19 hereinafter have IC50 values in test (b) of 1.2, 23, 3.9, 2.3, 0.63, 7.2, 10, 0.25, 0.86 and 0.52 ⁇ M, respectively.
  • a cyclopentaquinazoline of the present invention may itself be active or it may be a pro-drug which is converted in vivo to an active compound.
  • a cyclopentaquinazoline of the invention may be administered to a warm-blooded animal, including a human, in the form of a pharmaceutical composition which comprises the cyclopentaquinazoline in association with a pharmaceutically-acceptable diluent or carrier.
  • the composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; a form suitable for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; a form suitable for nasal use, for example a snuff, nasal spray or nasal drops; a form suitable for vaginal or rectal use, for example a suppository; a form suitable for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; a form suitable for sub-lingual or buccal use, for example a tablet or capsule; or a form suitable for parenteral use (including intravenous ' , subcutaneous, intramuscular, intravascular or infusion use), for example a sterile aqueous or oily solution, emulsion or suspension.
  • parenteral use including intravenous ' , subcutaneous, intramuscular, intra
  • compositions may be prepared in a conventional manner using conventional excipients.
  • the composition may contain, in addition to the cyclopentaquinazoline of the invention, one or more other anti-cancer substances selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; other antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example asparaginase; topoisomerase inhibitors, for example etoposide and biological response modifiers, for example interferon.
  • mitotic inhibitors for example vinblastine
  • alkylating agents for example cis-platin, carboplatin and cyclophosphamide
  • other antimetabolites for example 5-fluorouracil, cytosine arabinoside and hydroxyurea
  • the cyclopentaquinazoline will normally be administered to a warm-blooded animal at a dose within a range of 50-25000, particularly 50-5000, mg per square metre body area of the animal, i.e. approximately 1-500, particularly 1-100, mg/kg. Where desired, however, dosages outside this range may be employed and, in particular, where the preferred mode of administration involving subcutaneous infusion is used then the does range may be increased to 1-1000 mg/kg. Preferably a daily dose in the range 10-250 mg/kg is employed, particularly 30-150 mg/kg. However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • the present invention also includes a method for aiding regression and palliation of cancer in a patient, particularly a warm-blooded animal such as a human, in need of such treatment, which comprises administering to said patient an effective amount of a cyclopentaquinazoline as defined hereinbefore.
  • the invention also provides the use of such a cyclopentaquinazoline in the manufacture of a novel medicament for use in the treatment of cancer.
  • Cyclopentaquinazolines of the present invention are of interest for a wide range of anti-tumour activities, particularly in the human, including the treatment of breast, ovarian and liver cancer. In addition they are of interest in the context of the treatment of a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas.
  • the cyclopentaquinazolines of the present invention are also of interest for use in the treament of other conditions, for example allergic conditions such as psoriasis and inflammatory diseases such as rheumatoid arthritis.
  • allergic conditions such as psoriasis and inflammatory diseases such as rheumatoid arthritis.
  • the compound will normally be administered at a dose within the range 5-25000, particularly 5-500, mg per square metre body area of the animal, i.e. approximately 0.1-500, particularly 0.1-10, mg/kg. Where desired, however, dosages outside this range may be employed.
  • compositions containing the quinazolines may be formulated in unit dosage form, i.e. in the form of discrete portions each comprising a unit dose, or a multiple or sub-multiple of a unit dose, for example as a tablet or capsule.
  • a unit dosage form may, for example, contain an amount of the cyclopentaquinazoline in the range of 1-250 or 1-500 mg.
  • Examples 1 to 7 describe the preparation of cyclopentaquinazoline intermediates of formula (II) in reactive derivative form.
  • the compound of Example 2 is used in the preparation of the cyclopentaquinazolines of formula (I) as described in Examples 8 to 12 and that compound may be substituted in the procedures described in those examples by any of the other intermediates of Examples 1 and 3 to 7 to provide the alternative cyclopentaquinazoline of formula (I).
  • Example 4(4) prepared by a variation of the procedure described in Example 4 which is described in Example 13, is used in the preparation of the cyclopentaquinazolines of formula (I) as described in Examples 13 to 17 and 19 and corresponding compounds to that of Example 4(4) described in Examples 1 , 3 and 5 to 7 can also be used to provide alternative cyclopentaquinazolines (I).
  • Mass spectra were obtained using a VG 7070H spectrometer and VG 2235 data system with fast-atom bombardment ionization (FAB), chemical ionization (Cl) or electron impact ionization (El), a VG ZAB-SE spectrometer with fast-atom bombardment ionization (FAB) or a Finnigan TSQ 700 spectrometer with electrospray ionization (ESI). Where appropriate, either positive ion data or negative ion data were again collected.
  • FAB fast-atom bombardment ionization
  • Cl chemical ionization
  • El electron impact ionization
  • FAB VG ZAB-SE spectrometer with fast-atom bombardment ionization
  • ESI electrospray ionization
  • Pentafluorophenyl o-fluoro-ri-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)amino]benzoate A mixture of o-fluoro-r-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-
  • Example 3 Pentafluorophenyl o-fluoro-p . -[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]-quinazolin-6-yI)-N-(prop-2-ynyl)amino]- benzoate
  • Example 1 in DMA (15 ml) was added to a stirred mixture of p.-amino-o-fluoro- ⁇ , ⁇ - dimethylstyrene (2.03 g), calcium carbonate (2.7 g) and DMA (25 ml) which had been heated to 70°C. The mixture was stirred at 70°C for 1 hour. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic phase was washed with water, dried (MgSU4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluant.
  • the mixture was cooled to -70 °C and ozone gas was passed into the solution for 7.5 minutes. Argon gas was bubbled into the solution for 5 minutes. Dimethyl sulphide (4 ml) was added and the mixture was allowed to warm to ambient temperature. The mixture was evaporated and the residue was purified by column chromatography using a 1 :1 mixture of hexane and ethyl acetate as eluant.
  • p.-fluoro-rj-[H-((6RS)-2-methyl-4-oxo-3-pivaloyloxy-methyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoic acid was reacted with pentafluorophenyl trifluoroacetate to give pentafluorophenyl o-fluoro-r_;-[N-((6RS)-2-methyl-4-oxo-3-pivaloy
  • the r)-amino-o-fluoro- ⁇ , ⁇ -dimethylstyrene used in (1) was obtained as follows:- A mixture of o-fluoro-rj-nitrobenzaldehyde (3.35 g) and (2-methoxycarbonyl- prop-2-yl)triphenylphosphonium iodide (Synth. Comm.. 1982, 469; 11 g) was stirred and heated to 130°C for 20 minutes. The mixture was cooled to ambient temperature and purified by column chromatography using a 100:1 mixture of hexane and diethyl ether as eluant.
  • the mixture was cooled to 0°C and acidified to pH 4 by the addition of glacial acetic acid.
  • the precipitate was isolated and dried.
  • the precipitate was purified by column chromatography using initially a 9:1 mixture of methylene chloride and methanol and then a 9:1 :0.1 mixture of methylene chloride, methanol and acetic acid as eluant.
  • N-methylmorpholine was added (0.081 g, 0.8 mmol) followed by N-hydroxybenzotriazole (HOBT) (0.01 g).
  • HOBT N-hydroxybenzotriazole
  • the reaction mixture was stirred at room temperature for 4 hours and evaporated to dryness.
  • the solid obtained by trituration with ether and filtration was resuspended in a mixture of methanol/water (2 ml) and the pH adjusted to 2.5 with 2N HCI.
  • Example 1 1 (2S)-2- ⁇ 2-Fluoro-p-( -methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido ⁇ -4-(l-carboxymethyl- tetrazol-5-yl)butyric acid
  • Example 10 The procedure described in section (5) of Example 10 was repeated using methyl (2S)-2-amino-4-(l-methoxycarbonylmethyl-tetrazol-5-yl)butyrate (64 mg), anhydrous DMF (1.2 ml), pentafluorophenyl o-fluoro-r_-[N-methyl-N-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoate (129 mg), prepared as described in Example 2, and a catalytic amount of N-hydroxybenzotriazole (2.8 mg).
  • the crude product was purified by column chromatography using a gradient of ethyl acetate in dichloromethane (70 to 80%) as eluant. Subsequent reprecipitation from ethyl acetate (3 ml)/hexanes gave a white solid which was collected by filtration and dried in vacuo over phosphorus pentoxide.
  • the solution was diluted with water (12 ml), filtered, and concentrated by evaporation to a volume of approximately 7 ml. Further water (3 ml) was added and the solution was acidified to pH 3-4 by dropwise addition of IN aqueous hydrochloric acid with stirring. The resulting suspension was centrifuged and the supernatant removed. The precipitate was washed 3 times with water by resuspension, centrifugation, and removal of the supernatant, then dried in vacuo triturated with diethyl ether and further dried at 70-80°C for 6 hours.
  • Example 13 N- ⁇ E-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl ⁇ -L- ⁇ -glutamyl-N-methyl-L-glutamic acid
  • the aqueous layer was extracted with ethyl acetate (2 x 150 ml) and the combined organic solution was washed successively with saturated aqueous sodium hydrogen carbonate (300 ml), saturated brine (2 x 150 ml), saturated aqueous sodium hydrogen carbonate (150 ml) and saturated brine (150 ml), then dried (MgS04), treated with charcoal powder and evaporated to dryness.
  • a reflux condenser was fitted to the top of the dropping funnel and the mixture was stirred and heated under reflux under nitrogen for 4 hours.
  • the apparatus enabled solvent vapour to pass up the side tube of the dropping funnel and condense in the reflux condenser, and the condensed solvent to percolate through the molecular sieves before returning to the reaction flask.
  • the mixture was cooled to ambient temperature and a solution of sodium cyanoborohydride (1.0 g, 15.9 mmol) in methanol (18 ml) was added, followed immediately by acetic acid (1.0 ml). The mixture was stirred at ambient temperature for 18 hours and concentrated.
  • the residue was partitioned between saturated aqueous sodium hydrogen carbonate (150 ml) and ethyl acetate (150 ml).
  • the aqueous layer was extracted with ethyl acetate (3 x 25 ml) and the combined organic solution washed with brine (5 x 25 ml), dried (MgS ⁇ 4) and concentrated to dryness.
  • the residue was fractionated by chromatography with increasingly polar mixtures of dichloromethane and ethanol (ratio 100:0 to 100:4 v/v) as eluant.
  • silica gel (Merck Art 7734, 1.5 g) was added. The solvent was removed in vacuo and the free running yellow powder was placed on a silica gel column made up in ethyl acetate. The column was eluted with ethyl acetate (-400 ml) and then with 2% methanol in chloroform to give a white foam that reprecipitated from dichloromethane/hexane.
  • the reaction mixture was stirred at 0°C for 10 minutes, the ice-bath was then removed and stirring was continued for 2'/_ hours under nitrogen before being partitioned between ethyl acetate (80 ml) and water (80 ml). The two layers were separated and the aqueous layer was washed with ethyl acetate (2 x 80 ml). The organics were combined and successiveively washed with 10% aqueous citric acid (80 ml), saturated aqueous sodium bicarbonate (80 ml) and dilute brine (80 ml), dried (Na 2 SO4) and concentrated in vacuo to a yellow glass.
  • reaction mixture was stirrred at 0°C for 10 minutes under argon; then the ice-bath was removed and stirring was continued for 2 hours before the reaction mixture being partitioned between ethyl acetate (100 ml) and water (10 ml).
  • the two layers were separated and the aqueous layer was extracted with dichloromethane (80 ml) and ethyl acetate (2 x 100 ml).
  • the organics were combined and washed with 10% aqueous citric acid (100 ml), saturated aqueous sodium bicarbonate (100 ml), dilute brine (100 ml) and water (100 ml), dried (Na2SO4), and concentrated in vacuo to a yellow glass.
  • reaction mixture was then diluted with dichloromethane (200 ml) and washed with water (100 ml), 10% aqueous citric acid (2 x 100 ml), saturated aqueous sodium bicarbonate (100 ml) and dilute brine (100 ml), dried (Na SU4) and concentrated in vacuo to a yellow oil residue.
  • the catalyst was removed by filtration and the filtrate was concentrated in vacuo to a gummy residue which dried in vacuo over phosphorous pentoxide to give a white solid (0.182 g), a mixture of the starting material and methyl (2S)-2-amino-5-(lH-l,2,4-triazol-3-ylsulphonyl)pentanoate (ratio 0.6:1, as estimated by NMR). This was used without further purification.
  • the reaction mixture was stirred at room temperature for 2.5 hours then more IN aqueous sodium hydroxide (0.10 ml, 0.10 mmol) was added and stirring was continued at room temperature for 1 hour.
  • the solution was then diluted with water (3 ml), acidified to pH -4 with IN hydrochloric acid and the precipitated white solid was collected by filtration, washed with water (-3 ml) and dried in vacuo over phosphorous pentoxide.
  • Example 1 r4RV4- -(N-(p-[N-rf6RSV2-Methvl-4-oxo-3.4.7.78-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl ⁇ -L- ⁇ -glutamyl ⁇ amino ⁇ - 4-(tetrazol-5-yl)butyric acid
  • aqueous layer was extracted with further ethyl acetate (3 x 30 ml) and the combined organic solution washed with water (4 x 25 ml), dried (MgSO4) and evaporated.
  • a solution of the residue in dichloromethane (3 ml) was added dropwise to stirred hexane (20 ml) and the precipitate was collected, washed with hexane and dried to give tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-(tetrazol-5-yl)butyrate (1.462 g, 84%), m.p. 99-101 °C.
  • the precipitated white solid was collected by filtration, washed with ether, dried in vacuo over phosphorous pentoxide and then suspended in water (6.5 ml). To this suspension IN aqueous sodium hydroxide (1 ml) was added to give a clear solution which was stirred at room temperature for 10 minutes and then acidified to pH -4 with IN hydrochloric acid. The precipitated white solid was collected by filtration, washed with water (-5 ml) and dried in vacuo over phosphorous pentoxide.
  • Example 20 Formulation The following illustrate representative pharmaceutical dosage forms containing a cyclopentaquinazoline of formula (I), particularly in pharmaceutically acceptable salt form, for therapeutic or prophylactic use in humans:-
  • Maize starch paste (5% w/v paste) 2.25
  • the above formulations may be prepared by conventional procedures well known in the pharmaceutical art.
  • the tablets (a) to (c) may be enteric coated by conventional means, for example with a coating of cellulose acetate phthalate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cyclopentaquinazoline of formula (I), wherein R1 is hydrogen, amino, C¿1-4? alkyl, C1-4 alkoxy, C1-4 hydroxyalkyl or C1-4 fluoroalkyl; wherein R?2¿ is hydrogen, C¿1-4? alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl, C2-4 halogenoalkyl or C1-4 cyanoalkyl; Ar?1¿ is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, C¿1-4? alkyl and C1-4 alkoxy; and wherein R?3¿ is a group of the formula: -A?1-Ar2-A2-Y1¿, in which A1 is a bond between the α-carbon atom of the group -CONHCH(CO¿2?H)- and Ar?2¿ or is a C¿1-2? alkylene group; Ar?2¿ is phenylene, tetrazoldiyl, tiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C¿1-4? alkyl and C1-4 alkoxy; A?2¿ is a C¿1-3? alkylene or C2-3 alkenylene group; and a pharmaceutically acceptable salt or ester thereof are of therapeutic value particularly in the treatment of cancer.

Description

ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING
This invention relates to novel anti-cancer agents and more particularly it relates to cyclopentaquinazoline derivatives which possess anti-cancer activity.
One group of anti-cancer agents comprises antimetabolites having anti-folate activity, such as aminopterin and methotrexate. A newer compound of this type which showed considerable promise in clinical trials is known as CB3717 and is described and claimed in United Kingdom Patent No. 2 065 653B. Despite its promising activity against human breast, ovarian and liver cancer, however, CB3717 shows symptoms of toxicity in humans, particularly in relation to the liver and kidneys (Cancer Treatment Reports, 1986, 70, 1335). Such adverse side effects are reduced in compounds in which the 2-amino substituent of CB3717 is either missing or is replaced by one of various alternative substituents as described and claimed respectively in United Kingdom Patents Nos. 2 175 903 and 2 188 319.
Compounds of this type are believed to act as anti-cancer agents by inhibiting the enzyme thymidylate synthase which catalyses the methylation of deoxyuridine monophosphate to produce thymidine monophosphate which is required for DNA synthesis. The anti-cancer activity of CB3717 and like compounds may be assessed in vitro by determining their inhibitory effect on that enzyme, and in cell cultures by their inhibitory effect on cancer cell lines such as the mouse leukaemia cell line LI 210, the mouse lymphoma cell line L5178Y TK-/- and the human breast cancer cell line MCF-7.
Antimetabolites such as aminopterin and methotrexate which are inhibitors of enzymes which utilise folic acid derivatives have also shown promise in the treatment of various allergic diseases such as allergic rhinitis, atopic dermatitis and psoriasis.
Antimetabolites such as methotrexate have also shown promise in the treatment of various inflammatory diseases such as inflammation of the joints, especially rheumatoid arthritis, osteoarthritis and gout, and inflammation of the gastrointestinal tract, especially inflammatory bowel disease, ulcerative colitis and gastritis (New England J. Med., 1985, 312, 818). We have now found that certain cyclopentaquinazoline derivatives show a good level of activity both as regards their ability to inhibit thymidylate synthase and also as regards their anti-cancer activity against various cell lines.
Accordingly the present invention comprises a cyclopentaquinazoline of formula (I):-
Ar1- CONHCH(C02H) — R3
Figure imgf000004_0001
(I) wherein R* is hydrogen, amino, Cj_4 alkyl, Cj_4 alkoxy, Cj_4 hydroxyalkyl or j_4 fluoroalkyl; wherein R^ is hydrogen, Cj.4 alkyl, C3.4 alkenyl, C3.4 alkynyl, C2_4 hydroxyalkyl, C2_4 halogenoalkyl or C 1.4 cyanoalkyl;
Ar* is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, Cj_4 alkyl and Cj_4 alkoxy; and wherein R^ is a group of the formula:- -A^Ar^-Y1 in which A Ms a bond between the α-carbon atom of the group -CONHCH(Cθ2H)- and
A ~ or is a CJ.2 alkylene group;
Ar^ is phenylene, tetrazoldiyl, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, Cj_4 alkyl and Cj_4 alkoxy;
A^ is a C]_3 alkylene or C2_3 alkenylene group; and
Y* is carboxy, tetrazol-5-yl, N-(Cι_4 alkylsulphonyl)carbamoyl,
N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, Cj_4 alkyl and Cj_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or γl is a group of the formula:-
-CON(R)CH(Y2)Y3 in which R is hydrogen, C\_4 alkyl, C3.4 alkenyl or C3.4 alkynyl;
Y2 is carboxy, tetrazol-5-yl, N-(Cj_4 alkylsulphonyl)carbamoyl, N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, Cj_4 alkyl and
C]_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; and
Y3 is the residue of a naturally occurring amino acid NH2CH(CO2H)Y3; or
Y3 is a group of the formula:- -A4-CO2H in which A4 is a C2.g alkylene group other than ethylene; wherein R3 is a group of the formula:-
-A5-CON(R)CH(Y4)Y5 in which A^ is a Cj.^ alkylene group and R is as defined above; Y4 is carboxy, tetrazol-5-yl, N-(C \ .4 alkylsulphonyl)carbamoyl,
N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, Cj.4 alkyl and
Cj_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; and
Y-> is the residue of a naturally occurring amino acid NH2CH(CO2H)Y provided that when R is hydrogen and Y4 is carboxy it is not the residue of glutamic acid; or
Y^ is a group of the formula:-
-A4-C02H in which A4 is as defined above; or
Y^ is a group of the formula:- -A6-Ar3-A7-Y6 in which A^ is a bond between the α-carbon atom of the group -A^-CON(R)CH(Y4)- and ArJ or is a Cμ2 alkylene group;
Ar3 is phenylene, tetrazoldiyl, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C1.4 alkyl and C}_4 alkoxy; A' is a Cj_3 alkylene or C2.3 alkenylene group; and
Y° is carboxy, tetrazol-5-yI, N-(Cι_4 alkylsulphonyl)carbamoyl,
N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C1.4 alkyl and Cj_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or wherein R3 is a group of the formula:-
-A8-X-Ar4 in which A° is a Cj.4 alkylene group;
X is sulphinyl, sulphonyl or methylene; and Ar4 is 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl or, except when X is methylene, tetrazol-5-yl; the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester.
In this specification the terms alkyl, alkenyl, alkynyl and alkylene include both straight and branched chain groups but references to individual alkyl or alkylene groups, such as "propyl", are specific for the straight chain group only. An analogous convention applies to other generic terms. Moreover, the numbering system used for the cyclopenta(g)quinazoline nucleus is the conventional one as shown below.
Figure imgf000006_0001
Amino-acid residues are designated herein in the standard manner (Pure and Applied Chemistry, 1974, 40, 317 and European Journal of Biochemistry, 1984, 128, 9). Thus, for example, γ-glutamyl denotes the radical H2NCH(C02H)CH2CH CO- or -NHCH(C02H)CH2CH CO- according to the context, the carbon atoms in these radicals being numbered from the carbon atom of the α-carboxy group as position 1. It will be observed that a cyclopentaquinazoline of the invention contains at least two asymmetric carbon atoms [present at the point of attachment of the group -N(R2)- to the tri cyclic ring system and at the α-carbon atom of the group -CONHCH(CO2H)-] and can therefore exist in racemic and optically active forms. It is to be understood that this invention encompasses both racemic and optically active forms of the physiologically active cyclopentaquinazolines, it being a matter of common general knowledge how such optically active forms may be obtained by stereospecific synthesis or by separation of a mixture of isomeric compounds. It will be appreciated that one isomer may be of more interest than another due to the nature of the activity which it exhibits or due to superior physical properties, for example aqueous solubility.
It is also to be understood that a cyclopentaquinazoline of the formula (I) may exhibit the phenomenon of tautomerism and that the formulae shown in this specification represent only one of the possible tautomeric forms. Moreover, it will be appreciated that when, for example, Y', Y2, Y4 or Y" is a tetrazol-5-yl group, that group may be in the form of a lH-tetrazol-5-yl group or a 2H-tetrazol-5-yl group. It is to be understood therefore that the invention is not limited merely to any one tautomeric form which is illustrated.
It is also to be understood that certain cyclopentaquinazolines of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. A suitable value for R1 or R2 when it is C .4 alkyl, or for a Cμ4 alkyl substituent which may be present on Ar * , Ar2 or Ar3 or on a phenyl group-containing group γl , Y2, Y4 or Y^ present in R3, or for a group R present in R3 when it is
C-l-4 alkyl, is, for example, methyl, ethyl, propyl or isopropyl.
A suitable value for R^ when it is C 1.4 alkoxy or for a Cj_4 alkoxy substituent which may be present on Ar1 , Ar2 or Ar3 or on a phenyl-containing group Y1 , Y2, Y4 or γ6 is, for example, methoxy, ethoxy, propoxy, isopropoxy or butoxy.
A suitable value for a halogeno substituent which may be present on Ar Ar2 or Ar3 or on a phenyl-containing group Y*, Y2, Y4 or Y6 is, for example, fluoro, chloro or bromo. A suitable value for R^ when it is Cj_4 hydroxyalkyl is, for example, hydroxymethyl, 1 -hydroxyethyl, 2-hydroxy ethyl or 3-hydroxypropyl; and when it is C]_4 fluoroalkyl is, for example, fluoromethyl, difluoromethyl, trifluoromethyl or 2-fluoroethyl. A suitable value for R2 when it is C3.4 alkenyl or for a group R present in
R3 when it is alkenyl, is, for example, prop-2-enyl, but-2-enyl, but-3-enyl or 2-methylprop-2-enyl; and when R2 or R is C3.4 alkynyl is, for example, prop-2-ynyl or but-3-ynyl.
A suitable value for R2 when it is C2_4 hydroxyalkyl is, for example, 2-hydroxyethyl or 3-hydroxypropyl; when it is C _4 halogenoalkyl is, for example, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 3-fluoropropyl, 3-chloropropyl or 3-bromopropyl; and when it is Cj_4 cyanoalkyl is, for example, cyanomethyl, 2-cyanoethyl or 3-cyanopropyl.
A suitable value for Ar*, Ar2 or Ar3 when it is phenylene is, for example, 1,3- or 1 ,4-phenylene, especially 1 ,4-phenylene.
A suitable value for Ar* , Ar2 or Ar3 when it is thiophenediyl is, for example, thiophene-2,4-diyl or thiophene-2,5-diyl; when it is thiazolediyl is, for example thiazole-2,4-diyl or thiazole-2,5-diyl; when it is pyridinediyl is, for example, pyridine-2,4-diyl, pyridine-2,5-diyl, pyridine-2,6-diyl or pyridine-3,5-diyl; and when it is pyrimidinediyl is, for example, pyrimidine-2,4-diyl, pyrimidine-2,5-diyl or pyrimidine-4,6-diyl.
As indicated, Ar* and a phenylene group Ar2 or Ar3 or a phenyl group in Y may carry one or two substituents. A preferred level of substitution in Ar^, where substitution is present, is either two substituents or especially one substituent; and the one or two substituents may conveniently be at positions adjacent to the atom bonded to the group -CONHCH(C0 H)-R3, halogeno substituents such as fluoro being preferred. A preferred level of substitution on a phenylene group Ar2 or Ar3 or on a phenyl group in Y\ where substitution is present, is one substituent. When R3 is a group of the formula
-A^A A^Y1 a suitable value for A* when it is a Cj_2 alkylene group is, for example methylene or ethylene and for A2 when it is a C 1.3 alkylene group is, for example, methylene, ethylene or trimethylene. A suitable value for A2 when it is a C _3 alkenylene group is, for example, vinylene or especially propenylene (-CH2CH=CH- or -CH=CH-CH2-). A preferred value for both A* , when it is not a bond, and for A2 is methylene or ethylene. Suitable values for Ar2 include those which have been discussed hereinbefore, such as thiophenediyl or most especially phenylene, or additionally tetrazol-l,5-diyl or tetrazol-2,5-diyl. A suitable value for Y* or for Y2 in a group Y* of formula -CON(R)CH(Y2)Y3 when it is N-(C1. alkylsulphonyl)carbamoyl is, for example, N-methylsulphonylcarbamoyl, N-ethylsulphonylcarbamoyl or N-propy lsulphony 1 carbamoy 1.
In a group Y1 of formula -CON(R)CH(Y2)Y3 suitable values for C^ alkyl, C3.4 alkenyl and C3.4 alkynyl groups R have been discussed hereinbefore but R is preferably either methyl or especially hydrogen; a suitable value for Y3 when it is the residue of a naturally occurring amino acid is the residue of alanine (Y- = CH3), arginine (Y3 = (CH2)3NHC(NH2)=NH), aspartic acid (Y3 = CH2CO2H), cysteine (Y3 = CH2SH), isoleucine (Y3 = CH(CH3)CH2CH3), leucine (Y3 = CH2CH(CH3)CH3), ornithine (Y3 = (CH2)3NH2), phenylalanine (Y3 = CH2C6H5), serine (Y3 = CH2OH) and valine (Y3 = CH(CH3)2) and especially glutamic acid (Y3 = CH2CH2CO2H). A suitable value for A4 when Y3 is a group of the formula -A4-CO2H is trimethylene, pentamethylene or hexamethylene, A4 preferably being a C3.6 alkylene group with especially suitable values for Y3 being -(CH2)nCO2H where n is 3, 4 or 5.
A preferred value for Y or for Y2, Y4 and Y , is tetrazol-5-yl or especially carboxy.
When R3 is a group of the formula
-A5-CON(R)CH(Y4)Y5 a suitable value for A5 is, for example, methylene, ethylene, trimethylene, tetramethylene, pentamethylene or hexamethylene and a suitable value for R is as described hereinbefore. A suitable value for Y4 when it is N-(Cj_4 alkylsulphonyl)- carbamoyl is, for example, N-methylsulphonylcarbamoyl, N-ethylsulphonylcarbamoyl or N-propylsulphonylcarbamoyl. A suitable value for Y^ when it is the residue of a naturally occurring amino acid is alanine (Y5 = CH3), arginine (Y5 = (CH2)3NHC(NH2)=NH), aspartic acid (Y5 = CH2CO2H), cysteine (Y5 = CH2SH), isoleucine (Y5 = CH(CH3)CH2CH3), leucine (Y5 = CH2CH(CH3)CH3), ornithine (Y5 = (CH2)3NH2), phenylalanine (Y5 = CH C6H5), serine (Y5 = CH2OH) and valine (Y5 = CH(CH3) ). When Y5 is a group of the formula -A4-CO2H, suitable values for A4 and Y* are as described hereinbefore in relation to a group Y3 of the formula -A4-C02H.
A suitable value for A" in a group Y^ of the formula -A°-Ar3-A'-Y" is as described hereinbefore for A' and for A' is as described for A2. A suitable value for Ar3 is as described hereinbefore for Ar2. A suitable value for Y" in such a group Y^ when it is N-(Cj_4 alkylsulphonyl)carbamoyl is, for example, N-methylsulphonyl¬ carbamoyl, N-ethylsulphonylcarbamoyl or N-propylsulphonylcarbamoyl. When R3 is a group of the formula
-A8-X-Ar4 a suitable value for A8 is, for example, methylene, ethylene, trimethylene or tetramethylene.
Groups R3 of particular value have the formula -A^-Ar2-A2-Y', especially when γl is a group not of the formula -CON(R)CH(Y2)Y3, such as carboxy or tetrazol-5-yl. Specific examples of such groups R3 are groups -A*-Ar2-A2-γl in which A* is a bond or methylene or ethylene, Ar2 is phenylene, thiophenediyl or tetrazoldiyl, A2 is methylene, ethylene or trimethylene and Y* is carboxy or tetrazol-5-yl.
Other groups R3 of particular value have the formula -A5-CON(R)CH(Y4)Y5, especially when Y^ is a group of the formula -A°-Ar3-A'-Y° in which Ar3 is phenylene, thiophenediyl or tetrazoldiyl. Specific examples of such groups R^ are groups -A5-CON(R)CH(Y4)-A6-Ar3-A7-Y6 in which A5 is methylene or ethylene, R is hydrogen or methyl, Y4 is carboxy or tetrazol-5-yl, A^ is a bond or is methylene or ethylene, Ar3 is phenylene, thiophenediyl or tetrazoldiyl, A7 is methylene, ethylene or trimethylene and Y° is carboxy or tetrazol-5-yl.
A suitable pharmaceutically-acceptable salt form of a cyclopentaquinazoline of the invention is, for example, an acid addition salt with an inorganic or organic acid, for example hydrochloric, hydrobromic, trifluoroacetic or maleic acid; or an alkali metal, for example sodium, an alkaline earth metal, for example calcium, or ammonium, for example tetra(2-hydroxyethyl)ammonium, salt.
A suitable pharmaceutically-acceptable ester form of a cyclopentaquinazoline of the invention is, for example, an ester with an aliphatic alcohol of up to 6 carbon atoms, for example a methyl, ethyl or tert-butyl ester.
It is to be understood that R3 may contain several carboxy groups in addition to the carboxy group in the grouping -CONHCH(Cθ2H)-. When, for example, two carboxy groups are present in the cyclopentaquinazoline, a salt or ester may be mono-acid-mono-salt or -ester, di-salt or di-ester and when, for example, three carboxy groups are present a salt or ester may be mono-acid-di-salt or -ester, di-acid-mono-salt or -ester or even tri-salt or -ester. Particularly preferred values for the various symbols R* , R2 and Ar * individually are as expressed for the preferred cyclopentaquinazolines described hereinafter.
A preferred cyclopentaquinazoline of the invention has the formula (I) wherein Ri is hydrogen, amino, hydroxymethyl or especially methyl; wherein R2 is hydrogen, methyl, ethyl, propyl, prop-2-enyl, prop-2-ynyl, 2-hydroxyethyl, 2-fluoroethyl, 2-bromoethyl or 2-cyanoethyl; wherein Ar^ is 1 ,4-phenylene which may optionally bear one or two substituents selected from the group consisting of chloro and especially fluoro, thiophene-2,5-diyl, thiazole-2,5-diyl or pyridine-2,5-diyl; wherein R3 is a group of the formula -A'-Ar2-A2-Yl in which A Ms a bond or is methylene or ethylene, Ar2 is phenylene, thiophenediyl or tetrazoldiyl, A2 is methylene, ethylene or trimethylene and Y^ is carboxy or tetrazol-5-yl; or R3 is a group of the formula -A5-CON(R)CH(Y4)-A6-Ar3-A7-Y6 in which A* is methylene or ethylene, R is hydrogen or methyl, Y4 is carboxy or tetrazol-5-yl,
A" is a bond or is methylene or ethylene, Ar3 is phenylene, thiophenediyl or tetrazoldiyl, A ' is methylene, ethylene or trimethylene and Y" is carboxy or tetrazol-5-yl.
A further preferred cyclopentaquinazoline of the invention has the formula (I) wherein R' is amino, hydroxymethyl or methyl; wherein R2 is methyl, ethyl or prop-2-ynyl; and wherein Ar* is 1 ,4-phenylene or 1 ,4-phenylene having a 2-fluoro substituent as in
2,6-difluoro-l,4-phenylene or especially 2-fluoro-l,4-phenylene or is pyridine 2,5-diyl; and R3 is as just described above.
An especially preferred cyclopentaquinazoline of the invention has the formula (I) wherein R* is methyl; wherein R2 is ethyl or preferably methyl or prop-2-ynyl; wherein Ar^ is 1 ,4-phenylene or 2-fluoro-l,4-phenylene; and wherein R3 is p-carboxymethylphenyl, 2-(l-carboxymethyltetrazol-5-yl)ethyl,
2-(2-carboxymethyltetrazol-5-yl)ethyl or 2-(N-[p-carboxymethyl-α-carboxybenzyl]- carbamoyl)ethyl.
Other quinazolines of the invention of particular interest have the values of R ,
R2, and Ar ' and Ar in combination as indicated above but with R3 having any value as indicated hereinbefore. However, specific particularly preferred cyclopentaquinazolines of the invention are:
2-{E-[H-methyl-_-i-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)-quinazolin-
6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid,
2-{r_,-[N-ethyl-N.-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)-quinazolin- 6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{β-[N-(prop-2-ynyl)-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{E-[H-methyl-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{β-[N-ethyl-N.-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{rj-rji-prop-2-ynyl)-N-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{E-[N- ethyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido } -4-( 1 - or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{ri-[N-ethyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{rj-[N-(prop-2-ynyl)-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{o-fluoro-rj-[N-methyl-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{o-fluoro-r2-[N_e yl-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{o-fluoro-r5-[N-(prop-2-ynyl)-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l - or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{2-fluoro-r2-[N-methyl-N-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta-(g)-quinazolin-6-yl)amino]benzamido } -4-( 1 - or 2-carboxymethy Itetrazol- 5-yl) butyric acid, 2-{o.-fluoro-ri-[N-ethyl-N-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g) quinazolin-6-yl)amino]benzamido}-4-(l - or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{o-fluoro-ri-[N-(prop-2-ynyl)-N-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta(g)quinazolin-6-yl)amino]benzamido}-4-(l - or 2-carboxymethyltetrazol- 5-yl)butyric acid, 2-{o-fluoro-r2-[N-methyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H.-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{o-fluoro-β-[N-ethyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{Q-fluoro-ri-[H-prop-2-ynyl)-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, or a pharmaceutically acceptable salt or ester thereof.
Further specific particularly preferred cyclopentaquinazolines of the invention correspond firstly to those listed above but with a p-carboxymethylphenyl or 2-(N.-[p-carboxymethyl-a-carboxybenzyl]carbamoyl)ethyl group in place of the 2-(l- or 2-carboxymethyltetrazol-5-yl)ethyl group R3 thereof and secondly to those listed above but with a 2-(N- 1 ,3-dicarboxypropyl-]__-rnethylcarbamoyl)ethyl,
2-[l- or 2-(2-carboxyethyl)tetrazol-5-yl]ethyl, 2-{N-[l-carboxy-3-(l- or 2-carboxy- methyltetrazol-5-yl)propyl]carbamoyl} ethyl, 2-{l- or 2-[N-(l-carboxyethyl)- carbamoylmethyl]tetrazol-5-yl} ethyl, 3-(l,2,4-triazol-3-ylsulphonyl)propyl, 2- [N-(3 -carboxy- 1 -tetrazol-5-ylpropyl)carbamoyl]ethyl, 2-[H-(l -carboxyethyl)- carbamoyl]ethyl or 2-[N-(l ,4-dicarboxybutyl)carbamoyl]ethyl group in place of the 2-(l- or 2-carboxymethyltetrazol-5-yl)ethyl group R3 thereof.
Although the compounds of the present invention can exist as a mixture of stereoisomers it is preferred that they are resolved into one optically active isomeric form. Such a requirement complicates the synthesis of the compounds and it is preferred therefore that they contain as few asymmetric carbon atoms as possible consistent with achieving the desired activity.
As indicated previously, however, the cyclopentaquinazolines of the present invention contain at least two asymmetric carbon atoms. Of these, that at the 6 position of the ring system preferably has the 6S orientation rather than the 6R orientation, whilst the alpha carbon atom of the group -CONHCH(C0 H)- preferably has the L rather than the D configuration. The preferred compounds (I) described hereinbefore thus preferably have such a configuration at these two asymmetric carbon atoms or less preferably are a racemic mixture in which one or both of these asymmetric carbon atoms is unresolved. The asymmetric carbon atom of a residue R3 of the form -A1-Ar2-A2-CON(R)CH(Y2)Y3 or -A5-CON(R)CH(Y4)Y5 may be of the L- or D-configuration but the amide bond will be stabilised in vivo when it is of the D-configuration as it will also be when R is other than hydrogen. When Y3 or Y^ is the residue of a naturally occurring amino acid, however, the amino acid intermediate for the synthesis of the cyclopentaquinazoline will of course be more readily available when this asymmetric carbon atom is of the L-configuration.
A cyclopentaquinazoline of the invention may be prepared by any process known to be applicable to the preparation of chemically-related compounds.
The particularly preferred process (a) for the manufacture of a cyclopenta¬ quinazoline of the invention comprises the reaction of an acid of the formula (II):-
Figure imgf000015_0001
(II) or a reactive derivative thereof, with the terminal amino group of a compound of the formula NH2CH(CO2H)-R3^ wherein Ri, R2, R3 and Ar^ have the meanings stated hereinbefore, any amino group in
R3 and Ar* is protected by a conventional protecting group, and any amino group in R* , any hydroxy group in R , R2, R3 and Ar' and the carboxy group or groups in
NH CH(CO2H)-R3 may be protected by a conventional protecting group or alternatively such an amino, hydroxy or carboxy group need not be protected; and wherein R4 is hydrogen or a protecting group which can be removed to replace -NR4- by -NH-; whereafter any undesired protecting group including any protecting group R4 is removed, for example by conventional means. In this and the other processes described hereinafter the reactants, i.e. the compound NH CH(CO2H)-R3 and the cyclopentaquinazoline acid (II) in the case of the first process, conveniently have the stereochemical configuration at the asymmetric carbon atoms therein which is desired in the final cyclopentaquinazoline of formula (I). A suitable reactive derivative of an acid of the formula (II) may be, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid (II) and a phenol such as pentafluorophenol or an alcohol such as
N-hydroxybenzotriazole; the product of the reaction of the acid and a carbodiimide, for example dicyclohexylcarbodiimide; or particularly an acyl azide, for example an azide formed by the reaction of the acid and an azide such as diphenylphosphoryl azide or an acyl phosphonate, for example an acyl phosphonate formed by the reaction of the acid and a phosphonate such as diethylcyano phosphonate or ( 1 H- 1 ,2,3-benzotriazol- 1 - yloxy)-tris(pyrrolidino)-phosphonium hexafluorophosphate.
A suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group, especially a (C1.4 alkyl)carbonyl group such as acetyl, an alkoxycarbonyl group, especially a (C]_4 alkoxy)carbonyl group such as methoxy carbonyl, ethoxycarbonyl or tert-butoxycarbonyl, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid, for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions will vary with the choice of protecting group. Thus, for example an acyl or aroyl group may be removed, for example, by hydrolysis with a suitable base, such as an alkali metal hydroxide, for example lithium or sodium hydroxide. An arylmethyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal. It will be appreciated therefore that due to the conditions required for deprotection the use of an arylmethyl protecting group will not generally be suitable when R2 contains an alkenyl or alkynyl group. A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, thereby avoiding the possibility of racemization which can arise with groups removable by base. An alternative esterifying group is, for example, a benzyl group which can be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A further alternative protecting group for a carboxy group is, for example, an allyl group which may be removed, for example, using catalytic amounts of tetrakis triphenylphosphine palladium(O) in the presence of an excess of pyrrolidine.
Where the group R4 is a protecting group rather than hydrogen this may for example be one of the various forms of conventional protecting group such as are described hereinbefore as being generally suitable as a protecting group for an amino group, for example an alkoxycarbonyl group such as tert-butoxycarbonyl. However, other types of group may also be used and may be more suited to this particular situation, particularly (a) an alkyloxymethyl group such as methyloxymethyl removable, for example, with a suitable acid such as the Lewis acid boron tribormide, (b) an aralkyloxymethyl group such as benzyloxymethyl removable, for example, by palladium-catalysed hydrogenolysis, (c) an arylmethyl group such as a 4-methoxy- or 3,4- or 2,4-dimethoxy-benzyl removable, for example, with a suitable acid such as trifluoracetic acid, (d) a trialkylsilyl group such as tri-isopropyl- or tert-butyldimethyl- silyl removable, for example, with a suitable acid such as hydrochloric acid or with a fluoride salt such as tetra-n-butylammonium fluoride, and especially (e) an alkanoyloxymethyl group such as pivaloyloxymethyl removable, for example, with a suitable base such as sodium hydroxide or ammonia. The removal of the group R4 may involve the use of a suitable inert solvent or diluent, for example methanol or ethanol in case (e). In general care should be taken to avoid racemization when an optically active product is involved.
It will be appreciated that the protecting groups for the various carboxy groups in R3 may be esterifying groups such as permit the product after removal of any undesired protecting group in R*, R2, R3 and Ar^ and of any protecting group R4 to fall within the definition of a cyclopentaquinazoline of the invention. In such instance the esterified carboxy groups in R3 may if desired be retained in the final product. Alternatively either such a protecting group or a different protecting group used in R3 will be removed.
The reaction of the acid (II) and the compound NH2CH(CO2H)-R3 is preferably carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide, sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride or an organometallic base such as an alkyl-lithium, for example n-butyl-lithium, or a dialkylamino-lithium, for example lithium di-isopropylamide, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene. The reaction is also preferably carried out in a suitable inert solvent or diluent, for example tetrahydrofuran, 1,2-dimethoxyethane, M,N-dimethylformamide, N^N-dimethylacetamide, N_-methylpyrrolidin-2-one, dimethylsulphoxide or acetone, and at a temperature in the range, for example, of -78° to 150βC, conveniently at or near ambient temperature. The starting materials consisting of the acid (II) and the compound NH2CH(CO2H)R3, and also those used for the other processes described hereinafter, may be obtained by any of the various standard procedures of organic chemistry which are described in the literature, as illustrated by the specific Examples. Thus, for example, where peptides are being formed standard methods involving reaction in solution or solid phase methods may both be used. Preferably, however, the amide bond is produced by reaction of the appropriate two amino acids in solution, the amino group of one acid and the carboxy group of the other acid being protected, for example by protecting groups as described hereinbefore, particularly suitable groups being a benzyloxycarbonyl or trityl group and a tert-butyl or methyl esterifying group, respectively. The cyclopentaquinazoline acid (II) used as starting material may, for example, be obtained by the reaction of a compound of the formula (III):-
Figure imgf000019_0001
(III) wherein R* and R4 have the meanings stated hereinbefore and Z is a displaceable group, with a compound of the formula: HNR2-Ar1-W wherein R2 and Ar* have the meanings stated hereinbefore and W is a carboxy group or a group convertible to a carboxy group.
A suitable value for the displaceable group Z is, for example, a halogeno or sulphonyloxy group, particularly a chloro, bromo, methanesulphonyloxy (mesyloxy) or 4-toluenesulphonyloxy group. One particular example of a group W is the group -CO2R^ wherein R^ is a protecting group which can be removed from -CO2R^ to provide a carboxy group, the reactant then having the formula
HNR2-Ar1-CO2R5 A suitable value for R^ is, for example, an alkyl group such as a methyl or an ethyl group which may be removed by hydrolysis with a base, for example sodium hydroxide, or alternatively a tert-butyl group which may be removed by cleavage with an acid, for example an organic acid such as trifluoroacetic acid. The protecting group for the carboxy group provided by R* is preferably an esterifying group which can be removed while the protecting group for any amino, hydroxy and carboxy group in R , R2 and Ar' is retained.
A second particular example of a group W is the group -CONR"R ' wherein R^ and R7 are each separately hydrogen or a group such that -CONR"R7 is convertible to a carboxy group, preferably while the protecting group for any amino, hydroxy and carboxy group in R^ , R2 and Ar I is retained, the reactant then having the formula
HNR2-Ar1-CONR6R7 A suitable value for R° is, for example, hydrogen or an alkyl group such as methyl, ethyl, propyl or butyl and for R7 is, for example, hydrogen, a group -CH(Cθ2H)(CH2)2CO2H or an alkyl group such as methyl, ethyl, propyl or butyl. In the specific case where R° is hydrogen and R7 is a group
-CH(C02H)(CH2)2C02H, carboxypeptidase G2 enzyme may conveniently be used to remove the L-glutamic acid residue from a compound of formula (I) but in which R3 is instead -(CH2)2CO H thereby generating a carboxy group. Such an L-glutamic acid compound may itself be prepared from a compound of formula (III) by reaction with a compound of the formula NH(R2)-Ar l -CONHCH(C02H)-R3 in which R3 is instead a group -(CH )2CO2H using the process (b), including the protection procedures, described hereinafter. In the case where R" and R7 are each separately hydrogen or alkyl, conversion of the group -CONR"R7 to a carboxy group may be effected by any suitable procedure for hydrolysing amides. Although an alkali metal hydroxide such as potassium hydroxide or an alkali metal peroxide such as sodium peroxide may be used to effect direct conversion of the group to a carboxy group, the use of milder conditions is preferred to minimise unwanted reactions elsewhere in the molecule, for example a two stage procedure may be used involving N-acylation with a reagent such as β-acetoxypivaloyl chloride or di-tert-butyl dicarbonate followed by hydrolysis of the acylated product with a reagent such as lithium hydroxide.
As an alternative starting material to a compound (III) for the preparation of the cyclopentaquinazoline acid (II) it is possible to use a compound of the formula (IIIA):-
Figure imgf000021_0001
(IIIA) wherein R^ and R4 have the meanings stated hereinbefore. To produce the cyclopentaquinazoline acid (II) the compound (IIIA) is also reacted with a compound of the formula HNR2-Ar'-W which may particularly be of the formula HNR2-Ar1-CO2R5 or of the formula HN(R2)-Ar1-CONR6R7 as described hereinbefore, but in this case the reaction is carried out in two stages. In the first stage the compound (IIIA) and the compound HNR2-Ar -W are reacted in the presence of a suitable acid, for example a sulphonic acid such as p-toluene sulphonic acid, a
Lewis acid such as titanium (IN) chloride or titanium (IV) isopropoxide, a mineral acid such as hydrobromic acid or a carboxylic acid such as acetic acid, in a suitable inert solvent or diluent, for example 1,2-dimethoxy ethane. The reaction is conveniently effected at a temperature in the range of, for example 60-100°C, and preferably at or near 80°C, preferably at the reflux temperature of the inert solvent or diluent and in the presence of molecular sieve beads to aid the removal of the water formed during the condensation of the compound (IIIA) and the amino compound. In the second stage a suitable reducing agent is used to reduce the product of the condensation in a suitable inert solvent or diluent and at a suitable temperature depending upon the reducing agent used. Reducing agents include, by way of example, an alkali metal borohydride such as sodium cyanoborohydride, hydrogen in the presence of a catalyst such as platinum or tris (triphenylphosphine) rhodium (I) chloride and formic acid and the complex of borane with a suitable amine such as pyridine. The reduction is conveniently effected with sodium cyanoborohydride or other alkali metal borohydride in an inert solvent such as 1 ,2-dimethoxyethane and at a temperature in the range of, for example 10 to 30°C, preferably at or near ambient temperature.
It will be appreciated that the compounds of formula (IIIA) are useful intermediates for the preparation of the compounds (I) and as novel compounds are included within the scope of the present invention. Such compounds may, for example, be obtained by the oxidation with a suitable oxidising agent of the corresponding cyclopentaquinazoline lacking any substituent at the 6 position in a suitable inert solvent or diluent and at a suitable temperature depending upon the oxidising agent used. Oxidising agent systems may comprise, by way of example, various compounds containing chromium in oxidation state (VI) such as (a) chromium (VI) oxide in acetic acid, (b) pyridinium chlorochromate in benzene, (c) chromium (VI) oxide-70%- tert-butyl hydroperoxide in dichloromethane, (d) pyridinium dichromate -70% tert-butyl hydroperoxide in benzene and (e) bistriphenylsilyl chromate -70% tert-butyl hydroperoxide in dichloromethane, as well as compounds of a different type such as (f) 2,3-dichloro-5,6-dicyano-l ,4-benzoquinone (DDQ) in aqueous acetic acid. The systems (a), (c), (d), (e) may conveniently be used at a temperature in the range of 10 to 30°C and preferably at or near ambient temperature whilst the systems (b) and (f) may conveniently be used at or about the reflux temperature of the solvent.
An alternative process (b) for the manufacture of a cyclopentaquinazoline of the invention comprises the reaction of a compound of the formula (III) or the reductive amination of a compound of the formula (IIIA) with a compound of the formula:-
NH(R2)-Ar I -CONHCH(C02H)-R3 wherein in these compounds Ri, R2, R3, R , Ar* and Z have the meanings stated hereinbefore, any amino group in R3 and Ar' is protected by a conventional protecting group, for example as described hereinbefore, the carboxy group or groups in NH(R )-Ar -CONHCH(C02H)-R3 are protected by a conventional protecting group, for example as described hereinbefore, and any amino group in R^ and any hydroxy group in R', R2, R3 and Ar' may be protected by a conventional protecting group, for example as described hereinbefore, or alternatively such an amino or hydroxy group need not be protected; whereafter any undesired protecting group including any protecting group R4 is removed, for example by conventional means as described above
In the case of a compound (III), the reaction is preferably carried out in the presence of a suitable base, for example as described hereinbefore in relation to the process (a), in a suitable inert solvent or diluent, for example as described hereinbefore in relation to the process (a), and at a temperature in the range of, for example, 25° to 150°C, conveniently at or near 90βC.
In the case of a compound (IIIA), the reductive animation is preferably carried out as described previously for the reaction of a compound (IIIA) with a compound of the formula HNR2-Ar]-W.
A further alternative process (c) for the manufacture of a cyclopentaquinazoline of the invention in which R2 is not hydrogen comprises the alkylation of an amine of the formula (IV):-
— Ar1- C0NHCH(C02H) — R3
Figure imgf000023_0001
(IV) with an alkylating agent of the formula:
R2-Z wherein R* , R2, R3, R4, Ar I and Z have the meanings stated hereinbefore and any amino group in R*, R3 and Ar^ is protected by a conventional protecting group, for example as described hereinbefore.
The reaction is conveniently carried out in the presence of a suitable base, for example as described hereinbefore in relation to process (a), in a suitable inert solvent or diluent, for example as described hereinbefore in relation to process (a), and at a temperature in the range of, for example 25° to 150°C, preferably at or near 100°C. The compounds of formula (IV) do of course correspond to compounds of formula (I) in which R2 is hydrogen with optional protection at the 3-position and may be obtained by the use of a process (a) or particularly a process (b) as described hereinbefore to provide such a compound of formula (I).
A further alternative process (d) for the manufacture of a cyclopentaquinazoline of the invention in which R2 is a group whose attachment to the nitrogen atom to which it is bonded is through a methylene group comprises the reductive amination with an amine of the formula (IV) as described hereinbefore of a compound of the formula:
R8-CHO wherein R° is a group which corresponds to the group R2 lacking that methylene group, i.e. R°-CH2 corresponds to R2.
The reaction is conveniently performed in the presence of a suitable reducing agent, for example an alkali metal borohydride or cyanoborohydride such as sodium cyanoborohydride, in the presence of a suitable inert solvent or diluent, for example methanol, ethanol or acetic acid, and at a temperature in the range, for example, 10° to 60 °C, preferably at or near ambient temperature.
When a pharmaceutically acceptable salt of a novel compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or base using a conventional procedure. When a pharmaceutically acceptable ester of a novel compound of the formula (I) is required, it may be obtained, for example, by reaction of said compound with a suitable acid or alcohol using a conventional procedure. When an optically active form of a compound of the formula (I) is required, it may preferably be obtained by carrying out one of the aforesaid processes using an optically active starting material, or alternatively by resolution of a racemic form of said compound using a conventional procedure.
One example of a procedure for obtaining an optically active starting material is the controlled use of carboxypeptidase G2 enzyme on a compound of formula (I) having the 6RS configuration but in which R3 is instead -(CH2)2C02H, as described hereinbefore to produce a separable mixture of the same compound of the 6S configuration and of the corresponding compound of formula (II) having the 6R configuration in which the L-glutamic acid residue has been removed. A second example is the use of a reducing agent such as the complex of borane with an optically active amino alcohol, for example (R)-(+)-2-amino-3 -methyl- 1 , 1 -diphenylbutan- 1 -ol, in the second stage of the reaction of a compound (IIIA) with an amino compound HNR2-Ar!-W, for example HNR2-Ar1-CO2R5 or HN(R2)-Ar1-CONHCH(CO2H)-R3, as described hereinbefore, to effect reduction of the intermediate to produce a product enriched in the 6S isomer. As stated above, cyclopentaquinazolines of the present invention are believed to function as anti-cancer agents at least in part due to their ability to inhibit the enzyme thymidylate synthase. This anti-cancer activity may be assessed, for example, using one or more of the procedures set out below:-
(a) An in vitro assay which determines the ability of a test compound to inhibit the enzyme thymidylate synthase. Thymidylate synthase may be obtained in partially purified form from L1210 mouse leukaemia cells and utilised in the assay using the procedures described by Jackman et al (Cancer Res., 1986, 46, 2810) and Sikora et al. (Biochem. Pharmacol., 1988, 37, 4047);
(b) An assay which determines the ability of a test compound to inhibit the growth of the leukaemia cell line LI 210 in cell culture. The test may be similar to that described in UK Patent Specification No. 2065653B and has been described by Jones et al. (J. Med. Chem., 1985, 28, 1468);
(c) An assay which determines the ability of a test compound to inhibit the growth of the human breast cancer cell line MCF-7 in cell culture. The test is similar to that described by Lippman et al (Cancer Res., 1976, ϋ6, 4595); and
(d) An assay which determines the ability of a test compound to be cytotoxic to the lymphoma cell line L5178Y TK-/- in vitro. The lymphoma cell line L5178Y TK-/- is deficient in the enzyme thymidine kinase which phosphorylates thymidine and thus operates to generate a pool of thymidylate when de novo synthesis of thymidylate is prevented by the presence of an effective amount of an inhibitor of thymidylate synthase. The L5178Y TK-/- cell line is thereby more sensitive to the presence of an inhibitor of thymidylate synthase. [L5178Y TK-/- was obtained by mutation of the parent L5178Y cell line which is described by, for example, Fischer ≤t al. (Methods in Medical Research, 1964, 0, 247).] Although the pharmacological properties of the cyclopentaquinazolines of the invention depend on their detailed structure, in general the cyclopentaquinazolines of the invention possess activity in one or more of the above tests (a) to (d) as indicated below:- Test (a) IC50 in the range, for example, 0.0001-1 μM; Test (b) IC50 in the range, for example, 0.01-50 μM; Test (c) IC50 in the range, for example, 0.01-50 μM; Test (d) IC50 in the range, for example, 0.01-50 μM;
Thus, by way of example, the title cyclopentaquinazolines of Examples 8 and 10 to 19 hereinafter have IC50 values in test (a) of 0.0076, 0.0088, 0.0148, 0.0040, 0.00142, 0.00184, 0.00108, 0.0034, 0.00158, 0.00108 and 0.00184 μM, respectively, and the title cyclopentaquinazolines of Examples 10 to 19 hereinafter have IC50 values in test (b) of 1.2, 23, 3.9, 2.3, 0.63, 7.2, 10, 0.25, 0.86 and 0.52 μM, respectively.
A cyclopentaquinazoline of the present invention may itself be active or it may be a pro-drug which is converted in vivo to an active compound. A cyclopentaquinazoline of the invention may be administered to a warm-blooded animal, including a human, in the form of a pharmaceutical composition which comprises the cyclopentaquinazoline in association with a pharmaceutically-acceptable diluent or carrier.
The composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; a form suitable for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; a form suitable for nasal use, for example a snuff, nasal spray or nasal drops; a form suitable for vaginal or rectal use, for example a suppository; a form suitable for administration by inhalation, for example as a finely divided powder such as a dry powder, a microcrystalline form or a liquid aerosol; a form suitable for sub-lingual or buccal use, for example a tablet or capsule; or a form suitable for parenteral use (including intravenous', subcutaneous, intramuscular, intravascular or infusion use), for example a sterile aqueous or oily solution, emulsion or suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients. The composition may contain, in addition to the cyclopentaquinazoline of the invention, one or more other anti-cancer substances selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; other antimetabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example asparaginase; topoisomerase inhibitors, for example etoposide and biological response modifiers, for example interferon.
The cyclopentaquinazoline will normally be administered to a warm-blooded animal at a dose within a range of 50-25000, particularly 50-5000, mg per square metre body area of the animal, i.e. approximately 1-500, particularly 1-100, mg/kg. Where desired, however, dosages outside this range may be employed and, in particular, where the preferred mode of administration involving subcutaneous infusion is used then the does range may be increased to 1-1000 mg/kg. Preferably a daily dose in the range 10-250 mg/kg is employed, particularly 30-150 mg/kg. However, the daily dose will necessarily be varied depending upon the host treated, the particular route of administration and the severity of the illness being treated. Accordingly, the optimum dosage may be determined by the practitioner who is treating any particular patient.
Accordingly the present invention also includes a method for aiding regression and palliation of cancer in a patient, particularly a warm-blooded animal such as a human, in need of such treatment, which comprises administering to said patient an effective amount of a cyclopentaquinazoline as defined hereinbefore. The invention also provides the use of such a cyclopentaquinazoline in the manufacture of a novel medicament for use in the treatment of cancer.
Cyclopentaquinazolines of the present invention are of interest for a wide range of anti-tumour activities, particularly in the human, including the treatment of breast, ovarian and liver cancer. In addition they are of interest in the context of the treatment of a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas.
In view of the activity shown by antimetabolites such as aminopterin and methotrexate, which is discussed hereinbefore, the cyclopentaquinazolines of the present invention are also of interest for use in the treament of other conditions, for example allergic conditions such as psoriasis and inflammatory diseases such as rheumatoid arthritis. In using a cyclopentaquinazoline of the invention for such a purpose the compound will normally be administered at a dose within the range 5-25000, particularly 5-500, mg per square metre body area of the animal, i.e. approximately 0.1-500, particularly 0.1-10, mg/kg. Where desired, however, dosages outside this range may be employed. In general, for the treatment of an allergic condition such as psoriasis, topical administration of a cyclopentaquinazoline of the invention is preferred. Thus, for example, for topical administration a daily dose in the range, for example, of 0.1 to 10 mg/kg may be used. Compositions containing the quinazolines may be formulated in unit dosage form, i.e. in the form of discrete portions each comprising a unit dose, or a multiple or sub-multiple of a unit dose, for example as a tablet or capsule. Such a unit dosage form may, for example, contain an amount of the cyclopentaquinazoline in the range of 1-250 or 1-500 mg. The invention is illustrated by the following Examples.
Examples 1 to 7 describe the preparation of cyclopentaquinazoline intermediates of formula (II) in reactive derivative form. The compound of Example 2 is used in the preparation of the cyclopentaquinazolines of formula (I) as described in Examples 8 to 12 and that compound may be substituted in the procedures described in those examples by any of the other intermediates of Examples 1 and 3 to 7 to provide the alternative cyclopentaquinazoline of formula (I). The compound of Example 4(4), prepared by a variation of the procedure described in Example 4 which is described in Example 13, is used in the preparation of the cyclopentaquinazolines of formula (I) as described in Examples 13 to 17 and 19 and corresponding compounds to that of Example 4(4) described in Examples 1 , 3 and 5 to 7 can also be used to provide alternative cyclopentaquinazolines (I).
Procedures suitable for use in the preparation of alternative intermediates for reaction with the cyclopentaquinazoline intermediates of Examples 1 to 7 to provide further cyclopentaquinazolines of the invention are illustrated by the specific examples of UK patent applications 2 253 849 and 2 265 148, and in the equivalents thereof filed in other countries.
In Examples 1 to 7 and in Examples 8 and 9 and sections (1) and (2) of
Examples 10 and 12 the following apply unless otherwise stated:- (i) Evaporations were carried out by rotary evaporation in vacuo and work-up • procedures were carried out after removal of residual solids by filtration.
(ii) Operations were carried out at ambient temperature and under an atmosphere of an inert gas such as argon.
(iii) Column chromatography (by the flash procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or
Merck Lichroprep RP-18 reversed-phase silica (Art. 9303).
(iv) The structures of the title compounds of the Examples were generally confirmed by NMR spectra. Proton magnetic resonance spectra were determined using a Jeol FX 90Q or a Bruker AM200 spectrometer operating at a field strength of 200 MHz. Chemical shifts are reported in parts per million downfield from tetramethylsilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; d of d's, doublet of doublet's; t, triplet, m, multiplet.
(v) Intermediates were not generally fully characterised and purity was assessed by thin layer chromatographic, infra-red (IR) or NMR analysis. (vi) Melting points are uncorrected and were determined using a Mettler SP62 automatic melting point apparatus, a Koffler block or an oil-bath apparatus.
In Examples 10 to 19 [apart from sections (1) and (2) of Examples 10 and 12], the following variations apply:
(ii) The use of an atmosphere of an inert gas is specifically indicated. (iii) Column chromatography was performed using Merck Art 1511 l or Merck Art 7729 silica gel. Petroleum ether refers to the fraction of boiling point 60-80°C. (iv) and (v) The techniques used to confirm structures are indicated, being one or more of NMR and mass spectra, and elemental analysis for the title compounds. Proton magnetic resonance spectra were determined using a Bruker WM250 spectrometer operating at a field strength of 250 MHz. Chemical shifts and peak multiplicities are reported as before and the attribution believed to be appropriate for each signal is also indicated. Mass spectra were obtained using a VG 7070H spectrometer and VG 2235 data system with fast-atom bombardment ionization (FAB), chemical ionization (Cl) or electron impact ionization (El), a VG ZAB-SE spectrometer with fast-atom bombardment ionization (FAB) or a Finnigan TSQ 700 spectrometer with electrospray ionization (ESI). Where appropriate, either positive ion data or negative ion data were again collected.
(vi) Melting points are again uncorrected and were determined on a Koffler block. The following abbreviations have been used throughout Examples 1 to 11 :
THF tetrahydrofuran
DMF N,N-dimethylformamide
DMA N,N-dimethylacetamide
DMSO dimethylsulphoxide NMP N-methylpyrrolidin-2-one
EXAMPLES Example 1 : Pentafluorophenyl o-fluoro-]2-[N-((6RS)-2-methyl- 4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-6-yl)amino]benzoate
(1) 5-Acetamidoindan A mixture of 5-aminoindan (100 g), acetic anhydride (84 g), pyridine (65 g) and ethyl acetate (500 ml) was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residue was triturated under diethyl ether (800 ml). The solid was filtered off, washed with diethyl ether (500 ml) and with hexane (500 ml) and dried. There was thus obtained 5-acetamidoindan (104.5 g), m.p. 107°C. (2) 5-Acetamido-6-bromoindan
Bromine (105 g) was added dropwise to a stirred mixture of 5-acetamidoindan (104.5 g) and acetic acid (400 ml), the rate of addition being such that the temperature of the reaction mixture was maintained in the range 20 to 25 °C. The mixture was poured into a mixture (2 L) of ice and water. The precipitate was isolated, washed with water and dried. There was thus obtained 5-acetamido-6-bromoindan (143 g), m.p. 138βC.
(3) 5-Acetamido-6-cyanoindan
A mixture of 5-acetamido-6-bromoindan (143 g), cuprous cyanide (65.5 g) and NMP (600 ml) was stirred and heated to 125βC for 30 minutes. The mixture was cooled to ambient temperature and poured into a mixture of concentrated aqueous ammonia solution (specific gravity 0.88, 1 L) and ice (3 L). The mixture was stirred for 15 minutes. The precipitate was isolated and washed with water (3 L). A mixture of the solid so obtained and methylene chloride (2 L) was stirred at ambient temperature for 30 minutes. The mixture was filtered and the filtrate was dried (MgSO4) and evaporated. The residue was triturated under diethyl ether (1.5 L). There was thus obtained 5-acetamido-6-cyanoindan (104 g), m.p. 172°C.
(4) 2-Methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-4-one
A mixture of 5-acetamido-6-cyanoindan (104 g), hydrogen peroxide (30% solution in water, 400 ml), sodium hydroxide (35 g), water (200 ml) and ethanol (1 L) was stirred and heated to 50° C for 1 hour. The mixture was cooled to ambient temperature and evaporated. The residue was dissolved in water (2 L) and the solution was acidified to pH 5 by the addition of 2N aqueous hydrochloric acid. The precipitate was isolated, washed with water and dried under vacuum. There was thus obtained 2-methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-4-one (100 g), m.p. 284°C. (5) 2-Methyl-3-pivalyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]- quinazolin-4-one
Potassium Jert-butoxide (64 g) was added portionwise during 15 minutes to a stirred solution of 2-methyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-4-one (89 g) in DMSO (700 ml). The mixture was stirred at ambient temperature for 30 minutes. Chloromethyl pivaloate (131 g) was added dropwise during 30 minutes. The mixture was stirred at ambient temperature for 24 hours. The mixture was poured into a mixture of ammonium chloride (500 g) and a mixture (3 L) of ice and water. Ethyl acetate (2 L) was added and the mixture was filtered. The organic layer was dried (MgSO4) and evaporated. The residue was triturated under diethyl ether (500 ml). The mixture was cooled to 0°C for 2 hours. The solid was isolated, washed with diethyl ether and dried. There was thus obtained 2-methyl-3 -pivaloyloxymethy 1-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-4-one (72.4 g), m.p. 128°C.
(6) 6-Bromo-2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-4-one
A mixture of 2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]-quinazolin-4-one (50 g), N-bromosuccinimide (31.2 g), benzoyl peroxide (0.1 g) and carbon tetrachloride (500 ml) was stirred and heated to reflux for 90 minutes. The mixture was cooled to 0°C. The mixture was filtered and the filtrate was evaporated. The residue was triturated under diethyl ether (400 ml). The mixture was cooled to 0°C. The precipitate was isolated, washed with diethyl ether and dried. The solid so obtained was purified by column chromatography using a 1 :1 mixture of hexane and ethyl acetate as eluant. There was thus obtained 6-bromo-2-methyl-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-4-one (21 g), m.p. 98°C (decomposes);
NMR Spectrum: (CDCI3) 1.2 (s, 9H), 2.55 (m, 2H), 2.65 (s, 3H), 3.0 (m, 1H), 3.3 (m, 1H), 5.65 (d of d's, 1H), 6.1 (q, 2H), 7.5 (s, 1H), 8.3 (s, 1H). (7) 2-Fluoro-β-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoic acid
A mixture of 6-bromo-2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-4-one (26 g), ι amino-o.-fluorobenzoic acid 1,1 -dimethyl-2-hydroxyethylammonium salt (42 g), calcium carbonate (21.4 g) and DMSO (200 ml) was stirred at ambient temperature for 72 hours. The mixture was poured onto a mixture of ice and water (1 litre). The precipitate was isolated, washed with water and dried under vacuum. The product was purified by column chromatography using initially a 9:1 mixture of methylene chloride and methanol and then a 9: 1 :0.1 mixture of methylene chloride, methanol and acetic acid as eluant. There was thus obtained o-fluoro-r>-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)amino]benzoic acid as a gum (20 g).
(8) Pentafluorophenyl o-fluoro-ri-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)amino]benzoate A mixture of o-fluoro-r-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-
3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzoic acid (0.75 g), pentafluorophenol (1.77 g), N,N-dicyclohexylcarbodiimide (0.66 g), N-hydroxybenzotriazole (0.01 g) and methylene chloride (100 ml) was stirred at ambient temperature for 18 hours. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluant. There was thus obtained pentafluorophenyl o-fluoro-p.-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoate as a gum (0.72 g); NMR Spectrum: (CDC13) 1.23 (s, 9H), 2.05 (m, IH), 2.65 (s, 3H), 2.75 (m, IH), 3.13 (m, 2H), 4.8 (d, IH), 5.15 (s d's, IH), 6.1 (2 d's, 2H), 6.3 (m, 2H), 7.5 (s, IH), 7.95 (t, IH), 8.2 (s, IH). Example 2 : Pentafluorophenyl o-fluoro-rj-[N-methyl-N-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoate
An aqueous solution of formaldehyde (37% weight/volume, 17.55 ml) was added dropwise during 15 minutes to a stirred solution of pentafluorophenyl o.-fluoro-β-[H-((6RS)-2- methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)amino]benzoate (13 g), prepared as described in Example 1, in glacial acetic acid (100 ml). The mixture was stirred at ambient temperature for 1 hour. Sodium cyanoborohydride (1.36 g) was added portionwise during 30 minutes and the resultant mixture was stirred at ambient temperature for 2 hours. The mixture was poured onto a mixture of ice and water (500 ml) and extracted with ethyl acetate. The organic phase was dried (MgSO4) and evaporated. The product was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluant. There was thus obtained pentafluorophenyl o-fluoro-r_.-[N-methyl-N-((6RS)-2-methyI-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)amino]benzoate (11 g);
NMR Spectrum: (CDC13) 1.23 (s, 9H), 2.15 (m, IH), 2.55 (m, IH), 2.65 (s, 3H), 2.8 (s, 3H), 3.15 (m, 2H), 5.65 (t, IH), 6.1 (2 d's, 2H), 6.6 (2 d's, IH), 6.72 (2 d's, IH), 7.53 (s, IH), 7.97 (d, IH), 8.03 (s, IH).
Example 3 : Pentafluorophenyl o-fluoro-p.-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]-quinazolin-6-yI)-N-(prop-2-ynyl)amino]- benzoate
(1) o-Fluoro-p-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]-β,β-dimethylstyrene
A solution of 6-bromo-2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-4-one (2.4 g), prepared as described in section (6) of
Example 1, in DMA (15 ml) was added to a stirred mixture of p.-amino-o-fluoro-β,β- dimethylstyrene (2.03 g), calcium carbonate (2.7 g) and DMA (25 ml) which had been heated to 70°C. The mixture was stirred at 70°C for 1 hour. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic phase was washed with water, dried (MgSU4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluant. There was thus obtained o-fluoro-j_-[N_-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]-β,β- dimethylstyrene (1.4 g);
NMR Spectrum: (CDC13) 1.23 (s, 9H), 1.81 (s, 3H), 1.91 (s, 3H), 1.95 (m, IH), 2.64 (s, 3H), 2.70 (m, IH), 3.06 (m, 2H), 4.05 (broad s, IH), 5.03 (s, IH), 6.1 (m, 3H), 6.42 (m, 2H), 7.06 (m, IH), 7.48 (s, IH), 8.24 (s IH).
(2) o-Fluoro-rj-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]-β,β-dimethylstyrene
A mixture ofo-fluoro-r2-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]-β,β-dimethylstyrene (1.4 g), propargyl bromide (6.1 g), calcium carbonate (0.88 g) and DMA (20 ml) was stirred and heated to 80 °C for 6 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water and with brine, dried (MgSU4) and evaporated. The residue was purified by column chromatography using initially increasingly polar mixtures of hexane and ethyl acetate and then increasingly polar mixtures of methylene chloride and ethyl acetate as eluant. There was thus obtained o-fluoro-ri-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N,-(prop-2-ynyl)amino]-β,β- dimethylstyrene (1.04 g);
NMR Spectrum: (CDCI3) 1.23 (s, 9H), 1.81 (s, 3H), 1.91 (s, 3H), 2.2 (t, IH), 2.28-2.6 (m, 2H), 2.65 (s, 3H), 2.9-3.3 (m, 2H), 4.35 (2 d's, 2H), 5.5 (t, IH), 6.1 (s, 2H), 6.16 (s, IH), 6.66 (m, 2H), 7.13 (t, IH), 7.5 (s IH), 8.13 (s, IH). (3) o-Fluoro-p-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N- (prop-2-ynyl)amino]benzaldehyde j_-Fluoro-rj-[li-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N- (prop-2-ynyl)amino]-β,β-dimethylstyrene (0.626 g) was dissolved in a mixture of methylene chloride (2 ml) and ethanol (250 ml). The mixture was cooled to -70 °C and ozone gas was passed into the solution for 7.5 minutes. Argon gas was bubbled into the solution for 5 minutes. Dimethyl sulphide (4 ml) was added and the mixture was allowed to warm to ambient temperature. The mixture was evaporated and the residue was purified by column chromatography using a 1 :1 mixture of hexane and ethyl acetate as eluant. There was thus obtained o-fluoro-p.-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N- (prop-2-ynyl)amino]benzaldehyde (0.47 g); NMR Spectrum: (CDC13) 1.2 (s, 9H), 2.25 (m, 2H), 2.64 (m, 4H), 2.95-3.35 (m, 2H), 3.9 (m, 2H), 5.6 (t, IH), 6.1 (s, 2H), 6.65 (m, IH), 6.8 (m, IH), 7.53 (s, IH), 7.8 (t, IH), 8.1 (s, IH), 10.15 (s, IH).
(4) o-Fluoro-ri-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N- (prop-2-ynyl)amino]benzoic acid
Sodium chlorite (0.28 g) and sulphamic acid (0.24 g) were added portionwise to a stirred mixture of o-fluoro-t)-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzaldehyde (0.47 g), 0.2M sodium acetate in acetic acid buffer (pH 4, 70 ml) and tert-butanol (70 ml). The mixture was stirred at ambient temperature for 24 hours. The mixture was partitioned between methylene chloride and a saturated aqueous sodium dihydrogen phosphate solution. The organic phase was washed with brine, dried (MgSU4) and evaporated. The residue was purified by column chromatography to give o-fluoro-rj-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoic acid (0.41 g); NMR Spectrum: (CDCI3 + CD3SOCD3) 1.2 (s, 9H), 2.33 (m, 2H), 2.63 (m, 4H), 2.97-3.3 (m, 2H), 4.3 (m, 2H), 5.6 (t, IH), 6.1 (s, 2H), 6.72 (m, 2H), 7.52 (s, IH), 7.86 (t, IH), 8.05 (s, IH).
(5) Pentafluorophenyl β-fluoro-p.-[H-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N.-(prop-2-ynyl)amino]benzoate Using an analogous procedure to that described in section (5) of Example 6 p.-fluoro-rj-[H-((6RS)-2-methyl-4-oxo-3-pivaloyloxy-methyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoic acid was reacted with pentafluorophenyl trifluoroacetate to give pentafluorophenyl o-fluoro-r_;-[N-((6RS)-2- methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoate in 75% yield.
Footnote
The r)-amino-o-fluoro-β,β-dimethylstyrene used in (1) was obtained as follows:- A mixture of o-fluoro-rj-nitrobenzaldehyde (3.35 g) and (2-methoxycarbonyl- prop-2-yl)triphenylphosphonium iodide (Synth. Comm.. 1982, 469; 11 g) was stirred and heated to 130°C for 20 minutes. The mixture was cooled to ambient temperature and purified by column chromatography using a 100:1 mixture of hexane and diethyl ether as eluant. There was thus obtained o-fluoro-β-nitro-β,β-dimethylstyrene as an oil (3.05 g); NMR Spectrum: (CDCI3) 1.84 (s, 3H), 1.78 (s, 3H), 6.25 (s, IH), 7.4 (t, IH), 7.96 (m, 2H).
A portion (2.2 g) of the material so obtained was added to a stirred mixture of stannous chloride dihydrate (12.8 g) and ethyl acetate (200 ml) which had been heated to 50eC. The resultant mixture was stirred and heated to 70°C for 1.5 hours. The mixture was cooled to ambient temperature and poured into a dilute aqueous ammonium hydroxide solution. The mixture was extracted with ethyl acetate. The organic phase was washed with water and with brine, dried (MgSU4) and evaporated. There was thus obtained p-amino-o-fluoro-β,β-dimethylstyrene as an oil (1.85 g); NMR Spectrum: (CDCI3) 1.76 (s, 3H), 1.85 (s, 3H), 3.7 (broad s, 2H), 6.13 (s, IH), 6.38 (m, 2H), 7.0 (t, lH).
Example 4 : Pentafluorophenyl r [N-((6RS)-2-me yl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)-amino]benzoate
(1) Diethyl N-{β-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoyl}-L-glutamate
A mixture of 6-bromo-2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-4-one (21 g), prepared as described in section (6) of Example 1, diethyl g-aminobenzoyl-L-glutamate (52.5 g), prepared as described in the Journal of Medicinal Chemistry, 1985, 28, 1428, calcium carbonate (27.5 g) and DMA (200 ml) was stirred and heated to 110°C for 30 minutes. The mixture was cooled to ambient temperature. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was dried (MgS04) an<^ evaporated. The residue was purified by column chromatography using initially a 1 : 1 mixture of hexane and ethyl acetate as eluant and then a 1 :3 mixture of hexane and ethyl acetate as eluant. There was thus obtained a gum which on trituration under diethyl ether gave diethyl N-{β-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzoyl}-L-glutamate (13.5 g), m.p. 156°C; NMR Spectrum: (CD3SOCD3) 1.13 (s, 9H), 1.2 (2 t's, 6H), 2.0 (m, 3H), 2.45 (t, 2H), 2.6 (s, 3H), 3.05 (m, 2H), 4.05 (2 q's, 4H), 4.4 (m, IH), 5.2 (broad t, IH), 6.05 (q, 2H), 6.65 (broad s, IH), 6.8 (d, 2H), 7.5 (s, IH), 7.7 (d, 2H), 7.95 (s, IH), 8.25 (d, IH).
(2) Diethyl N- {β-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)-amino]benzoyl}- L-glutamate
A mixture of diethyl N-{r [N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6- yl)amino]benzoyl}-L-glutamate (13.5 g), propargyl bromide (32 g), calcium carbonate (10.7 g) and DMA (250 ml) was stirred and heated to 110βC for 5 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and water. The organic phase was washed with water, dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluant. There was thus obtained diethyl -{p.-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-K-(prop-2-ynyl)-amino]benzoyl}- L-glutamate as a foam (9 g).
(3) N-{p.-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta- [g] quinazolin-6-y l)-N-(prop-2-y nyl)amino]benzoy 1 } -L-glutamic acid
A mixture of diethyl N-{rj-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3 ,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl } - L-glutamate (9 g), in aqueous sodium hydroxide (60 ml) and methanol (300 ml) was stirred at ambient temperature for 24 hours. The mixture was concentrated by evaporation to a volume of approximately 20 ml. Water (200 ml) was added and the mixture was acidified to pH 4 by the addition of 2N aqueous hydrochloric acid. The precipitate was isolated, washed with water and dried under vacuum. There was thus obtained N- {r_-[N-((6RS)-2-methyl-4-oxo-3 ,4,7,8-tetrahydro-6H-cyclopenta- [gjquinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoyl} -L-glutamic acid (7 g), m.p. 188°C; NMR Spectrum: (CD3SOCD3) 2.0 (m, 2H), 2.2 (m, 2H), 2.35 (m, 5H), 3.05 (s, IH), 3.1 (m, 2H), 3.35 (m, IH), 4.05 (m, IH), 4.35 (q, IH), 5.75 (t, 3H), 7.0 (d, 2H), 7.5 (s, IH), 7.75 (d, 2H), 7.8 (s, IH), 8.1 (d, IH), 12.0 (s, IH). Elemental Analysis: Found C, 60.5; H, 5.2; N, 10.5; C27H26N4°6 1 H2° °-25 NaC1 requires C, 60.6; H, 5.2; N, 10.5%.
(4) r>-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoic acid
A mixture of N-{r_-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl} -L-glutamic acid (6 g), carboxypeptidase G2 (2000 units) and tris buffer [prepared by mixing -amino-2- hydroxymethyl-l,3-propanediol (12.11 g), zinc chloride (0.035 g) and distilled water (950 ml), by adjusting the basicity of the mixture to pH 7.3 by the addition of 2N aqueous hydrochloric acid and by adding sufficient distilled water to give a final volume of 1 L; 750 ml] was stirred and heated to 37°C for 30 hours. A second portion of carboxypeptidase G2 (2000 units) was added and the mixture was heated to 37°C for a further 24 hours. The mixture was cooled to 0°C and acidified to pH 4 by the addition of glacial acetic acid. The precipitate was isolated, washed with water and dried under vacuum. There was thus obtained p.-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N_- (prop-2-ynyl)amino]benzoic acid as a solid (4 g), m.p. 264°C;
NMR Spectrum: (CD3SOCD3) 2.2 (m, 2H), 2.35 (s, 3H), 3.0 (m, 2H), 3.1 (s, IH), 3.85 (m, IH), 4.1 (m, IH), 5.75 (t, IH), 7.05 (d, 2H), 7.5 (s, IH), 7.8 (s, IH), 7.85 (d, 2H), 12.1 (broad s, 2H).
(5) Pentafluorophenyl r)-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoate
Using an analogous procedure to that described in section (3) of Example 5
N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-
H-(prop-2-ynyl)amino]benzoic acid was reacted with pentafluorophenol to give pentafluorophenyl p.-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta-
[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoate.
Example 5 : Pentafluorophenyl p-Q__-((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoate
(1) N-{β-[H-((6S)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl} -L-glutamic acid
A mixture of N-{£-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L- glutamic acid (5.5 g), prepared as described in section 3 of Example 4, carboxypeptidase G2 (3. Med. Chem.. 1992, 3__5, 859; Eur. J. Biochem.. 1985, 48, 447; 2000 units) and tris buffer (700 ml) was stirred and heated to 37°C for 2.75 hours. The mixture was cooled to 0°C and acidified to pH 4 by the addition of glacial acetic acid. The precipitate was isolated and dried. The precipitate was purified by column chromatography using initially a 9:1 mixture of methylene chloride and methanol and then a 9:1 :0.1 mixture of methylene chloride, methanol and acetic acid as eluant. There were thus obtained:- N-{t)-[N-((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoyl} -L-glutamic acid (2.7 g), m.p. 218βC; NMR Spectrum: (CD3SOCD3) 2.0 (m, 2H), 2.2 (m, 2H), 2.35 (m, 5H), 3.05 (s, IH), 3.1 (m, 2H), 3.35 (m, IH), 4.05 (m, IH), 4.35 (q, IH), 5.75 (t, 3H), 7.0 (d, 2H), 7.5 (s, IH), 7.75 (d, 2H), 7.8 (s, IH), 8.1 (d, IH), 12.0 (s, IH); and t)-[N-((6R)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)- N_-(prop-2-ynyl)amino]benzoic acid (2.0 g); NMR Spectrum: (CD3SOCD3) 2.2 (m, 2H), 2.35 (s, 3H), 3.0 (m, 2H), 3.1 (s, IH), 3.85 (m, IH), 4.1 (m, IH), 5.75 (t, IH), 7.05 (d, 2H), 7.5 (s, IH), 7.8 (S, IH), 7.85 (d, 2H), 12.1 (broad s, 2H).
(2) r>-[N-((6S)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yI)-N-(prop-2-ynyl)amino]benzoic acid A mixture of N-{β-[N-((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta-
[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino}-L-glutamic acid (1 g), carboxypeptidase G2 (1000 units) and tris buffer (200 ml) was stirred and heated to 37°C for 24 hours. A second portion of carboxypeptidase G2 (1000 units) was added and the mixture was stirred at 37°C for a further 24 hours. The mixture was cooled to 0°C and acidified to pH 4 by the addition of glacial acetic acid. The precipitate was isolated and dried under vacuum. The precipitate was purified by column chromatography using a 9:1 mixture of methylene chloride and methanol as eluant. There was thus obtained p.-[N-((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)- N-(prop-2-ynyl)amino]benzoic acid (0.7g); NMR Spectrum: (CD3SOCD3) 2.2 (m, 2H), 2.35 (s, 3H), 3.0 (m, 2H), 3.1 (s, IH), 3.85 (m, IH), 4.1 (m, IH), 5.75 (t, IH), 7.05 (d, 2H), 7.5 (s, IH), 7.8 (s, IH), 7.85 (d, 2H), 12.1 (broad s, 2H).
(3) Pentafluorophenyl β-[ -((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoate
A solution of p.-[N-((6S)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta-
[g]quinazolin-6-yl)- -(prop-2-ynyl)amino]benzoic acid (0.7 g) in DMA (25 ml) was added to a stirred mixture of pentafluorophenol (1.2 g), N,N-dicyclohexylcarbodiimide
(0.45 g) and DMA (50 ml). The resultant mixture was stirred at 50°C for 18 hours. The mixture was evaporated and the residue was purified by column chromatography using initially a 40:1 and then a 20:1 mixture of methylene chloride and methanol as eluant.
There was thus obtained pentafluorophenyl p.-[N-((6S)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)-amino]benzoate as a solid
(0.57 g); NMR Spectrum: (CD3SOCD3) 2.2 (m, 2H), 2.35 (s, 3H), 3.05 (m, 2H), 3.2 (s, IH),
3.95 (m, IH), 4.2 (m, IH), 5.9 (t, IH), 7.05 (d, 2H), 7.5 (s, IH), 7.8 (s, IH),
8.05 (d, 2H).
Example 6 : Pentafluorophenyl 5-[]__-methyl-N-((6RS)-2-methyl-4-oxo-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylate
(1) Methyl 5-[N-(tert-butoxycarbonyl)-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2- carboxylate
A solution of methyl 5-[N-(tert-butoxycarbonvl amino]pyridine-2-carboxylate (J. Med. Chem.. 1991, 1594; 0.32 g) in DMA (10 ml) was added dropwise to a stirred suspension of sodium hydride [60% dispersion in mineral oil, 0.051 g, from which the oil was removed using hexane] in DMA (5 ml). The mixture was stirred at ambient temperature for 30 minutes. This mixture was added dropwise to a stirred solution of 6-bromo-2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-4-one (0.5 g), prepared as described in section 6 of Example 1, in DMA (10 ml) which had been cooled to -10°C. The resultant mixture was stirred at ambient temperature for 18 hours. The mixture was evaporated and the residue was partitioned betwen ethyl acetate and water. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate to give methyl 5-[N-(tert-butoxycarbonyl)- H-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)amino]pyridine-2-carboxylate as a gum (0.3 g).
(2) Methyl 5-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylate
A mixture of methyl 5 - [N-ftert-butoxycarbony 1)-N-((6RS V2-methy l-4-oxo-3 - pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine- 2-carboxylate (0.3 g) and trifluoroacetic acid (10 ml) was stirred at ambient temperature for 1 hour. The mixture was evaporated and the residue was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluant. There was thus obtained methyl 5-[H-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6jH-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylate (0.24 g);
NMR Spectrum: (CDC13) 1.2 (s, 9H), 2.02 (m, IH), 2.52 (m, IH), 2.64 (s, 3H), 3.12 (m, 2H), 3.98 (s, 3H), 4.56 (d, IH), 5.15 (2 d's, IH), 6.1 (2 d's, 2H), 7.02 (2 d's, IH), 7.5 (s, IH), 8.0 (d, IH), 8.18 (d, IH), 8.22 (s, IH).
(3) Methyl 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy-methyl-3, 4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-amino]pyridine-2-carboxylate
A mixture of methyl 5-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy-methyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- pyridine-2-carboxylate (0.24 g), an aqueous solution of formaldehyde (37% weight/volume, 0.52 ml) and glacial acetic acid (5 ml) was stirred at ambient temperature for 30 minutes. Sodium cyanoborohydride (0.05 g) was added portionwise during 5 minutes and the mixture was stirred at ambient temperature for 30 minutes. The mixture was poured onto a mixture of ice and water (20 ml) and extracted with ethyl acetate. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using ethyl acetate as eluant. There was thus obtained methyl 5-[N-methyl-N_-((6RS)-2- methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)amino]pyridine-2-carboxylate as a gum (0.185 g);
NMR Spectrum: (CDC13) 1.22 (s, 9H), 2.15 (m, IH), 2.57 (m, IH), 2.64 (s, 3H), 2.82 (s, 3H), 3.13 (m, 2H), 3.98 (s, 3H), 5.65 (t, IH), 6.1 (2 d's, 2H), 7.15 (2 d's, IH), 7.52 (s, IH), 8.03 (d, IH), 8.06 (s, IH), 87.35 (d, IH).
(4) 5-[N-Methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)amino]pyridine-2-carboxylic acid
A mixture of methyl 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2- carboxylate (0.185 g), sodium hydroxide (0.06 g), water (2 ml) and methanol (10 ml) was stirred at ambient temperature for 18 hours. The mixture was evaporated. Water (20 ml) was added and the mixture was acidified to pH 5 by the addition of 2N aqueous hydrochloric acid. The precipitate was isolated, washed with water and dried under vacuum. There was thus obtained 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylic acid (0.01 g).
(5) Pentafluorophenyl 5-[ -methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylate
A mixture of 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylic acid (0.01 g), pentafluorophenyl trifluoroacetate (0.16 g; prepared by the reaction of pentafluorophenol and trifluoroacetic acid), pyridine (0.045 g) and DMA (5 ml) was stirred at ambient temperature for 5 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluant. There was thus obtained pentafluorophenyl 5-[N_-methyl- H-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- pyridine-2-carboxylate as a foam (0.1 g);
NMR Spectrum: (CD3SOCD3) 2.1 (m, IH), 2.35 (s, 3H), 2.55 (m, IH), 2.81 (s, 3H), 3.1 (m, 2H), 5.98 (t, IH), 7.48 (2 d's, IH), 7.5 (s, IH), 7.75 (s, IH), 8.14 (d, IH), 8.57 (d, H). 12.19 (s. IH).
(4) 5-[N-Methyl-M-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)amino]pyridine-2-carboxylic acid
A mixture of methyl 5-[ -methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2- carboxylate (0.185 g), sodium hydroxide (0.06 g), water (2 ml) and methanol (10 ml) was stirred at ambient temperature for 18 hours. The mixture was evaporated. Water (20 ml) was added and the mixture was acidified to pH 5 by the addition of 2N aqueous hydrochloric acid. The precipitate was isolated, washed with water and dried under vacuum. There was thus obtained 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylic acid (0.01 g).
(5) Pentafluorophenyl 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylate
A mixture of 5-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]pyridine-2-carboxylic acid (0.01 g), pentafluorophenyl trifluoroacetate (0.16 g; prepared by the reaction of pentafluorophenol and trifluoroacetic acid), pyridine (0.045 g) and DMA (5 ml) was stirred at ambient temperature for 5 hours. The mixture was evaporated and the residue was partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of ethyl acetate and methanol as eluant. There was thus obtained pentafluorophenyl 5-[N-methyl-N- ((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]qUinazolin-6-yl)amino]- pyridine-2-carboxylate as a foam (0.1 g); NMR Spectrum: (CD3SOCD3) 2.1 (m, IH), 2.35 (s, 3H), 2.55 (m, IH), 2.81 (s, 3H), 3.1 (m, 2H), 5.98 (t, IH), 7.48 (2 d's, IH), 7.5 (s, IH), 7.75 (s, IH), 8.14 (d, IH), 8.57 (d, H). 12.19 (s. IH).
Example 7 : Pentafluorophenyl 5-[ -((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-M-(prop-2-ynyl)amino]- pyridine-2-carboxylate
(1) Methyl 5-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]-pyridine-2-carboxylate
A solution of potassium tert-butoxide (8.6 g) in a mixture oftert-butanol (100 ml) and DMA (100 ml) was added dropwise during 20 minutes to a stirred solution of a mixture of 6-bromo-2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetr--hydro-6H- cyclopenta[g]quinazolin-4-one (30 g), prepared as described in section (6) of Example 1 , and methyl 5-[N-(prop-2-ynyl)amino]- pyridine-2-carboxylate [14.5 g; obtained in quantitative yield by treating methyl 5-[N-(tert-butoxycarbonyl)- N-(prop-2-ynyDamino]pyridine-2-carboxvlate CJ. Med. Chem.. 1991, 1594) with trifluoroacetic acid at 0°C for 1 hour] in DMA (300 ml) which had been cooled to -20 "C. The mixture was allowed to warm to ambient temperature and was stirred for 24 hours. The mixture was evaporated. A mixture of ice and water (1 L) was added to the residue and the mixture was extracted with ethyl acetate. The organic phase was dried (MgS04) and evaporated. The residue was purified by column chromatography using initially increasingly polar mixtures of hexane and ethyl acetate and then a 19:1 mixture of methylene chloride and methanol as eluant. There was thus obtained methyl 5-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)-amino]pyridine-2-carboxylate (10.1 g); NMR Spectrum: (CDCI3) 1.2 (s, 9H), 2.25 (t, IH), 2.35 (m, IH), 2.6 m, IH), 2.65 (s, 3H), 3.1 (m, IH), 3.3 (m, IH), 3.88 (2 d's, IH), 3.98 (s, 3H), 4.03 (2 d's, IH), 5.65 (t, IH), 6.1 (2 d's, 2H), 7.3 (2 d's, IH), 7.55 (s, IH), 8.08 (d, IH), 8.1 (s, IH),
8.4 (s, IH).
(2) 5-[ -((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)-N_-( rop-2-ynyl)amino]pyridine-2-carboxylic acid
A mixture of methyl 5-H-((6RS)-2-methyl-4-oxo-3-pivaloyloxy-methyl-3, 4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]pyridine-2- carboxylate (1 g), sodium hydroxide (0.32 g), water (10 ml) and methanol (30 ml) was stirred at ambient temperature for 24 hours. The mixture was evaporated. Water
(60 ml) was added and the mixture was acidified to pH 5 by the addition of 2N aqueous hydrochloric acid. The precipitate was isolated, washed with water and dried under vacuum. There was thus obtained 5-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]pyridine-2-carboxylic acid (0.68 g);
NMR Spectrum: (CD3SOCD3) 2.25 (m, IH), 2.3 (s, 3H), 2.5 (m, IH), 3.0 (s, IH),
3.05 (m, 2H), 3.9 (2 d's, IH), 4.15 (2 d's, IH), 5.8 (t, IH), 7.4 (2 d's, IH), 7.5 (s, IH), 7.8 (s, IH), 7.9 (d, IH), 8.35 (d, IH).
(3) Pentafluorophenyl 5-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]- pyridine-2-carboxylate
Using an analogous procedure to that described in section (5) of Example 6, 5-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)- N-(prop-2-ynyl)amino]pyridine-2-carboxylic acid was reacted with pentafluorophenyl trifluoroacetate to give pentafluorophenyl 5-[N-((6RS)-2-methyl-4-oxo-3, 4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]-pyridine-2- carboxylate as a foam. Examcie . : (2S)-2- {o-Fluoro-r_-[ -methyl-N-((6RS)-2-methyl-4-oxo-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]-benzamido}-2-[p-(carboxy- methyl)phenyl]acetic acid
(1) α-tert-Butoxycarbonylamino-p-hydroxyphenylacetic acid To an aqueous solution of L(+)-α-amino-p-hydroxyphenylacetic acid
(10 g, 60 mmol) and NaHCθ3 (5.1 g, όOmrnol) in 80 ml of water was added dropwise a solution of di-tert-butyl-di-carbonate (14.4 g, 66 mmol) in 80 ml of dioxane. Stirring was maintained for 24 hours. The reaction mixture was then diluted with water and extracted with ether. The aqueous layers were acidified (pH 2.5) with 6N HCI and extracted with ether. The resulting ether layers were washed with brine, dried (MgSθ4) and evaporated to give α-tert-butoxycarbonylamino-p-hydroxyphenylacetic acid (17 g) as a white foam in quantitative yield.
(2) Methyl α-tert-butoxycarbonylamino-p-hydroxyphenylacetate Diazomethane was bubbled through a solution of α-tert-butoxycarbonylamino- β-hydroxyphenylacetic acid (17 g, 60 mmol) in 200 ml of ether cooled to 0°C until a yellow colour appeared when the excess of diazomethane was immediately destroyed with acetic acid. The solution was evaporated to dryness. Trituration of the resulting crude oil with hexane/ether gave methyl α-tert-butoxycarbonylamino-p-hydroxyphenyl acetate (14.8 g, 94%) as a white solid, m.p. 138-139.4°C; NMR Spectrum: (CDC13) 1.68 (s, 9H), 3.7 (s, 3H), 5.2 (d, IH), 5.5 (m, IH), 5.8 (s, IH), 6.74 (d, 2H), 7.2 (d, 2H).
(3) Methyl α-tert-butoxycarbonylamino-p-trifluoromethanesulphonyloxyphenyl- acetate
To a solution of methyl α-tert-butoxycarbonylamino-p-hydroxyphenylacetate (14.3 g, 51 mmol) in 50 ml of pyridine cooled to 0°C under stirring was added dropwise trifluoromethanesulphonic acid anhydride (15.8 g, 56 mmol). Stirring was maintained for 6 hours. The red solution was diluted with water and extracted with ether. The organic layers were washed in turn with IN HCI, water and brine, dried (MgSO4), filtered and evaporated to give an oil which after trituration with hexane crystallized to give methyl α-tert-butoxycarbonylamino-p-trifluoromethanesulphonyloxyphenyl- acetate (19.3 g, 92%) as a white solid, m.p. 67-67.6°C; NMR Spectrum: (CDC13) 1.4 (s, 9H), 3.74 (s, 3H), 5.35 (s, IH), 5.7 (s, IH), 7.25 (d, 2H).
(4) Methyl p-allyl-α-tert-butoxycarbonylaminophenylacetate
To a solution of methyl α-tert-butoxycarbonylamino-p-trifluoromethane- sulphonyloxyphenylacetate (8.26 g, 20 mmol) in DMF (60 ml) was added under stirring LiCI (2.1 g, 50 mmol) and tributyl tin allyl (7.6 g, 23 mmol). The flask was purged six times with argon.
Figure imgf000049_0001
was added rapidly to the reaction mixture and after purging the flask twice more with argon the reaction mixture was heated at 100° C for 90 minutes. After evaporation of the DMF, the green oil was diluted with water and extracted with ether. The organic layers were washed with water and brine, dried and evaporated to give a yellow oil (17 g). Purification by flash chromatography gave methyl p-al lyl- α -tert-butoxy carbonylaminophenvlacetate (4.95 g, 81%) as a yellow oil which crystallized when triturated with hexane, m.p. 60.6-62 °C; NMR Spectrum: (CDCI3) 1.42 (s, 9H), 3.36 (s, 2H), 3.7 (s, 3H), 5.05 (m, 2H), 5.3 (d, IH), 5.5 (m, IH), 5.95 (m, IH), 7.15 (d, 2H), 7.25 (d, 2H).
(5) Methyl α-tert-butoxycarbonylamino-p-carboxymethylphenylacetate
To a solution of methyl p-allyl-α-tert-butoxycarbonylamino- phenylacetate (2.44 g, 8 mmol) in acetonitrile (20 ml) and carbon tetrachloride (20 ml) was added under stirring 30 ml of water followed by NaIO4 (6.8 mg, 0.032 mmol) and RUO2.IH2O (50 mg). After 6 hours stirring 0.5 ml of methanol was added and stirring was maintained for a further 10 minutes. The reaction mixture was diluted with water, acidified to pH 3 and extracted with dichloromethane. The organic layers were dried (MgSU4) and evaporated to give a grey solid which was further purified by acid/base extraction to give methyl α-tert-butoxycarbonylamino-p-carboxymethylphenylacetate (1.37 g, 53%) as a white solid, m.p. 123.2-124°C;
NMR Spectrum: (CDC13) 1.42 (s, 9H), 3.63 (s, 2H), 3.71 (s, 3H), 5.31 (d, IH), 5.55 (s, IH), 7.2-7.4 (m, 4H).
(6) Methyl α-tert-butoxycarbonylamino-p-methoxycarbonylmethylphenylacetate Diazomethane was bubbled through a solution of methyl α-tert-butoxycarbonyl- amino-p-carboxymethylphenylacetate (2.75 g, 8.5 mmol) in 50 ml of ether and 10 ml of CH2CI2 at 0βC until a yellow colour appeared. The solution was then evaporated to dryness to give methyl α-tert-butoxycarbonylamino-p-methoxycarbonylmethylphenyl- acetate (2.9 g, 100%) as a yellow oil which crystallized on standing; NMR Spectrum: (CDCI3) 1.45 (s, 9H), 3.61 (s, 2H), 3.69 (s, 3H), 3.71 (s, 3H), 5.3 (s, IH), 5.55 (s, IH), 7.3 (d, 2H), 7.4 (d, 2H).
(7) Methyl α-amino-j>-methoxycarbonylmethylphenylacetate To a solution of methyl α-tert-butoxycarbonylamino-p-methoxvcarbonylmethyl- phenylacetate (2.86 g, 8.5 mmol) in CH2CI2 (10 ml) cooled at 0°C was added 10 ml of TFA. After stirring for 1 hour at room temperature the reaction mixture was evaporated to dryness. The resulting solid was dissolved in ethyl acetate and water and the pH was adjusted to 8 with NaHCθ3- After extraction with ethyl acetate the organic layers were washed with brine, dried and evaporated to give a yellow oil. After dissolution of this oil in a mixture of etheπmethanol (10:1 v/v) a saturated solution of HCI in ether was added to give, after filtration, methyl α-amino-rj-methoxycarbonyl-methylphenylacetate (2.2 g, 96%) as a white solid, m.p. 189.2-189.6°C; NMR Spectrum: (DMSO) 3.6 (s, 3H), 3.7 (s, 5H), 5.26 (s, IH), 7.35 (s, 2H), 7.45 (s, 2H), 9.0 (s, 2H). (8) (RS)-α-Amino-r_-carboxymethylphenylacetic acid
A suspension of methyl α-amino-β-methoxycarbonylmethylphenylacetate (2.3 g, 7 mmol) in 60 ml of 6N HCI was refluxed for 12 hours. After cooling white needles were collected. The aqueous layers were extracted with ethyl acetate. The organic layers were evaporated and the solids combined to give (RS)-α-amino-r_,-carboxymethylphenylacetic acid (1.45 g, 83%); NMR Spectrum: (DMSO/TFA) 3.6 (s, 3H), 5.1 (s, IH), 7.3 (d, 2H), 7.45 (d, 2H).
(9) (S)-α-Amino-rj-carboxymethylphenylacetic acid
To a suspension of (RS)-α-amino-β-carboxymethylphenylacetic acid (3.2 g, 15 mmol) in 50 ml of water was added S(-)phenylethylamine (1.85 g, 15 mmol) dropwise. The resulting solution was left standing overnight at room temperature. The resulting crystals were filtered off, washed with cold water and dried to give a solid (2.3 g). The solid was recrystallized with 30 ml of water. After standing overnight the resulting solid was filtered off. It was then dissolved in 2N HCI (3 equivalents) and 2 equivalents of propylene oxide were added to the solution with stirring. After 30 minutes cooling at 0°C, filtration gave (S)-α-amino-p-carboxymethyl- phenylacetic acid as a solid, m.p. 250-250.4;
NMR Spectrum: (DMSO/TFA) 3.6 (s, 2H), 5.15 (s, IH), 7.35 (d, 2H), 7.45 (d, 2H). Optical Activity: (IN HCI) [α]2 } 5" + 106.7° (c = 1).
(10) (2S)-2- {o-Fluoro-E-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}- 2-[β-(carboxymet-ιyl)phenyl]acetic acid
To a solution of (S)-α-amino-g-carboxymethylphenylacetic acid (0.1 g, 0.48 mmol) and pentafluorophenyl o-fluoro-r [N-methyl-N-((6RS)-2-methyl-4- oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzoate (0.213 g, 0.4 mmol), prepared as described in Example 2, in 5 ml of DMF was added bistrimethyl silyl acetamide (BSA) (0.194 g, 0.96 mmol). After stirring under N2 for 20 minutes N-methylmorpholine was added (0.081 g, 0.8 mmol) followed by N-hydroxybenzotriazole (HOBT) (0.01 g). The reaction mixture was stirred at room temperature for 4 hours and evaporated to dryness. The solid obtained by trituration with ether and filtration was resuspended in a mixture of methanol/water (2 ml) and the pH adjusted to 2.5 with 2N HCI. The resulting precipitate was filtered off, washed with water and dried to give (2S)-2-{β-fluoro-E-[N-methyl-K-((6RS)-2-methyl-3- pivaloyloxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzamido}-2-[E-(carboxymethyl)phenyl]acetic acid (140 mg, 64%) as a yellow solid; NMR Spectrum: (DMSO/TFA) 1.14 (s, 9H), 2-2.15 (m, IH), 2.5 (m, IH), 2.65-2.8 (m, 6H), 3-3.1 (m, IH), 3.15-3.25 (m, IH), 3.55 (s, 2H), 5.55 (s, IH), 5.8 (t, IH), 6.1 (q, 2H), 6.8-6.95 (m, 2H), 7.25 (d, 2H), 7.4 (d, 2H), 7.6 (s, IH), 7.65 (t, IH), 7.8 (s, IH).
(11) (2S)-2-{o-Fluoro-r_-[N-rnethyl-l_.-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-2-[β-(carboxymethyl)phenyl]- acetic acid A solution of (2S)-2-{β-fluoro-r2-[N-methyl-N-((6RS)-2-methyl-3-ρivaloyloxy- methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}- 2-[rj-(carboxymethyl)phenyl]acetic acid (0.14 g, 0.2 mmol) in 1 ml of methanol containing 0.6 ml of IN NaOH was stirred for 90 minutes at room temperature. After dilution with water and filtration the pH was adjusted to 2.5 with 2N HCI. The resulting solid was filtered off, washed with water, dried and triturated with ether to give (2S)-2-{o-fluoro-β-[N-me yl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)amino]benzamido}-2-[rj-(carboxymethyl)phenyl]acetic acid (0.103 g, 93%) as a white solid, m.p. 196-200°C; NMR Spectrum: (DMSO/TFA) 2.05-2.2 (m, IH), 2.5 (m, IH), 2.66 (s, 3H), 2.68 (s, 3H), 3-3.15 (m, IH), 3.2-3.3 (m, IH), 3.58 (s, 2H), 5.5 (s, IH), 5.87 (t, IH), 6.8-6.9 (m, 2H), 7.3 (d, 2H), 7.45 (d, 2H), 7.65 (s, IH), 7.68 (t, IH), 7.78 (s, IH). Mass Spectrum: (FAB) 559 [(M+H)+], 581 [(M+Na)+]. Elemental Analysis: Found C, 62.9; H, 5.2; N, 9.9;
C30H27FN4°6 H2° requires C, 62.5; H, 5.07; N, 9.7.
The enantiomeric purity as measured by chiral HPLC was 95% (2S): 5% (2R).
Example 9 : (2R)-2-{o-Fluoro-E-[H-methyl-N-((6RS)-2-methyl-4-oxo-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-2-[2-(carboxy- methyl)phenyl]acetic acid
(1) (R)-α-Amino-p.-carboxymethylphenylacetic acid
To a suspension of (RS)-α-amino-j carboxymethylphenylacetic acid
(5.4 g, 26 mmol), prepared as described in Example 8(8), in 23 ml of water was added R(+)phenylethylamine (3.13 g, 26 mmol) dropwise. The resulting solution was left standing overnight at room temperature. The crystals were then filtered off, washed with cold water and dried to give a solid (2.5 g). The solid was recrystallized with 32 ml of water. After standing overnight the resulting solid was filtered off. It was then dissolved in 2N HCI (3 equivalents) and 2 equivalents of propylene oxide were added to the solution with stirring. After 2 hours cooling at 0°C, filtration gave
(R)-α-amino-r carboxymethylphenylacetic acid (1.2 g, 44%) as a solid, m.p.
249-250°C;
NMR Spectrum: (DMSO/TFA) 3.6 (s, 2H), 5.15 (s, IH), 7.35 (d, 2H), 7.45 (d, 2H).
Optical Rotation: (IN HCI) [α]2 ) 5"- 107.5° (c=l).
(2) (2R)-2-{o-Fluoro-E-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}- 2- [p-(carboxymethyl)phenyl] acetic acid
A solution of (R)-α-amino-p.-carboxymethylphenylacetic acid (0.1 g, 0.48 mmol) and bis trimethylsilyl acetamide (0.195 g, 0.96 mmol in 5 ml of DMF) was stirred for 20 minutes at room temperature. To the solution was then added pentafluorophenyl o.-fluoro-p.-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivalyloxymethyl-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]benzoate (0.213 g, 0.4 mmol), prepared as described in Example 2, followed by N-hydroxybenzotriazole (10 mg) and the stirring was maintained for a further 5 hours. The reaction mixture was then evaporated to dryness and the crude material redissolved in ether. The ether layers were extracted with NaHCO3- The aqueous layers were acidified to pH 2.5 with 2N HCI and the precipiate was filtered off, washed with water and dried under vacuum to give (2R)-2-{fi-fluoro-r2-[M-methyl-H-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-2-[E-(carboxy- methyl)phenyl]acetic acid (0.19 g), 85%) as a white solid; NMR Spectrum: (DMSO) 1.13 (s, 9H), 2-2.15 (m, IH), 2.5 (m, IH), 2.6 (s, 3H), 2.7 (s, 3H), 2.95-3.05 (m, IH), 3.1-3.2 (m, IH), 3.55 (s, 2H), 5.5 (d, IH), 5.8 (t, IH), 6.05 (q, 2H), 6.8-6.9 (m, 2H), 7.25 (d, 2H), 7.4 (d, 2H), 7.55 (s, IH), 7.65 (t, IH), 7.72 (s, IH), 8.15 (t, IH).
(3) (2R)-2-{β-Fluoro-rj-[H-methyl-H-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-2-[p.-(carboxymethyl)phenyl]- acetic acid
A suspension of (2R)-2- {o.-fluoro-rj-[N-methyl-N-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzamido}-2-[β-(carboxymethyl)phenyl]- acetic acid (0.190 g, 0.34 mmol) in 1.5 ml of methanol containing 1 ml of IN NaOH was stirred at room temperature for 90 minutes. After dilution with water the pH was adjusted to 2.5 with 2N HCI. The precipitate was filtered off, washed with water and dried under vacuum to give (2R)-2-{β-fluoro-rj- |Ji-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)amino]benzamido}-2-[β-(carboxymethyl)phenyl]acetic acid (0.135 g, 71%) as a white solid, m.p. 195-198°C; NMR Spectrum: (DMSO/TFA) 2.05-2.15 (m, IH), 2.5 (m, IH), 2.66 (s, 3H),
2.68 (s, 3H), 3.0-3.15 (m, IH), 3.2-3.3 (m, IH), 3.58 (s, 2H), 5.52 (s, IH), 5.85 (t, IH), 6.8-6.9 (m, 2H), 7.25 (d, 2H), 7.45 (d, 2H), 7.65 (s, IH) 7.68 (t, IH), 7.78 (s, IH). Mass Spectrum: (FAB) 559 [(M+H)+], 581 [(M+Na)+]. Elemental Analysis: Found C, 62.2; H, 5.08; N, 9.79; C30H27FN4O6 1.1 H2O requires C, 62.3; H, 5.09; N, 9.69. Enantiomeric purity as measured by chiral HPLC was 91% (2R): 9% (2S).
Example 10 : (2S)-2-{( Fluoro-p-D^-methyl-E-((6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido } -4-(2-carboxymethyl- tetrazol-5-yl)butyric acid
(1) Methyl (2S)-2-benzyloxycarbonylamino-4-cyanobutyrate
A solution of N-benzyloxycarbonyl-L-glutamine methyl ester (25 g) in THF (500 ml) was added dropwise to a stirred solution of triphenylphosphine (44.5 g) in carbon tetrachloride (1 L). The mixture was heated to 50 °C for 2 hours. The mixture was evaporated. The resultant oil was triturated in ethyl acetate. The mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatogaphy using a 1 : 1 mixture of hexane and ethyl acetate as eluant. There was thus obtained methyl (2S)-2-benzyloxycarbonylamino-4-cyanobutyrate (19.38 g, 83%).
(2) Methyl (2 S)-2-benzyloxycarbonylamino-4-(tetrazol-5-yl)butyrate
A mixture of methyl (2S)-2-benzyloxycarbonylamino-4-cyanobutyrate (10 g), tri-n-butyltin azide [prepared according to the method in Rec. Trav. Chim. Pavs-Bas.
1963, 81, 286; 12 g] and THF (60 ml) was stirred and heated to reflux for 40 hours.
The mixture was evaporated. The resultant brown oil was triturated in diethyl ether which had been saturated with hydrogen chloride gas. The precipitate was isolated and washed with diethyl ether. There was thus obtained methyl (2S)-2-benzyloxycarbonyl- amino-4-(tetrazol-5-yl)butyrate (2.23 g, 32%);
NMR Spectrum: (CD3SOCD3) 1.95-2.35 (m, 2H), 2.95 (t, 2H), 3.64 (s, 3H),
4.15 (m, IH), 5.04 (s, 2H), 7.36 (s, 5H), 7.88 (d, IH), 13.0 (s, IH). (3) Methyl (2S)-2-(benzyloxycarbonylamino)-4-(2-methoxycarbonylmethyltetrazol- 5-yl)butyrate and
Methyl (2S)-2-(benzyloxycarbonylamino)-4-(l-methoxycarbonylmethyltetrazol- 5-yl)butyrate To a stirred solution of methyl bromoacetate (2.45 g, 16.0 mmol) in anhydrous dichloromethane (35 ml) under argon was added methyl (2S)-2-(benzyloxycarbonyl- amino)-4-(tetrazol-5-yl)butyrate (2.55 g, 8.0 mmol) and then triethylamine (0.970 g, 9.6 mmol). The resultant solution was stirred at room temperature for 3 hours, then diluted with ethyl acetate (200 ml) and washed with saturated aqueous sodium bicarbonate (2 x 150 ml) and water (150 ml), dried (Na2SO4) and concentrated. Purification by column chromatography, on gradient elution with ethyl acetate in dichloromethane (20 to 40%), gave in order of elution:
(a) Methyl (2S)-2-(benzyloxycarbonylamino)-4-(2-methoxycarbonylmethyltetrazol- 5-yl)butyrate (0.95 g, 30%) as a colourless oil; NMR Spectrum: (CD3SOCD3) 1.98-2.20 (m, 2H, 3-CH2),
2.95 (t, J = 7.0 Hz, 2H, 4-CH2), 3.64, 3.72 (2 x s, 6H, 2 x CO2CH3), 4.15 (m, IH, 2-CH), 5.05 (s, 2H, PhCH2), 5.79 (s, 2H, CH2C02CH3), 7.36 (m, 5H, ArH), 7.92 (d, J = 7.8 Hz, 1 H, CONH). Mass Spectrum: (Cl) m/e 392 [(M+H)+]. Elemental Analysis: Found C, 52.02; H, 5.46; N, 17.65; C17H21N5°6 requires C, 52.17; H, 5.41; N, 17.89%.
(b) Methyl (2S)-2-(benzyloxycarbonylamino)-4-( 1 -methoxycarbonylmethyltetrazol- 5-yl)butyrate (1.55 g, 49%) as a white solid, m.p. 91-94°C. NMR Spectrum: (CD3SOCD3) 1.95-2.18 (m, 2H, 3-CH2), 2.92 (m, 2H, 4-CH2),
3.64, 3.72 (2 x s, 6H, 2 x C02CH3), 4.24 (m, IH, 2-CH), 5.05 (s, 2H, PhCH2),
5.51 (s, 2H, CH2C02CH3), 7.36 (m, 5H, ArH), 7.87 (d, J = 7.9 Hz, IH, CONH).
Mass Spectrum: (Cl) m/e 392 [(M+H)+].
Elemental Analysis: Found C, 52.13; H, 5.43; N, 17.64; C17H2ιN5O6 requires C, 52.17; H, 5.41 ; N, 17.89%. (4) Methyl (2S)-2-amino-4-(2-methoxycarbonylmethyltetrazol-5-yl)butyrate To a solution of methyl (2S)-2-(benzyloxycarbonylamino)-4-(2-methoxy- carbonylmethyltetrazol-5-yl)butyrate (0.820 g, 2.10 mmol) in ethyl acetate (100 ml) was added 10% Pd/C (0.220 g). The black reaction mixture was stirred at room temperature for 15 hours under a hydrogen atmosphere. The catalyst was removed by filtration and the filtrate was concentrated to give methyl (2S)-2-amino-4-(2-methoxycarbonylmethyl- tetrazol-5-yl)butyrate (0.410 g, 76%) as a colourless oil. This was immediately used in section (5) below without further purification.
(5) Methyl (2S)-2- {Q-fluoro-ι.-[H-methyl-H-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-4-
(2-methoxycarbonylmethyltetrazol-5-yl)butyrate
To a stirred solution of methyl (2S)-2-amino-4-(2-methoxycarbonylmethyl- tetrazol-5-yl)butyrate (74 mg) in anhydrous DMF (1.2 ml) under argon was added pentafluorophenyl o-fiuoro-r [N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxy- methyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoate (129 mg), prepared as described in Example 2, followed by a catalytic amount of N-hydroxybenzotriazole (2.8 mg). The resultant yellow solution was stirred at room temperature for 16 hours under argon and then partitioned between ethyl acetate (50 ml) and water (40 ml). The two layers were separated and the organic layer was washed with saturated aqueous sodium bicarbonate (40 ml) and water (40 ml), dried (Na2SO4), and concentrated. Purification by column chromatography on gradient elution with ethyl acetate in dichloromethane (50 to 60%) afforded a gum which was triturated with hexanes. The precipitated solid was collected by filtration and washed with hexanes (10 ml). There was thus obtained methyl (2S)-2-{o-fluoro-rj-fJ_.-methyl- N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)amino]benzamido}-4-(2-methoxycarbonylmethyltetrazol-5-yl)- butyrate (103 mg) as a white solid, m.p. 86-88 °C (softens); NMR Spectrum: (CD3SOCD3) 1.13 (s, 9H, C(CH3)3), 2.10, 2.25, 2.45 (3 x m, 4H, 3-CH2 and cyclopenta[g]quinazoline 7-CH2), 2.59, 2.66 (2 x s, 6H, cyclopenta[g]quinazoline 2-CH3 and N-CH3), 2.95-3.22 (m, 4H, 4-CH2 and cyclopenta[g]quinazoline 8-CH2), 3.66, 3.72 (2 x s, 6H, 2 x CO2CH3), 4.53 (m, 1 H, 2-CH), 5.79 (m, 2H, CH2CO2CH3) and cyclopenta[g]quinazoline 6-CH), 6.03 (ABq, J = 10.9 Hz, 2H, (CH3)3CC02CH ), 6.82 (d, J = 13.9 Hz, IH, 3'-ArH), 6.86 (d, J = 7.4 Hz, IH, 5'-ArH), 7.53 (s, IH, cyclopenta[g]quinazoline 9-H), 7.59 (t, J = 8.9 Hz, IH, 6'-ArH), 7.72 (s, IH, cyclopenta[g]quinazoline 5-H), 8.26 (dd, J = 4.4, 11.6 Hz, IH, CONH). Mass Spectrum: fESD m/e 721 frM+Hri.
(6) (2S)-2-{o-Fluoro-rj-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-4-(2-carboxymethyltetrazol-5-yl)- butyric acid
To a solution of methyl (2S)-2-{o-fluoro-β-[ -methyl-N-((6RS)-2-methyl-4- oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzamido}-4-(2-methoxycarbonylmethyltetrazol-5-yl)butyrate (87 mg) in methanol (2 ml) was slowly added an aqueous solution of NaOH (IN, 0.72 ml). The resultant solution was stirred at room temperature for 4 hours then more aqueous IN NaOH (0.36 ml) was added and stirring was continued at room temperature for 1 hour. Next the solution was diluted with water (3 ml) and acidified to pH 4 with IN hydrochloric acid. The precipitated solid was collected by filtration, washed with water (15 ml), and dried in vacuo over phosphorus pentoxide. There was thus obtained (2S)-2-{o-fluoro-p- rN-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6- yl)-amino]benzamido}-4-(2-carboxymethyltetrazol-5-yl)butyric acid (57 mg) as a pale yellow solid, m.p. 196-199°C;
NMR Spectrum: (CD3SOCD3) 2.03, 2.25, 2.44 (3 x m, 4H, 3-CH2 and cyclopenta[g]quinazoline 7-CH2), 2.33, 2.66 (2 x s, 6H, cyclopenta[g]quinazoline 2-CH3 and N-CH3), 2.92-3.22 (m, 4H, 4-CH2 and cycloρenta[g]quinazoline 8-CH2), 4.46 (m, IH, 2-CH), 5.54 (s, 2H, CH2CO2CH3), 5.79 (t, J = 7.9 Hz, IH, cyclopenta[g]quinazoline 6-CH), 6.88 (m, 2H, 3',5'-ArH), 7.48 (s, IH, cyclopenta[g]quinazoline 9-H), 7.62 (t, J = 8.9 Hz, IH, 6'-ArH), 7.68 (s, IH, cyclopenta[g]quinazoline 5-H), 8.08 (t, J = 6.9 Hz, IH, CONH), 12.17 (s, lH, lactam NH).
Mass Spectrum: (ESI) m/e 579 [(M+H)+].
Elemental Analysis: Found C, 53.51; H, 4.82: N, 18.43;
C27H27FN8O6 1.5 H2O requires C, 53.55; H, 4.99; N, 18.50%.
Example 1 1 : (2S)-2-{<2-Fluoro-p-( -methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-4-(l-carboxymethyl- tetrazol-5-yl)butyric acid
( 1 ) Methyl (2S)-2-amino-4-( 1 -methoxycarbonylmethyltetrazol-5-yl)butyrate
The procedure described in section (4) of Example 10 was repeated using methyl (2S)-2-(benzyloxycarbonylamino)-4-(l-methoxycarbonylmethyltetrazol-5-yl)butyrate (0.470 g, 1.20 mmol), prepared as described in section (3) of Example 10, ethyl acetate (55 ml) and 10% Pd/C (0.120 g). There was thus obtained methyl (2S)-2-amino-4- (l-methoxycarbonylmethyltetrazol-5-yl)butyrate (0.310 g, 98%) as a colourless oil. This was immediately used in section (2) below without further purification.
(2) Methyl (2S)-2-{o-fluoro-E-[M-methyl-H-((6RS)-2-methyl-4-oxo-3-pivaloyl- oxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-
4-( 1 -methoxycarbonylmethyltetrazol-5-yl)butyrate
The procedure described in section (5) of Example 10 was repeated using methyl (2S)-2-amino-4-(l-methoxycarbonylmethyl-tetrazol-5-yl)butyrate (64 mg), anhydrous DMF (1.2 ml), pentafluorophenyl o-fluoro-r_-[N-methyl-N-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoate (129 mg), prepared as described in Example 2, and a catalytic amount of N-hydroxybenzotriazole (2.8 mg). The crude product was purified by column chromatography using a gradient of ethyl acetate in dichloromethane (70 to 80%) as eluant. Subsequent reprecipitation from ethyl acetate (3 ml)/hexanes gave a white solid which was collected by filtration and dried in vacuo over phosphorus pentoxide. There was thus obtained methyl (2S)-2-{_^fluoro-β-[N_-methyl-N (6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzamido}-4-(l-methoxycarbonylmethyltetrazol-5-yl)-butyrate (93 mg) as a white solid, m.p. 95 °C (softens);
NMR Spectrum: (CD3SOCD3) 1.12 (s, 9H, C(CH3)3), 2.05, 2.25, 2.44 (3 x m, 4H, 3-CH2 and cyclopenta[g]quinazoline 7-CH2), 2.59, 2.66 (2 x s, 6H, cyclopenta[g]quinazoline 2-CH3 and N-CH3), 2.91-3.20 (m, 4H, 4-CH and cyclopen.a[g]quinazoline 8-CH ), 3.65, 3.71 (2 x s, 6H, 2 x CO2CH3), 4.56 (m, IH, 2-CH), 5.52 (s, 2H, CH2CO2CH3), 5.80 (t, J = 8.0 Hz, IH, cyclopenta[g]quinazoline 6-CH), 6.03 (ABq, J = 10.9 Hz, 2H, (CH3)3C02CH2), 6.84 (m, 2H, 3',5'-ArH), 7.53 (s, IH, cyclopenta[g]quinazoline 9-H), 7.59 (t, J = 9.3 Hz, IH, 6'-ArH), 7.71 (s, IH, cyclopenta[g]quinazoline 5-H), 8.24 (dd, J = 7.3, 12.1 Hz, IH, CONH). Mass Spectrum: (ESI) m/e 721 [(M+H)+].
(3) (2S)-2-{o-Fluoro-E-[N-methyl-N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido}-4-(l-carboxymethyltetrazol-5-yl)- butyric acid
The procedure described in section (6) of Example 10 was repeated using methyl (2S)-2-{o-fluoro-E-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzamido } -4-( 1 -methoxycarbonyl- methyltetrazol-5-yl)butyrate (70 mg), methanol (1.8 ml) and an aqueous solution of NaOH (IN, 0.6 ml). The resultant solution was stirred at room temperature for 4 hours, then more aqueous IN NaOH (0.3 ml) was added and stirring was continued at room temperature for 1 hour. There was thus obtained (2S)-2-{o-fluoro-E-[N-methyl-N- ((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)- amino]benzamido}-4-(l-carboxymethyltetrazol-5-yl)butyric acid (35 mg) as a pale yellow solid, m.p. 232-235 °C.
NMR Spectrum: (CD3SOCD3) 2.04, 2.25, 2.44 (3 x m, 4H, 3-CH2 and cyclopenta[g]quinazoline 7-CH2), 2.33, 2.66 (2 x s, 6H, cyclopenta[g]quinazoline 2-CH3 and N-CH3), 2.92-3.20 (m, 4H, 4-CH2 and cyclopenta[g]quinazoline 8-CH2), 4.51 (m, IH, 2-CH), 5.33 (s, 2H, CH.2CO2CH3), 5.79 (t, J = 8.5 Hz, IH, cyclopenta[g]quinazoline 6-CH), 6.80 (d, J = 15.9 Hz, IH, 3'-ArH), 6.85 (d, J = 8.7 Hz, IH, 5'-ArH), 7.48 (s, IH, cyclopenta[g]quinazoline 9-H), 7.62 (t, J = 9.1 Hz, IH, 6'- ArH), 7.67 (s, IH, cyclopenta[g]quinazoline 5-H), 8.08 (t, J = 7.0 Hz, IH, CONH), 12.15 (s, IH, lactam NH). Mass Spectrum: (ESI) m/e 579 [(M+H)+].
Elemental Analysis: Found C, 54.81; H, 4.86; N, 18.94; C27H27FN806 0.75 H20 requires: C, 54.77; H, 4.81, N, 18.92%.
Example 12: (2RS)-2-{N-{N-{o-Fluoro-r_-[N-methyl-N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoyl}-L-γ-glutamyl}- amino}-2-[β-(carboxymethyl)phenyl]acetic acid
(1) Methyl (2RS)-2-{N-[α-benzyl-N-(tert-butoxycarbonyl)-L-γ-glutamyl]amino}- 2-fe-(methoxycarbonylmethyl)phenyl]acetate
To a solution of α-benzyl N-ftert-butoxycarbonylVL-glutamate (1.35 g, 4 mmol) and methyl α-amino-β-methoxycarbonylmethylphenyl- acetate (1.1 g, 4 mmol), prepared as described in section (7) of Example 8, in 20 ml of CHC13 was added l-ethoxycarbonyl-2-ethoxy- 1 ,2-dihydroquinoline (EEDQ) (1.1 g, 4.4 mmol) and N-methylmorpholine (0.44 g, 4.4 mmol). The reaction mixture was stirred for 48 hours at 4°C. The organic layers were then washed in turn with 2N HCI, saturated NaHCO3, water and brine, then dried (MgSO4). After evaporation of the solvent the resulting oil was crystallized from petroleum ether to give methyl (2RS)-2-{N-[α-benzyl-N-(tert- butoxycarbonyl)-L-γ-glutamyl]amino}-2-[p-(methoxycarbonylmethyl)-phenyl]acetate (1.45 g, 65%) as a white solid. NMR Spectrum: (DMSO Acetic acid) 1.4 (s, 9H), 1.7-1.85 (m, IH), 1.9-2.05 (m, IH), 2.3 (m, 2H), 3.6 (s, 6H), 3.7 (s, 2H), 4.0-4.1 (m, IH), 5.1 (q, 2H), 5.4 (m, IH), 7.25 (d, 2H), 7.3-7.4 (m, 7H).
(2) Methyl (2RS)-2-[N-(α-benzyl-L-γ-glutamyl)amino]-2-[rj-(methoxycarbonyl- methyl)phenyl]acetate
To a solution of methyl (2RS)-2-{M-[α-be__zyl-N-(I§rt-butoxycarbonyl)-L-γ- glutamyl]amino}-2-fe-(methoxycarbonylmethyl)phenyl]acetate (1.35 g, 2.4 mmol) in 5 ml of dichloromethane was added 5 ml of TFA and 0.5 ml of water. After stirring for 1 hour at room temperature the solution was evaporated to dryness and the resulting solid was azeotroped with toluene to give methyl (2RS)-2-[N-(α-benzyl-L-γ-glutamyl)- amino]-2-[β-(methoxycarbonylmethyl)phenyl]acetate (1.4 g) as a gummy solid; NMR Spectrum: (DMSO/TFA) 1.95-2.15 (m, 2H), 2.35-1.55 (m, 2H), 3.6 (s, 6H), 3.7 (s, 2H), 4.15 (m, IH), 5.15-5.3 (m, 2H), 5.4 (m, IH), 7.25-7.45 (m, 9H). Mass Spectrum: (ESI) 457 [(M+H)+].
(3) Methyl (2RS)-2-{N-{N-{o-fluoro-E-[N-methyl-N-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzoyl}-α-benzyl-L-γ-glutamyl}amino}-2-[p.-(methoxycarbonylmethyl)phenyl]- acetate
A mixture of pentafluorophenyl o-fluoro-r2-[N-methyl-N-((6RS)-2-methyl-4- oxo-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta- [g]quinazolin-6-yl)amino]- benzoate (0.093 g, 0.144 mmol), prepared as described in Example 2, methyl (2RS)-2- [N-(α-benzyl-L-γ-glutamyl)amino]-2-[p-(methoxycarbonylmethyl)phenyl]acetate, trifluoroacetic acid salt (0.106 g, 0.186 mmol), triethylamine (0.026 g, 0.26 mmol), N-hydroxybenzotriazole (0.002 g), and dry DMF (1 ml) was stirred under nitrogen at ambient temperature for 17 hours. The resulting solution was evaporated and the residue partitioned between ethyl acetate (20 ml) and saturated aqueous sodium hydrogen carbonate (15 ml). The aqueous layer was extracted with ethyl acetate (3 x 5 ml) and the combined ethyl acetate solution washed with water (5 x 5 ml), dried over magnesium sulphate, and evaporated. The residue was twice redissolved in toluene and evaporated, then purified by silica gel column chromatography using a gradient of ethyl acetate in dichloromethane (0 to 40% ethyl acetate) as eluant. The product was triturated with hexane and the resulting white solid isolated by decanting off the hexane, and dried in vacuo. There was thus obtained methyl (2RS)-2-{H-{N- {2-fluoro-r2-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoyl}-α-benzyl-L-γ-glutamyl}- amino}-2-[β-(methoxycarbonylmethyl)phenyl]acetate (0.078 g, 59%), m.p. 85-90°C; NMR Spectrum: (CD3SOCD3) 1.13 (s, 9H, C(CH3)3), 2.05 (m, 3H, glu β-CH2 and cyclopenta[g]quinazoline 7-H), 2.34 (m, 2H, glu γ-CH2), 2.45 (m, IH, partly obscured, cyclopenta[g]quinazoline 7-H), 2.59 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.66 (s, 3H, N-CH3), 3.07 (m, 2H, cyclopenta[g]quinazoline 8-H), 3.60 (2 x s, 6H, 2 x COOCH3), 3.67 (s, 2H, -C6H4CH2), 4.48 (m, IH, glu α-CH), 5.15 (s, 2H, PhCH2), 5.37 (d, J 6.9 Hz, IH, α'-CH), 5.81 (t, J 8.2 Hz, IH, cyclopenta[g]quinazoline 6-H), 6.04 (m, 2H, cyclopenta[g]quinazoline N3-CH2), 6.84 (m, 2H, 3',5'-ArH), 7.30 (m, 9H, C6H5- and -C6H4-), 7.53 (s, IH, cyclopenta[g]quinazoline 9-H), 7.60 (t, J 9.0 Hz, IH, 6'- ArH), 7.71 (s, IH, cyclopenta[g]quinazoline 5-H), 8.13 (m, IH, glu NH), 8.76 (d, J 6.8 Hz, IH, α'-NH). Mass Spectrum: (ESI) m/e 920 [(M+H)+]. Elemental Analysis: Found C, 65.09; H, 6.06; N, 7.38% C50H54FN5°11 requires C, 65.28; H, 5.92; N, 7.61%.
(4) (2RS)-2-{H-{N-{o-Fluoro-r2-[N-methyl-N-((6RS)-2-methyl-4-oxo-3, 4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoyl}-L-γ-glutamyl}amino}- 2-[] (carboxymethyl)phenyl] acetic acid Aqueous sodium hydroxide solution (IN, 0.72 ml) was added to a solution of methyl (2RS)-2-{H-{N- {o-fl oro-E-[N-methyl-N-((6RS)-2-methyl-4-oxo-3-pivaloyl- oxymethyl-3 ,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoy 1 } - α-benzyl-L-γ-glutamyl}amino}-2-[p.-(methoxycarbonylmethyl)phenyl]acetate (0.066 g, 0.072 mmol) in methanol (3 ml) and the resulting solution was stirred at ambient temperature under argon in the dark for 24 hours. The solution was diluted with water (12 ml), filtered, and concentrated by evaporation to a volume of approximately 7 ml. Further water (3 ml) was added and the solution was acidified to pH 3-4 by dropwise addition of IN aqueous hydrochloric acid with stirring. The resulting suspension was centrifuged and the supernatant removed. The precipitate was washed 3 times with water by resuspension, centrifugation, and removal of the supernatant, then dried in vacuo triturated with diethyl ether and further dried at 70-80°C for 6 hours. There was thus obtained (2RS)-2-{N-{M-{_^fluoro-^Q_J-methyl- N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzoyl}-L-γ-glutamyl}amino}-2-[τ)-(carboxymethyl)phenyl]acetic acid (0.037 g, 72%), m.p. 175-177°C;
NMR Spectrum: (CD3SOCD3) 2.01 (m, 3H, glu β-CH2 and cyclopenta[g]quinazoline 7-H), 2.20-2.60 (m, 6H, partly obscured, glu γ-CH2, cyclopenta[g]quinazoline 2-CH3 and cyclopenta[g]quinazoline 7-H), 2.66 (s, 3H, N-CH3), 3.08 (m, 2H, cyclopenta[g]quinazoline 8-H),
3.55 (s, 2H, -C6H4CH -), 4.37 (m, IH, glu α-CH), 5.27 (d, J 7.3 Hz, IH, α'-CH), 5.79 (t, J 8.1 Hz, IH, cyclopenta[g]quinazoline 6-H), 6.82 (m, 2H, 3',5'-ArH), 7.27 (m, 4H, -C6H4-), 7.48 (s, IH, cyclopenta[g]quinazoline 9-H), 7.63 (m, 2H, 6'- ArH and cyclopenta[g]quinazoline 5-H), 7.90 (m, IH, glu NH), 8.63 (m, IH, α'-NH), 12.17 (s, 1 H, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (ESI) m/e 688 [(M+H)+]. Elemental Analysis: Found C, 58.89; H, 5.25; N, 9.03% C35H34FN5O9 1.8 H20 requires C, 58.38; H, 5.26; N, 9.73%.
Example 13 : N-{E-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-γ-glutamyl-N-methyl-L-glutamic acid
( 1 ) 2-Methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 4,6-dione
70% lert-Butyl hydroperoxide solution (111 ml, 0.81 mol) was added during 3 minutes to a stirred suspension of chromium (VI) oxide (0.59 g, 5.9 mmol) in dichloromethane (232 ml) in a flask fitted with a reflux condenser, whilst cooling the mixture in a bath of water at room temperature. 2-Methyl-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-4-one (36.586 g, 0.116 mol), prepared as described in Example 1 (5), was added in portions during 2 minutes and the mixture was stirred at ambient temperature for 16 hours. It was then cooled to 0°C and 10% aqueous sodium metabisulphite solution (195 ml) was added at such a rate that the temperature did not exceed 10°C. The resulting mixture was allowed to warm to room temperature and stirred for 2 _ hours. It was then partitioned between ethyl acetate (400 ml) and half-saturated brine (300 ml). The aqueous layer was extracted with ethyl acetate (2 x 150 ml) and the combined organic solution was washed successively with saturated aqueous sodium hydrogen carbonate (300 ml), saturated brine (2 x 150 ml), saturated aqueous sodium hydrogen carbonate (150 ml) and saturated brine (150 ml), then dried (MgS04), treated with charcoal powder and evaporated to dryness. A portion of ethyl acetate was added and evaporated and the residue was crystallised from hexane-ethyl acetate to give 2-methyl-3-pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-4,6-dione (10.371 g, 27%), m.p. 203-205 °C. NMR Spectrum: (CD3SOCD3) 1.15 (s, 9H, C(CH3)3), 2.64 (s, 3H, 2-CH3), 2.72 (m, 2H, 7-CH2), 3.24 (m, 2H, 8-CH2), 6.06 (s, 2H, N3-CH2), 7.72 (s, IH, 9-CH), 8.27 (s, IH, 5-H).
Mass Spectrum: (El) m/e 328 (25%, M+), 243 (5%), 227 (56%), 214 (77%). IR Spectrum: (KBr disc) vmaχ 1612, 1684, 1711, 1729 cm'1. Elemental Analysis: Found C, 65.71 ; H, 6.17; N, 8.54% C18H20N2°4 requires C, 65.84; H, 6.14; N, 8.53%.
(2) Diethyl N-{rj-[N-((6RS)-2-methyl-4-oxo-3-ρivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoyl}-L-glutamate A reaction flask was charged with 2-methyl-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-4,6-dione (3.332 g, 10.15 mmol), diethyl r aminobenzoyl-L-glutamate (6.54 g, 20.3 mmol), prepared as described in the Journal of Medicinal Chemistry, 1985, 2_ 1428, β-toluenesulphonic acid monohydrate (0.12 g, 0.6 mmol), and dry 1,2-dimethoxyethane (100 ml), and fitted with a pressure equalising dropping funnel containing activated 3 A molecular sieve beads
(4-8 mesh; 41 g). A reflux condenser was fitted to the top of the dropping funnel and the mixture was stirred and heated under reflux under nitrogen for 4 hours. The apparatus enabled solvent vapour to pass up the side tube of the dropping funnel and condense in the reflux condenser, and the condensed solvent to percolate through the molecular sieves before returning to the reaction flask. The mixture was cooled to ambient temperature and a solution of sodium cyanoborohydride (1.0 g, 15.9 mmol) in methanol (18 ml) was added, followed immediately by acetic acid (1.0 ml). The mixture was stirred at ambient temperature for 18 hours and concentrated. The residue was partitioned between saturated aqueous sodium hydrogen carbonate (150 ml) and ethyl acetate (150 ml). The aqueous layer was extracted with ethyl acetate (3 x 25 ml) and the combined organic solution washed with brine (5 x 25 ml), dried (MgSθ4) and concentrated to dryness. The residue was fractionated by chromatography with increasingly polar mixtures of dichloromethane and ethanol (ratio 100:0 to 100:4 v/v) as eluant. The appropriate fractions were combined and evaporated and the residue triturated with diethyl ether to give diethyl N-{rj-[N-((6RS)-2-methyl-4-oxo-3- pivaloyloxymethyl-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]- benzoyl}-L-glutamate (2.847 g, 44%), m.p. 171 °C. NMR Spectrum: (CD3SOCD3) 1.12 (s, 9H, C(CH3)3), 1.18 (m, 6H, 2 x CH2CH3), 2.0 (m, 3H, glu β-CH and cyclopenta[g]quinazoline 7-H), 2.43 (t, 2H, glu γ-CH ), 2.60 (m, 4H, cycloρenta[g]quinazoline 2-CH3 and 7-H), 3.00 (m, IH, cyclopenta[g]quinazoline 8-H), 3.08 (m, IH, cyclopenta[g]quinazoline 8-H), 4.06 (m, 4H, 2 x CH2CH3), 4.39 (m, IH, glu α-CH), 5.18 (q, IH, cyclopenta[g]quinazoline 6-H), 6.04 (m, 2H, cyclopenta[g]quinazoline N3-CH2), 6.72 (d, J 8.2 Hz, IH, cyclopenta[g]quinazoline C6-NH), 6.79 (d, J 8.8 Hz, 2H, 3*,5'-ArH), 7.50 (s, IH, cyclopenta[g]quinazo_ine 9-H), 7.71 (d, J 8.7 Hz, 2H, 2',6'-Ar H), 7.94 (s, IH, cyclopenta[g]quinazoline 5-H), 8.30 (d, J 7.4 Hz, IH, glu NH). Mass Spectrum: (FAB) m/e 657 [100%, (M+Na)+], 635 [8%, (M+H)+], 432 (24%); 313 (20%), 199 (18%).
Elemental Analysis: Found C, 64.29; H, 6.65; N, 8.81% C34H42N4°8 requires C, 64.34; H, 6.67; N, 8.83%.
(3) Diethyl N-{r2-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-
L-glutamate
Diethyl N2{r-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)amino]benzoyl } -L-glutamate was converted to diethyl N-{rj-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethyl-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl } - L-glutamate by the procedure described in Example 4(2).
(4) N-{p.-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-glutamic acid
Diethyl N-{p.-[N-((6RS)-2-methyl-4-oxo-3-pivaloyloxymethy 1-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-
L-glutamate was converted to N-{p-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl} -L-glutamic acid by the procedure described in Example 4(3). (5) β-[H-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N_-(prop-2-ynyl)amino]benzoic acid
N-{p.-[H-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoyl} -L-glutamic acid was converted to p.-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl- -(prop-2-ynyl)amino]benzoic acid by the procedure described in Example 4(4).
(6) Tri-tert-butvl N-{E-D_l-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-l_I-(prop-2-ynyl)amino]benzoyl } -L-γ -glutamyl- N-methyl-L-glutamate Diethyl cyanophosphonate (0.16 g, 0.99 mmol) and triethylamine
(0.10 g, 0.99 mmol) were added successively to a stirred mixture of -t-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)- N-(prop-2-ynyl)amino]benzoic acid (0.171 g, 0.448 mmol), tri-tert-butyl L-γ-glutamyl- N-methyl-L-glutamate (0.267 g, 0.582 mmol), prepared as described in Example 1 of UK Patent Application GB 2265148 A, and DMF (2.4 ml) at 0°C. After 5 minutes the mixture was allowed to warm to room temperature and stirred in the dark for 5 hours. It was then partitioned between ethyl acetate (30 ml) and water (30 ml). The aqueous layer was extracted with ethyl acetate (4 x 15 ml) and the combined ethyl acetate solution was washed successively with 10% citric acid solution (2 x 15 ml), saturated aqueous sodium hydrogen carbonate (30 ml) and half-saturated brine (4 x 30 ml), dried (MgSθ4) and evaporated. The residue was chromatographed using increasingly polar mixtures of dichloromethane and ethanol (100:0 to 95:5 v/v) as eluant and the glass obtained was triturated with hexane to give tri-tert-butyl H-{E-[N-((6RS)-2- methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)- amino]benzoyl}-L-γ-glutamyl-N-methyl-L-glutamate (0.238 g, 65%), m.p. 108-110°C. NMR Spectrum: (CD3SOCD3) 1.37, 1.38, 1.41 (3 x s, 27H, C(CH3)3), 1.87, 2.00, 2.17 (3 x m, 7H, glu β-CH2, N-Me-glu β-CH2, N-Me-Glu γ-CH2, cyclopenta[g]quinazoline 7-H), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.5 (m, 3H, partly obscured by solvent signal, glu γ-CH2, cyclopenta[g]quinazoline 7-H), 2.63, 2.82 (2 x s, 3H, N-CH3), 3.02 (m, IH, cyclopenta[g]quinazoline 8-H), 3.13 (m, 2H, C=CH, cyclopenta[g]quinazoline 8-H), 3.83 (m, IH, CH2C--C), 4.09 (m, IH, CH2C*C), 4.30 (m, IH, glu α-CH), 4.51, 4.82 (2 x m, IH, N-Me-glu α-CH), 5.76 (t, J 8 Hz, IH, cyclopenta[g]quinazoline 6-H), 7.01 (d, J 8.8 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.80 (m, 3H, 2',6*-ArH), cyclopenta[g]quinazoline 5-H), 8.33 (m, 1 H, glu NH), 12.14 (s, IH, cyclopenta[g]quinazoline N3-H).
Mass Spectrum: (FAB) m/e 836 [5%, (M+Na)+], 814 [10%, (M+H)+], 459 (8%), 356 (100%). Elemental Analysis: Found C, 66.03; H, 7.30; N, 8.53%. C45H59N5O9 requires C, 66.40; H, 7.31; N, 8.60%.
(7) N-{p.-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-γ-glutamyl- N-methyl-L-glutamic acid
A solution of tri-tert-butyl N-{t)-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-γ-glutamyl-
H-methyl-L-glutamate (0.159 g, 0.195 mmol) in trifluoroacetic acid (8.4 ml) was stirred at ambient temperature in the dark for 75 minutes, then evaporated. The residual glass was triturated with diethyl ether, dried and dissolved in 0.5 M aqueous sodium hydrogen carbonate (3 ml). The solution was filtered, and acidified to pH 4 with 1 M hydrochloric acid whilst cooling in ice. The resulting suspension was centrifuged and the precipitate washed 4 times by resuspension in water, centrifugation and removal of the supernatant, then dried. There was thus obtained N-{β-[N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}- L-γ-glutamyl-N-methyl-L-glutamic acid (0.096 g, 73%), m.p. 168°C. NMR Spectrum: (CD3SOCD3) 1.75-2.3 (m, 7H, glu β-CH2, N-Me-glu β-CH , N-Me-glu γ-CH2, cyclopenta[g]quinazoline 7-H), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.5 (m, 3H, partly obscured by solvent signal, glu γ-CH2, cyclopenta[g]quinazoline 7-H), 2.65, 2.82 (2 x s, 3H, N-CH3), 3.02 (m, IH, cyclopenta[g]quinazoline 8-H), 3.14 (m, 2H, C--CH and cyclopenta[g]quinazoline 8-H), 3.83 (m, IH, CH2C*C), 4.09 (m, IH, CH C=C), 4.35 (m, IH, glu α-CH), 4.57, 4.92 (2 x m, IH, N-Me-glu α-CH), 5.76 (t, J 7.9 Hz, IH, cyclopenta[g]quinazoline 6-H), 7.01 (d, J 7.8 Hz, 2H, 3*,5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.8 (m, 3H, 2',6'-ArH, cyclopenta[g]quinazoline 5-H), 8.35 (m, IH, glu NH), 12.15 (s, IH, cyclopenta[g]quinazoline N3-H), 12.49 (br. s, 3H, 3 x COOH).
Mass Spectrum: (FAB) m/e 646 [13%, (M+H)+], 356 (100%). Elemental Analysis: Found C, 59.17; H, 5.66; N, 10.42% C33H35N5°9 1-5 H2O requires C, 58.92; H, 5.69; N, 10.41%.
Example 14 : (2S)-2-{r_-[H-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}- 4-[l -(2-carboxyethyl)tetrazol-5-yl]butyric acid
(1) Dimethyl N-[N-(benzyloxycarbonyl)-L-γ-glutamyl]-β-alaninate
To a stirred solution of α-methyl N-(benzyloxycarbonyl)-L-glutamate (1.33 g, 4.54 mmol) in dry tetrahydrofuran (12 ml) and N-methylmorpholine (0.454 g, 4.5 mmol) cooled to -20°C was added isobutyl chloroformate (0.612 g, 4.5 mmol) (a white precipitate had formed). Stirring was continued at -20°C for 10 minutes and then a suspension of β-alanine methyl ester hydrochloride (0.628 g, 4.5 mmol) in N-methylmorpholine (0.454 g, 4.5 mmol) and dry tetrahydrofuran (8 ml) was added into the reaction mixture which was stirred at -20°C for 10 minutes and then for 2 hours at room temperature. The N-methylmorpholine hydrochloride was removed by filtration and the filtrate was concentrated in vacuo to a yellow oily residue. Purification by column chromatography on elution with 40% ethyl acetate in dichloromethane gave dimethyl N_-[N-(benzyloxycarbonyl)-L-γ- glutamyl]-β-alaninate as colourless viscous oil (1.54 g, 89%);
NMR Spectrum: (CD3SOCD3) 1.75, 1.94 (2 x m, 2H, glu β-CH2), 2.13 (t, J = 7.4 Hz, 2H, glu γ-CH2), 2.42 (t, J = 6.8 Hz, 2H, NHCH2CH2CO2Me), 3.22 (q, J = 6.2 Hz, 2H, NHCH2CH2C02Me), 3.57, 3.61 (2 x s, 6H, 2 x CO2Me), 4.02 (m, IH, glu α-CH), 5.02 (s, 2H, PhCH2), 7.35 (m, 5H, Ph), 7.73 (d, J = 7.7 Hz, IH, glu NH), 7.93 (t, J = 5.15 Hz, IH, CH2CONHCH2) Mass Spectrum: (Cl) m/e 381 [(M+H)+]. Elemental Analysis: Found C, 56.63; H, 6.38; N, 7.16; Cj gH24N207 requires C, 56.83; H, 6.36; N, 7.36%.
(2) Methyl (2S)-2-(benzyloxycarbonylamino)-4-[l -(2-methoxycarbonylethyl)- tetrazol-5-yl]butyrate
To a stirred solution of phosphorous pentachloride (1.29 g, 6.2 mmol) in chloroform (15 ml) was added quinoline (1.60 g, 12.4 mmol) (a pale yellow precipitate had formed). The reaction mixture was stirred at room temperature for 20 minutes under nitrogen and then a solution of dimethyl N-[N-(benzyloxycarbonyl)-L-γ- glutamyl]-β-alaninate (2.36 g, 6.2 mmol) in chloroform (12 ml) was added dropwise into the reaction mixture while the temperature was maintained below 20 °C (a clear solution had obtained). Stirring was continued at temperature lower than 25 °C for 25 minutes and then a solution of hydrazoic acid in benzene (prepared as described in Fieser and Fieser, Reagents for Organic Synthesis, Vol. 1, John Wiley and Sons, New York, 1967, p 446; 18ml) was added into the reaction mixture and the resulting orange solution was stirred at room temperature for 2!Λ hours before being evaporated. The residue was partitioned between ethyl acetate (180 ml) and water (180 ml). The two layers were separated and the organic layer was washed with IN aqueous hydrochloric acid (180 ml), half saturated aqueous sodium bicarbonate (180 ml) and water (200 ml), dried (Na Sθ4) and concentrated in vacuo to an oily residue. Purification by column chromatography, on elution with v/v 1 : 1 ethyl acetate/hexanes gave methyl (2S)-2-(benzyloxycarbonylamino)-4-[l-(2-methoxycarbonylethyl)- tetrazol-5-yl]butyrate as a colourless viscous oil (0.55 g, 22%) that solidified on standing at -20°C for a few weeks, m.p. 80-81 °C.
NMR Spectrum: (CD3SOCD3) 2.00-2.25 (m, 2H, CHCH2CH2), 2.99 (m, 4H, CHCH2CH2 and NCH2CH.2CO2Me), 3.58, 3.64 (2 x s, 6H, 2 x CO2Me), 4.23 (m, IH, CH.CH2CH2), 4.49 (t, J = 6.5 Hz, 2H, NCH2CH2CO2Me), 5.05 (s, 2H, PhCH2), 7.36 (m, 5H, Ph), 7.92 (d, J = 7.9 Hz, IH, CONH). Mass Spectrum: (Cl) m/e 406 [(M+H)"1"]. Elemental Analysis: Found C, 52.95; H, 5.71; N, 17.00; C18H23N5O6 requires C, 53.33; H, 5.72; N, 17.27%.
(3) Methyl (2S)-2-amino-4-[l -(2-methoxycarbonylethyl)tetrazol-5-yl]butyrate To a solution of methyl (2S)-2-(benzyloxycarbonylamino)-4-[l-(2-methoxy- carbonylethyl)tetrazol-5-yl]butyrate (0.233 g, 0.575 mmol) in ethyl acetate (25 ml) was added 10% Pd/C (0.045 g). The resulting black mixture was degassed and then stirred at 24 °C for 4 hours under hydrogen. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to a colourless viscous oil that dried in vacuo over phosphorous pentoxide. There was thus obtained methyl (2S)-2-amino-4-[l-(2- methoxycarbonylethyl)tetrazol-5-yl]butyrate (0.146 g, 94%) as a colourless viscous oil. This was used in the next step without any further purification. NMR Spectrum: (CD3SOCD3) 1.80, 2.10 (2 x m, 2H, CHCH2CH2), 2.99 (m, 4H,
CHCH2CH2 and NCH2CH2C02Me), 3.38 (dd, J = 6.3, 11.2 Hz, IH, CHCH2CH2),
3.59, 3.62 (2 x s, 6H, 2 x C02Me), 4.52 (t, J = 6.5 Hz, 2H, NCH2CH2C02Me). Mass Spectrum: (ESI) m/e 272 [(M+H)+].
(4) Methyl (2S)-2-{β-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-4-[l-(2-methoxy- carbonylethyl)tetrazol-5-yl]butyrate
To a stirred solution of methyl (2S)-2-amino-4-[l-(2-methoxycarbonylethyl)- tetrazol-5-yl]butyrate (0.135 g. 0.50 mmol) in anhydrous DMF (3.5 ml) cooled to 0°C was added β-[H-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoic acid (0.171 g, 0.46 mmol), prepared as described in Example 13(5), followed by diethyl phosphorocyanidate (0.164 g, 1.01 mmol) and triethylamine (0.102 g, 1.01 mmol) (a clear solution had obtained after a few seconds). Stirring was continued at 0°C for 10 minutes, the ice-bath was then removed and the reaction mixture was stirred for a further 2 hours before being partitioned between ethyl acetate (100 ml) and water (80 ml). The two layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 80 ml). The ethyl acetate extracts were combined and washed with aqueous 10% citric acid (80 ml), saturated aqueous sodium bicarbonate solution (80 ml), dilute brine (80 ml), dried (Na2SO4) and concentrated in vacuo to a glass. This was dissolved in dichloromethane and to this solution silica gel (Merck Art 7734, 1.5 g) was added. The solvent was removed in vacuo and the free running yellow powder was placed on a silica gel column made up in ethyl acetate. The column was eluted with ethyl acetate (-400 ml) and then with 2% methanol in chloroform to give a white foam that reprecipitated from dichloromethane/hexane. There was thus obtained methyl (2S)-2-{β-[N-((6RS)-2-methyl-4-oxo-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzamido } -4- [l-(2-methoxycarbonylethyl)tetrazol-5-yl]butyrate (0.150 g, 52%) as a white solid, m.p. 125°C (dec) then melted at 184-188°C. NMR Spectrum: (CD3SOCD3) 2.30-2.40 (m, 4H, CHCH2CH2 and cyclopenta[g]quinazoline 7-CH2), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.90-3.20 (m, 7H, CHCH2CH2, NCH2CH2CO2Me, cyclopenta[g]quinazoline 8-CH2 and C--CH), 3.57, 3.65 (2 x s, 6H, 2 x CO2Me), 3.98 (ABq, J = 18.5 Hz, 2H, CH2C=C), 4.51 (t, J = 6.6 Hz, 2H, NCH2CH2CO2Me), 4.60 (m(obscured), IH, CHCH2CH2), 5.77 (t, J = 7.9 Hz, IH, cyclopenta[g]quinazoline 6-H), 7.02 (d, J = 8.4 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.78 (s, IH, cyclopenta[g]quinazoline 5-H), 7.81 (d, J = 9.0 Hz, 2H, 2',6'-ArH), 8.59 (d, J = 7.60 Hz, IH, CONH), 12.14 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 627 [(M+H)+]. Elemental Analysis: Found C, 60.54; H, 5.42; N, 17.43;
C32H34N8°6 0.5 H20 requires C, 60.46; H, 5.55; N, 17.63%. (5) (2S)-2-{β-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-4-[l-(2- carboxyethyl)tetrazol-5-yl]butyric acid
To a stirred suspension of methyl (2S)-2-{β-[JH(6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-4-[l- (2-methoxycarbonylethyl)tetrazol-5-yl]butyrate (0.110 g, 0.175 mmol) in methanol (2.5 ml) was added IN aqueous sodium hydroxide (0.7 ml, 0.7 mmol) to give a clear solution. Stirring was continued at room temperature for 4 hours, then more IN aqueous sodium hydroxide (0.35 ml, 0.35 mmol) was added. The reaction mixture was stirred at room temperature for a further 1 hour then diluted with water (6 ml) and acidified to pH 3.5 with IN hydrochloric acid. The white precipitate was collected by filtration, washed with water (5 ml) and dried in vacuo over phosphorous pentoxide. There was thus obtained (2S)-2-{p.-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-4-[l-(2- carboxyethyl)tetrazol-5-yl]butyric acid (0.083 g, 80%) as a white solid m.p. 170°C (dec).
NMR Spectrum: (CD3SOCD3) 2.14-2.30 (m, 4H, CHCH2CH2 and cyclopenta[g]quinazoline 7-CH2), 2.34 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.90-3.20 (m, 7H, CHCH2CH2, NCH2CH2CO2Me, cyclopenta[g]quinazoline 8-CH2 and C--CH), 3.97 (ABq, J = 19.1 Hz, 2H, CH2C≡C), 4.47 (t, J = 6.6 Hz, 2H,
NCH2CH2C02Me), 4.53 (m(obscured), IH, CHCH2CH2), 5.77 (t, J = 8.07 Hz, IH, cyclopenta[g]quinazoline 6-H), 7.03 (d, J = 8.7 Hz, 2H, 3',5'-ArH), 7.50 (s, IH, cyclopenta[g]quinazoline 9-H), 7.80 (s, IH, cyclopenta[g]quinazoline 5-H), 7.82 (d, J = 9.0 Hz, 2H, 2',6'-ArH), 8.47 (d, J = 7.7 Hz, IH, CONH), 12.14 (s, IH, cyclopenta[g]quinazoline N3-H).
Mass Spectrum: (FAB) m/e 599 [(M+H)+].
Elemental Analysis: Found C, 57.51; H, 5.04; N, 17.94;
C30H3oN806 1.5 H20 requires C, 57.59; H, 5.31 ; N, 17.91%. Example 15 : (2S)-2-{N-{N-{E-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N_-(prop-2-ynyl)amino]benzoyl } -L-γ-glutamyl } amino } - 4-(l -carboxymethyltetrazol-5-yl)butyric acid
(1) Methyl (2S)-2-{N-[α-methyl-H-(benzyloxycarbonyl)-L-γ-glutamyl]amino}- 4-( 1 -methoxycarbonylmethyltetrazol-5-yl)butyrate
To a stirred solution of α-methyl H-(benzyloxycarbonyl)-L-glutamate (0.295 g, 1.0 mmol) in dry tetrahydrofuran (5 ml) and N-methylmorpholine (0.100 g, 1.0 mmol) cooled to -20°C was added isobutyl chloroformate (0.137 g, 1.0 mmol) (a white precipitate had formed). Stirring was continued at -20° C for 10 minutes and then a solution of methyl (2S)-2-amino-4-(l-methoxy- carbonylmethyltetrazol-5-yl)butyrate (prepared as described in Example 11(1); 0.260 g, 1.0 mmol) in dry tetrahydrofuran (4 ml) was added into the reaction mixture which was stirred at -20 °C for 10 minutes and then at room temperature for 1 Vi hours. The N-methylmorpholine hydrochloride was removed by filtration and the filtrate was concentrated in vacuo to a colourless viscous oil. This was twice purified by column chromatography, first on elution with 1 % methanol in ethyl acetate and then on elution with 30% dichloromethane in ethyl acetate. There was thus obtained methyl (2S)-2-{N-[α-methyl-N-(benzyloxycarbonyl)-L-γ-glutamyl]amino}-4-(l-methoxy- carbonylmethyltetrazol-5-yl)butyrate as a viscous oil (0.467 g, 87%) which solidified on standing at -20°C for a few weeks, m.p. 64-65 °C;
NMR Spectrum: (CD3SOCD3) 1.80, 1.90-2.20 (2 x m, 4H, 2 x CHCH2CH2), 2.24 (t, = 7.5 Hz, 2H, CHCH2CH2CONH), 2.87 (t, J = 8.0 Hz, 2H, CHCH2CH2), 3.61, 3.62, 3.72 (3 x s, 9H, 3 x CO2Me), 4.04 (m, IH, ZHNCHCO2Me), 4.40 (m, IH, CH2CONHCHC02Me), 5.01 (s, 2H, PhCH2), 5.50 (s, 2H, NCH2C02Me), 7.36 (m, 5H, Ph), 7.78 (d, J = 7.9 Hz) and 8.36 (d, J = 7.6 Hz, 2H, 2 x CONH). Mass Spectrum: (Cl) m/e 535 [(M+H)+]. Elemental Analysis: Found C, 51.77; H, 5.70; N, 15.35; C23H30N6O9 requires C, 51.68; H, 5.66; N, 15.72%. (2) Methyl (2S)-2-[N-(α-methyl-L-γ-glutamyl)amino]-4-(l-methoxycarbonyl- methyltetrazol-5 -y -)butyrate
To a solution of methyl (2S)-2-{N-[α-methyl-N-(benzyloxycarbonyl)- L-γ -glutamy 1] amino } -4-( 1 -methoxycarbonylmethyltetrazol-5-yl)butyrate (0.309 g, 0.575 mmol) in ethyl acetate (25 ml) was added 10% Pd/C (0.046 g). The resulting black mixture was degassed and then stirred at room temperature (11°C) for 7 hours under hydrogen. TLC (20% dichloromethane in ethyl acetate) indicated incomplete reaction. Therefore more catalyst (0.045 g) was added and stirring was continued at 22 °C for 16 hours under a hydrogen atmosphere. The catalyst was then removed by filtration and the filtrate was concentrated in vacuo. There was thus obtained methyl (2S)-2-[N-(α-methyl-L-γ-glutamyl)amino]-4-(l -methoxycarbonyl- methyltetrazol-5-yl)butyrate (0.220 g, 96%) as a viscous oil. NMR Spectrum: (CD3SOCD3) 1.60, 1.80, 2.10 (3 x m, 4H, 2 x CHCH2CH2), 2.23 (t ,J = 8.0 Hz, 2H, CHCH2CH2CO), 2.88 (t, J = 8.0 Hz, 2H, CHCH2CH2), 3.29 (dd, J = 5.2, 8.1 Hz, IH, H2NCHCO2Me), 3.62, 3.73 (2 x s, 9H, 3 x CO2Me), 4.38 (m, IH, CH2CONHCHCO2Me), 5.52 (s, 2H, NCH2C02Me), 8.37 (d, J = 7.6 Hz, 1H, C0NH). Mass Spectrum: (ESI) m/e 401 [(M+H)+].
(3) Methyl (2S)-2-{N-{N-{p.-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-α-methyl-L-γ- glutamy 1 } amino } -4-( 1 -methoxycarbonylmethyltetrazol-5-y l)butyrate
To a stirred solution of methyl (2S)-2-[N-(α-methyl-L-γ-glutamyl)amino]-4- (l-methoxycarbonylmethyltetrazol-5-yl)butyrate (0.220 g, 0.575 mmol) in anhydrous DMF (3.5 ml) cooled to 0°C under nitrogen was added p.-[N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoic acid (0.171 g, 0.46 mmol), prepared as described in Example 13(5), followed by diethyl phosphorocyanidate (0.164 g, 1.01 mmol) and triethylamine (0.102 g, 1.01 mmol) to give a clear solution after about 1 minute. The reaction mixture was stirred at 0°C for 10 minutes, the ice-bath was then removed and stirring was continued for 2'/_ hours under nitrogen before being partitioned between ethyl acetate (80 ml) and water (80 ml). The two layers were separated and the aqueous layer was washed with ethyl acetate (2 x 80 ml). The organics were combined and succesively washed with 10% aqueous citric acid (80 ml), saturated aqueous sodium bicarbonate (80 ml) and dilute brine (80 ml), dried (Na2SO4) and concentrated in vacuo to a yellow glass. This was dissolved in dichloromethane-methanol and to this solution silica gel (Merck Art 7734, 1.2 g) was added. The solvents were removed in vacuo to give a free running powder which was placed on a silica gel column made up in ethyl acetate. Elution of the column with ethyl acetate (-100 ml) and then with a gradient of methanol in chloroform (2 to 3%) afforded a pale yellow solid which reprecipitated from dichloromethane ( 10 ml)-methanol (2 ml)/hexanes to give the title compound as a white solid (0.143 g). Because of the low yield, the initial aqueous washing and the citric acid washings, obtained during the work-up, were combined and then extracted with ethyl acetate (2 x 150 ml), dried (Na2SO4) and concentrated in vacuo to give methyl (2S)-2-{N-{N-{r [N-((6RS)-2- methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)- amino]benzoyl}-α-methyl-L-γ-glutamyl}amino}-4-(l-methoxycarbonylmethyltetrazol- 5-yl)butyrate as a white solid. Purification as described above afforded an additional 0.060 g of the product, m.p. 197-200°C; NMR Spectrum: (CD3SOCD3) 1.83-2.30 (m, 8H, 2 x CHCH2CH2, CHCH2CH.2CONH and cyclopenta[g]quinazoline 7-CH2), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.88 (t, J = 7.9 Hz, 2H, CHCH CH2), 2.94-3.24 (m, 3H, cyclopenta[g]quinazoline 8-CH and C≡CH), 3.61, 3.64, 3.72 (3 x s, 9H, 3 x CO2Me), 3.96 (ABq, J = 19.8 Hz, 2H, CH2C=C), 4.40 (m, 2H, 2 x CHCH2CH2), 5.52 (s, 2H, N-CH2C02Me), 5.76 (t, J = 7.9 Hz, IH, cyclopenta[g]quinazoline 6-H), 7.00 (d, J = 9.0 Hz, 2H, 3',5'-ArH), 7.49 (s, 1 H, cyclopenta[g]quinazoline 9-H), 7.77 (s, IH, cyclopenta]g]quinazoline 5-H),
7.79 (d, J = 8.9 Hz, 2H, 2',6'-ArH), 8.40 (d, J = 7.6 Hz) and 8.49 (d, J = 7.5 Hz,
2H, 2 x CONH), 12.13 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 756 [(M+H)+]. Elemental Analysis: Found C, 57.61 ; H, 5.37; N, 16.21 ;
C37H41N9°9 0.8 H20 requires C, 57.70; H, 5.57; N, 16.37% (4) (2S)-2-{H-{N-{E-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl } -L-γ-glutamyl } amino } - 4-( 1 -carboxymethyltetrazol-5-yl)butyric acid
To a stirred suspension of methyl (2S)-2-{N-{H-{E-[N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoyl}- α-methyl-L-γ-glutamyl } amino } -4-( 1 -methoxycarbonylmethyltetrazol-5-yl)butyrate (0.120 g, 0.16 mmol) in methanol (3.2 ml) was slowly added IN aqueous sodium hydroxide (0.96 ml, 0.96 mmol) (a clear solution had formed). Stirring was continued at room temperature for 4 hours then more IN aqueous sodium hydroxide (0.48 ml, 0.48 mmol) was added and the reaction mixture was stirred at room temperature for a further 1 hour. The solution was diluted with water (4 ml), acidified to pH 3.5 with IN HCI and the precipitated white solid was collected by filtration, washed with water (5 ml) and dried in vacuo over phosphorous pentoxide. There was thus obtained (2S)-2-{N-{N-{rj-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-y l)-N-(prop-2-ynyl)amino]benzoyl } -L-γ-glutamyl } amino } - 4-(l-carboxymethyltetrazol-5-yl)butyric acid as a white solid (0.090 g, 79%), m.p. 176°C (dec);
NMR Spectrum: (CD3SOCD3) 1.80-2.27 (m, 8H, 2 x CHCH2CH2, CHCH CH2CONH and cyclopenta[g]quinazoline 7-CH2), 2.34 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.87 (t, J = 7.8 Hz, 2H, CHCH2CH2), 2.94-3.20 (m, 3H, cyclopenta[g]quinazoline 8-CH2 and CH ≡CU), 3.96 (ABq, J = 18.3 Hz, 2H, CH2CsC), 4.35 (m, 2H, 2 x CHCH2CH2), 5.35 (s, 2H, N-CH2CO2Me), 5.75 (t, J = 7.6 Hz, IH, cyclopenta[g]quinazoline 6-H), 7.01 (d, J = 8.8 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.80 (s, IH, cyclopenta[g]quinazoline 5-H), 7.82 (d, J = 6.8 Hz, 2H, 2',6'-ArH), 8.24 (d, J = 7.8 Hz) and 8.34 (d, J = 7.7 Hz, 2H, 2 x CONH), 12.09 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 714 [(M+H)+]. Elemental Analysis: Found C, 54.97; H, 5.09; N, 16.85; C34H35N9O9 1.5 H20 requires C, 55.13; H, 5.17; N, 17.01%. Example 16 : (2S)-2-{E-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g[quinazolin-6-yl)-M- (prop-2-ynyl)amino]ben__amido}-4- { 1 -[N-(( I R)- 1 -carboxyethyl)carbamoylmethyl]tetrazol-5-yl } butyric acid
(1) Methyl (2R)-2-[N-(bromoacetyl)amino]propanoate To a stirred solution of bromoacetic acid (1.00 g, 7.2 mmol) in anhydrous
THF (10 ml) cooled to -10°C and under argon was added N-methylmorpholine (0.72 g, 7.2 mmol) followed by isobutyl chloroformate (0.98 g, 7.2 mmol) when a white precipitate formed. Stirring was continued at -10°C for 7 minutes and then a slurry of D-alanine hydrochloride methyl ester (1.00 g, 7.2 mmol) in anhydrous THF (12 ml) and N-methylmorpholine (0.720 g, 7.2 mmol) was added into the reaction mixture. Stirring was continued at -10°C for 10 minutes, then the dry ice/acetone bath was removed and the reaction mixture was allowed to stir for a further 15 minutes. The N-methymorpholine hydrochloride was removed by filtration, the filtrate was concentrated in vacuo to give a pale yellow oil. Purification by column chromatography, on elution with 40% ethyl acetate in hexanes, afforded a colourless oil which solidified on standing at room temperature. There was thus obtained methyl (2R)-2-[N-(bromoacetyl)amino]propanoate as a white solid (1.0 g, 63%), m.p. 51-52°C. NMR Spectrum: (CD3SOCD3) 1.28 (d, J = 7.3 Hz. 3H, CHCH3), 3.63 (s, 3H, OCH3), 3.88 (s, 2H, BrCH2), 4.27 (m, IH, CHCH3), 8.76 (d, J = 6.9 Hz, IH, CONH). Mass Spectrum: (FAB) m/e 224, 226 [(M+H)+].
Elemental Analysis: Found C, 32.47; H, 4.47; N, 6.22; C6H10BrNO3 requires C, 32.16; H, 4.50; N, 6.25%.
(2) Methyl (2S)-2-[N-(benzyloxycarbonyl)amino]-4-{l-[N-((lR)-l-
(methoxycarbony l)ethy l)carbamoylmethyl]tetrazol-4-y 1 } butyrate To a stirred solution of methyl (2R)-2-[N-(bromoacetyl)amino]propanoate
(0.270 g, 1.2 mmol) in anhydrous dichloromethane (2 ml) was added methyl
(2S)-2-(benzyloxycarbonylamino)-4-(tetrazol-5-yl)butyrate (0.319 g, 1.0 mmol), prepared as described in Example 10(2), followed by triethylamine (0.121 g, 1.2 mmol). Stirring was continued at room temperature for 24 hours under argon (a white precipitate was obtained). The reaction mixture was then diluted with ethyl acetate (100 ml) and the white precipitate was filtered off and washed with more ethyl acetate (- 15 ml). The filtrate was concentrated in vacuo to an oily residue which was purified by column chromatography using a gradient of ethyl acetate in hexanes (60 to 80% ) as eluant. There was thus obtained in order of elution:
(A) me yl (2S)-2-[ -(benzyloxycarbonyl)amino]-4-{2-[H-((lR)-l-(methoxy- carbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl}butyrate as a gum which solidified on standing at room temperature to a white solid (0.105 g, 23%), m.p. 106-107°C; NMR Spectrum: (CD3SOCD3) 1.32 (d, J = 7.3 Hz, 3H, CHCH3),
1.90-2.20 (m, 2H, CHCH2CH2), 2.91 (t, J = 6.7 Hz, 2H, CHCH2CH2), 3.63 (s, 6H, 2 x CO2CH3), 4.16 (m, IH, ZHNCH), 4.31 (m, IH, CHCH3), 5.04 (s, 2H, PhCH2), 5.44 (s, 2H, NCH2CONH), 7.36 (m, 5H, Ph), 7.93 (d, J = 7.8 Hz, IH, ZHNCH), 8.97 (d, J = 7.0 Hz, IH, NHCHCH3). Mass Spectrum: fFAB^ m/e 463 [rM+m+J.
Elemental Analysis: Found C, 51.92; H, 5.69; N, 18.07; C2oH26 6θ7 requires C, 51.94; H, 5.67; N, 18.17%.
(B) methyl (2S)-2-[N-(benzyloxycarbonyl)amino]-4-{ 1 -[ _-(( 1 R)-l -(methoxy- carbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl}butyrate as a gum which solidified on standing at room temperature. This was triturated with dichloromethane/hexanes to give a white solid which collected by filtration (0.242 g, 52%), m.p. 153-154°C; NMR Spectrum: (CD3SOCD3) 1.31 (d, J = 7.3 Hz, 3H, CHCH3), 1.95-2.20 (m, 2H, CHCH2CH2), 2.88 (t, J = 6.6 Hz, 2H, CHCH2CH2), 3.62, 3.64 (2 x s, 6H, 2 x C02CH3), 4.15-4.40 (m, 2H, ZHNCH and CHCH3), 5.04 (s, 2H, PhCH2), 5.21 (s, 2H, NCH2CONH), 7.36 (m, 5H, Ph),
7.90 (d, J = 7.9 Hz, IH, ZHNCH), 8.99 (d, J = 7.0 Hz, IH, NHCHCH3). Mass Spectrum: (FAB) m/e 463 [(M+H)+]. Elemental Analysis: Found C, 51.86; H, 5.66; N, 18.14; C2oH26N607 requires C, 51.94; H, 5.67; N, 18.17%. (3) Methyl (2S)-2-amino-4-{l-[ -((lR)-l-(methoxycarbonyl)ethyl)- carbamoylmethyl]tetrazol-5-yl } butyrate
To a stirred solution of methyl (2S)-2-[N-(benzyloxycarbonyl)amino]-4- { 1 -[N-(0 R)-l -(methoxycarbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl}butyrate (0.266 g, 0.575 mmol) in ethyl acetate (25 ml) and ethanol (10 ml) was added 10% Pd/C (0.050 g). The black mixture was degassed and then stirred at 24 °C for 4 hours under hydrogen. The palladium catalyst was removed by filtration, the filtrate was concentrated in vacuo and the residue was dried in vacuo over phosphorous pentoxide. There was thus obtained methyl (2S)-2-amino-4-{l-[N-((lR)-l-(methoxycarbonyl)- ethyl)carbamoylmethyl]tetrazol-5-yl } butyrate as a white solid (0.169 g, 90%), m.p. 87-89°C;
NMR Spectrum: (CD3SOCD3) 1.32 (d, J = 7.3 Hz, 3H, CHCH3), 1.90, 2.02 (2 x m, 2H, CHCH2CH2), 2.88 (t, J = 7.3 Hz, 2H, CHCH2CH2), 3.38 (dd(obscured), J = 4.8, 8.7 Hz, IH, H2NCH), 3.61, 3.63 (2 x s, 6H, 2 x CO2CH3), 4.30 (m, IH, CHCH3), 5.21 (ABq, J = 16.7 Hz, 2H, NCH2CONH), 8.99 (d, J = 7.0 Hz, IH, NHCHCH3). Mass Spectrum: (FAB) m/e 329 [(M+H)+].
(4) Methyl (2S)-2-{r>-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-4- { 1 -[N-(( I R)- 1 -(methoxycarbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl } butyrate To a stirred solution of methyl (2S)-2-amino-4-{ 1 -[£_-(( 1R)-1- (methoxycarbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl} butyrate (0.165 g, 0.50 mmol) in anhydrous DMF (3.5 ml) cooled to 0°C was added p.-[N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoic acid (0.171 g, 0.46 mmol), prepared as described in Example 13(5), followed by diethyl phosphorocyanidate (0.164 g, 1.01 mmol) and then triethylamine (0.102 g, 1.01 mmol). The reaction mixture was stirrred at 0°C for 10 minutes under argon; then the ice-bath was removed and stirring was continued for 2 hours before the reaction mixture being partitioned between ethyl acetate (100 ml) and water (10 ml). The two layers were separated and the aqueous layer was extracted with dichloromethane (80 ml) and ethyl acetate (2 x 100 ml). The organics were combined and washed with 10% aqueous citric acid (100 ml), saturated aqueous sodium bicarbonate (100 ml), dilute brine (100 ml) and water (100 ml), dried (Na2SO4), and concentrated in vacuo to a yellow glass. This was dissolved in dichloromethane/methanol and to the resulting solution silica gel (Art Merck 7734, 1.5 g) was added. The solvents were removed in vacuo and the yellow free running powder was placed on a silica gel column made up in ethyl acetate. The column was eluted with 2% methanol in ethyl acetate (-300 ml) and then a gradient of methanol in chloroform (1 to 3%). The product, a white solid, was reprecipitated from methanol (2 ml)-dichloromethane (7 ml)/hexanes. There was thus obtained methyl (2S)-2-{E-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]- quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido } -4- { 1 -[!__-(( 1 R)- 1 -(methoxy- carbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl} butyrate as a white solid (0.130 g, 42%), m.p. 228-230°C; NMR Spectrum: (CD3SOCD3) 1.27 (d, J = 7.3 Hz, 3H, CHCH3), 2.24 (m, 4H, CHCH2CH2), and cyclopenta[g]quinazoline 7-CH2), 2.32 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.91 (t, J = 7.9 Hz, 2H, CHCH2CH2), 2.97-3.20 (m, 3H, cyclopenta[g]quinazoline 8-CH and C=CH), 3.60, 3.64 (2 x s, 6H, 2 x CO2Me), 3.96 (ABq, J = 18.8 Hz, 2H, CH2C--C), 4.27 (m, IH, CHCH3), 4.54 (m, IH, -C6H4-CONHCH), 5.21 (s, 2H, NCH2CONH),
5.75 (t, J = 7.9 Hz, cyclopenta[g]quinazoline 6-CH), 7.00 (d, J = 8.7 Hz, 2H, 3',5'-ArH),
7.48 (s, IH, cyclopenta[g]quinazoline 9-H), 7.77 (s, IH, cyclopenta[g]quinazoline 5-H),
7.79 (d, J = 8.6 Hz, 2H, 2',6'-ArH), 8.55 (d, J = 7.5 H\z, IH, -C6H4-CONH),
8.97 (d, J = 6.9 Hz, IH, N-CH2CONH), 12.13 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 684 [(M+H)+].
Elemental Analysis: Found C, 58.81; H, 5.41; N, 18.05;
C34H37N907 0.5 H20 requires C, 58.95; H, 5.52; N, 18.20%. (5) (2S)-2-{β-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzamido}-4- { l-N-((lR)-l-carboxyethyl)carbamoylmethyl]tetrazol-5-yl}butyric acid
To a stirred suspension of methyl (2S)-2-{β-[H-((6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-4- { 1 -N-(( 1 R)- 1 -(methoxycarbonyl)ethyl)carbamoylmethyl]tetrazol-5-yl } butyrate (0.085 g, 0.124 mmol) in methanol (2.0 ml) was slowly added IN aqueous sodium hydroxide (0.5 ml, 0.5 mmol) followed by water (1 ml). Stirring was continued at room temperature for 4 hours, then more IN aqueous sodium hydroxide (0.25 ml, 0.25 mmol) was added and the reaction mixture was stirred for a further 1 hour at room temperature. The solution was diluted with water ( 6 ml), acidified to pH -3.5 wih IN hydrochloric acid and the precipitated white solid was collected by filtration, washed with water (5 ml), and dried in vacuo over phosphorous pentoxide. There was thus obtained (2S)-2-{β-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzamido } -4- { 1 -[N-(( 1 R)- 1 -carboxyethyl)carbamoyl- methyl]tetrazol-5-yl} butyric acid as a white solid (0.062 g, 77%), m.p. 182-189°C; NMR Spectrum: (CD3SOCD3) 1.27 (d, J = 7.3 Hz, 3H, CHCH3), 2.24 (m, 4H, CHCH2CH2 and cyclopenta[g]quinazoline 7-CH2), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.89-3.25 (m, 5H, CHCH2CH2, cyclopenta[g]quinazoline 8-CH2 and C≡CH), 3.96 (ABq, J = 19.0 Hz, 2H, CH2C--C), 4.18 (m, IH, CHCH3), 4.46 (m, IH, -C6H4-CONHCH), 5.21 (s, 2H, NCH2CONH), 5.76 (t, J = 8.4 Hz, cyclopenta[g]quinazoline 6-CH), 7.01 (d, J = 8.0 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.78 (s, IH, cyclopenta[g]quinazoline 5-H), 7.80 (d, J = 8.6 Hz, 2H, 2',6'-ArH), 8.44 (d, J - 7.8 Hz, IH, -C6H4CONH), 8.86 (d, J = 7.2 Hz, IH, N-CH2CONH), 12.14 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 656 [(M+H)+]. Elemental Analysis: Found C, 56.34; H, 5.16; N, 18.27; C32H33N907 1.5 H20 requires C, 56.30; H, 5.31 ; N, 18.46%. Example 17 : (2S)-2-{r [N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-61i- cyclopenta[g]quinazolin-6-yl)-N_-(prop-2-ynyl)amino]benzamido}-5-
(lH-l,2,4-triazol-3-ylsulphonyl)pentanoic acid
(1) Methyl (2S)-2-[H-(benzyloxycarbonyl)amino]-5-hydroxypentanoate To a stirred solution of α-methyl N_-(benzyloxycarbonyl)-L-glutamate
(4.0 g, 13.56 mmol) in dry THF (33 ml) cooled to -10°C and under argon was added triethylamine (2.05 g, 20.34 mmol) followed by ethyl chloroformate (1.83 g, 16.95 mmol). After stirring at -10°C for 10 minutes, sodium boronhydride (1.54 g, 40.68 mmol) was added in one portion followed by dropwise addition of methanol (40 ml) over a 15 minute period while the temperature was maintained below 0°C. Stirring was continued at 0°C for 40 minutes and then the reaction mixture was neutralised with IN aqueous sodium hydroxide. The organic solvents were then removed in vacuo and the residue was extracted with ethyl acetate (2 x 180 ml). The combined ethyl acetate extracts were washed with saturated aqueous sodium bicarbonate (2 x 100 ml), water (100 ml), dried (Na2Sθ4), and concentrated in vacuo to an oily residue. This was purified by column chromatography using a gradient of ethyl acetate in hexanes (50 to 90%) as eluant. There was thus obtained methyl (2S)-2-[N- (benzyloxycarbonyl)amino]-5-hydroxypentanoate (1.98, 52%) as a colourless oil. NMR Spectrum: (CD3SOCD3) 1.40-1.80 (m, 4H, 3-CH2 and 4-CH2), 3.37 (q(obscured), 2H, J = 5.9 Hz, CH2OH), 3.62 (s, 3H, C02Me), 4.02 (m, IH, 2-CH), 4.47 (t, J = 5.2 Hz, CH2OH, exchangeable with D2O), 5.03 (s, 2H, PhCH2), 7.35 (m, 5H, Ph), 7.77 (d, J = 7.7 Hz, IH, CONH). Elemental Analysis: Found C, 59.64; H, 6.72; N, 4.98; C14H19N05 requires C, 59.78; H, 6.81; N, 4.98%.
(2) Methyl (2S)-2-[N-(benzyloxycarbonyl)amino]-5-(methylsulphonyloxy)- pentanoate
To a solution of methyl (S)-2-[N-(benzyloxycarbonyl)amino]-5-hydroxy- pentanoate (1.84 g, 6.98 mmol) in dichloromethane (27 ml) cooled to -10°C under argon was added triethylamine (1.057 g, 10.47 mmol) and then methanesulphonyl chloride (0.99 g, 8.72 mmol) over a 2 minute period. Stirring was continued for 35 minutes while the temperature was maintained below 0°C. The reaction mixture was then diluted with dichloromethane (200 ml) and washed with water (100 ml), 10% aqueous citric acid (2 x 100 ml), saturated aqueous sodium bicarbonate (100 ml) and dilute brine (100 ml), dried (Na SU4) and concentrated in vacuo to a yellow oil residue. Purification by column chromatography, on elution with 1:1 v/v ethyl acetate/hexanes, afforded methyl (2S)-2- {N-(benzyloxycarbonyl)amino]-5-(methylsulphonyloxy)- pentanoate as a colourless viscous oil (2.40 g, 96%); NMR Spectrum: (CD3SOCD3) 1.72 (m, 4H, 3-CH2 and 4-CH2), 3.15 (s, 3H, OS02Me), 3.64 (s, 3H, C02Me), 4.08 (m, IH, 2-CH), 4.18 (t, J = 5.3 Hz, CH2OS02Me), 5.05 (s, 2H, PhCH2), 7.35 (m, 5H, Ph), 7.78 (d, J = 7.8 Hz, IH, CONH). Mass Spectrum: (FAB) m/e 360 [(M+H)+]. Elemental Analysis: Found C, 50.04; H, 5.84; N, 3.84; S, 8.99; C15H21NO7S requires C, 50.13; H, 5.89; N, 3.90; S, 8.92%.
(3) Methyl (2S)-2-[N-(benzyloxycarbonyl)amino]-5-(lH-l,2,4-triazol-3-ylthio)- pentanoate To a stirred solution of methyl (2S)-2-[N-(benzyloxycarbonyl)amino]-5-
(methylsulphonyloxy)pentanoate (2.35 g, 6.54 mmol) in anhydrous DMF (6.5 ml) and under argon was added lH-l,2,4-triazole-3-thiol (0.86 g, 8.50 mmol) followed by triethylamine (0.86 g, 8.50 mmol). The reaction mixture was stirred at room temperature for 90 hours, then it was diluted with ethyl acetate (200 ml) and the resulting solution was washed with 10% aqueous citric acid (100 ml), brine (100 ml) and water (100 ml), dried (Na2Sθ4) and concentrated in vacuo to a yellow oily residue. Purification by column chromatography, on gradient elution with ethyl acetate in hexanes (40 to 80%) afforded a gum (1.84 g, 77%) which solidifed on standing at room temperature. There was thus obtained methyl (2S)-2-[N-(benzyloxycarbonyl)- amino]-5-(lH-l,2,4-triazol-3-ylthio)pentanoate as a white solid, m.p. 99-100°C; NMR Spectrum: 1.63-1.90 (m, 4H, 3-CH2 and 4-CH2), 3.06 (t, J = 6.3 Hz, 2H, CH2S-), 3.61 (s, 3H, CO2Me), 4.05 (m, IH, 2-CH), 5.03 (s, 2H, PhCH2), 7.35 (m, 5H, Ph), 7.80 (d, J = 7 8 Hz, IH, CONH), 8.4 (br s, N = CH). Mass Spectrum: (FAB) m e 365 [(M+H)+]. Elemental Analysis: Found C, 52.95; H, 5.56; N, 15.41; S, 8.83; C16H20N4°4S requires C, 52.73; H, 5.53; N, 15.37; S, 8.80%.
(4) Methyl (2S)-[N-(ber_zyloxycarbonyl)amino]-5-(lH-l,2,4-triazol-3- ylsulphonyl)pentanoate
To a stirred solution of methyl (2S)-2-[H-(benzyloxycarbonyl)amino]-5- (lH-l,2,4-triazol-3-ylthio)pentanoate (0.660 g, 1.8 mmol) in chloroform (8 ml) cooled to -10°C and under argon was added a suspension of m-chloroperoxybenzoic acid (technical 80-90%, 0.775 g, -3.6 mmol) in chloroform (8 ml) (precooled to -10°C) using chloroform (4 ml) to aid the transfer. Stirring was continued at -10°C for 5 minutes and then the reaction mixture was allowed to stand at -20 °C for 23 hours. The white solid was filtered off, the filtrate was concentrated in vacuo to a semisolid residue which was purified by column chromatrography using a gradient of ethyl acetate in hexanes (50 to 100%) as eluant. There was thus obtained methyl (2S)-2-[N-(benzyloxy- carbonyl)amino]-5-(lH-l,2,4-triazol-3-ylsulphonyl)pentanoate as a gummy solid (0.410 g, 58%). NMR Spectrum: 1.63-1.90 (m, 4H, 3-CH2 and 4-CH2), 3.42 (m, 2H, CH2SO2-), 3.61 (s, 3H, C02Me), 4.06 (m, IH, 2-CH), 5.03 (s, 2H, PhCH2), 7.36 (m, 5H, Ph), 7.80 (d, J = 7.8 Hz, IH, CONH), 8.9 (s, IH, N=CH). Mass Spectrum: (FAB) m/e 397 [(M+H)+]. Elemental Analysis: Found C, 48.65; H, 5.05; N, 13.82; S, 7.84; C16H2oN406S requires C, 48.48; H, 5.09; N, 14.13; S, 8.09%. (5) Methyl (2S)-2-amino-5-(l H- 1 ,2,4-triazol-3-ylsulphonyl)pentanoate
To a solution of methyl (2S)-2-[N-benzyloxycarbonyl)amino]-5-(lH-l,2,4- triazol-3-ylsulphonyl)pentanoate (0.330 g, 0.83 mmol) in ethanol (24 ml) was added 10%) Pd/C (0.350 g). The resulting black mixture was degassed and stirred at 26°C for 4 hours under hydrogen. More catalyst (0.050 g) was then added and stirring was continued at 26 °C for a further 2 hours. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to a gummy residue which dried in vacuo over phosphorous pentoxide to give a white solid (0.182 g), a mixture of the starting material and methyl (2S)-2-amino-5-(lH-l,2,4-triazol-3-ylsulphonyl)pentanoate (ratio 0.6:1, as estimated by NMR). This was used without further purification.
(6) Methyl (2S)-2-{p.-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-5-(lH-l,2,4- triazol-3-ylsulphonyl)pentanoate
To a stirred solution of methyl (2S)-2-amino-5-(lH-l,2,4-triazol-3- ylsulphonyl)pentanoate (0.182 g, supposedly 0.36 mmol of free amine) in anhydrous DMF (2.5 ml) cooled to 0°C under argon was added ]_.-[N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoic acid (0.112 g, 0.30 mmol), prepared as described in Example 13(5), followed by (1H-1 ,2,3-benzotriazol-l -yloxy-tris[pyrrolidino]-phosphonium hexafluorophosphate [PyBOP (registered trade mark), 0.163 g, 0.315 mmol] and then dusopropylethylamine (0.116 g, 0.9 mmol). A clear solution was obtained after -1 minute. This was stirred at -0°C for 5 minutes, the ice-bath was then removed and stirring was continued for a further 3 hours before the reaction mixture being concentrated in vacuo to a gummy residue. This was triturated with dichloromethane (5 ml), the precipitated brown solid was filtered off and the filtrate was concentrated in vacuo to brownish oily residue which was purified by column chromatography using a gradient of methanol in chloroform (2 to 7%) as eluant. The product, still impure, was rechromatographed using 10% methanol in dichloromethane as eluant to give a white solid which was triturated with hexanes, collected by filtration and washed with hexanes. There was thus obtained methyl (2S)-2- {β-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-5-(lH-l,2,4-triazol- 3-ylsulphonyl)pentanoate as a white solid (0.050 g, 27%), m.p. 174-178°C (softens); NMR Spectrum: (CD3SOCD3) 1.60-2.00, 2.21 (2 x m, 6H, 3-CH2 and 4-CH2 and . cyclopenta[g]quinazoline 7-CH2, 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.90-3.20 (m, 3H, cyclopenta[g]quinazoline 8-CH2 and C=CH),
3.44 (m, 2H, CH2SO2-), 3.96 (ABq, J = 18.94 Hz, 2H, CH2C=C),
3.61 (s, 3H, CO2Me), 4.39 (m, IH, 2-CH), 5.76 (t, J = 7.5 Hz, cyclopenta[g]quinazoline 6-CH), 7.02 (d, J = 8.0 Hz, 2H, 3',5*-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.75 (d, J = 8.9 Hz, 2H, 2',6*-ArH), 7.79 (s, IH, cyclopenta[g]quinazoline 5-H),
8.45 (d, J = 7.4 Hz, IH, CONH), 8.85 (s, IH, N=CH), 12.14 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 618 [(M+H)+].
(7) (2S)-2-{β-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-5- (1H-1 ,2,4-triazol-3-ylsulphonyl)pentanoic acid
To a solution of methyl (2S)-2-{β-[N-((6RS)-2-methyl-4-oxo-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzamido}-5- (lH-l,2,4-triazol-3-ylsulphonyl)pentanoate (0.038 g, 0.062 mmol) in methanol (1 ml) was slowly added IN aqueous sodium hydroxide (0.15 ml, 0.15 mmol) followed by water (1 ml). The reaction mixture was stirred at room temperature for 2.5 hours then more IN aqueous sodium hydroxide (0.10 ml, 0.10 mmol) was added and stirring was continued at room temperature for 1 hour. The solution was then diluted with water (3 ml), acidified to pH -4 with IN hydrochloric acid and the precipitated white solid was collected by filtration, washed with water (-3 ml) and dried in vacuo over phosphorous pentoxide. There was thus obtained (2S)-2-{β-[N-((6RS)-2-methyl-4- oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]- benzamido}-5-(lH-l,2,4-triazol-3-ylsulphonyl)pentanoic acid as a white solid (0.021 g, 57%), m.p. 180°C (dec). NMR Spectrum: (CD3SOCD3) 1.60-2.00, 2.20 (2 x m, 6H, 3-CH2 and 4-CH2 and cyclopenta[g]quinazoline 8-CH2), 2.34 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.90-3.23 (m, 3H, cyclopenta[g]quinazoline 7-CH2 and C=CH), 3.40 (m, 2H, CH2SO2-), 3.96 (ABq, J = 18.53 Hz, 2H, CH2C=C), 4.32 (m, IH, 2-CH), 5.76 (t, J = 7.2 Hz, cyclopenta[g]quinazoline 6-CH), 7.02 (d, J = 8.3 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.77 (d, J = 8.9 Hz, 2H, 2',6'-ArH), 7.80 (s, IH, cyclopenta[g]quinazoline 5-H), 8.32 (d, J = 7.7 Hz, IH, CONH), 8.87 (s, IH, N=CH), 12.10 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 604 [(M+H)+]. Elemental Analysis: Found C, 54.92; H, 5.07; N, 15.47;
C29H29N706S 1.5 H20 requires C, 55.23; H, 5.11; N, 15.55%.
Example 1 : r4RV4- -(N-(p-[N-rf6RSV2-Methvl-4-oxo-3.4.7.78-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl } -L-γ-glutamyl } amino} - 4-(tetrazol-5-yl)butyric acid
(1) tert-Butyl (4R)-4-(benzyloxycarbonylamino)-4-carbamoylbutyrate
A stirred solution of N-benzyloxycarbonyl-D-glutamic acid γ -tert-butyl ester (4.75 g, 14 mmol) and triethylamine (2.0 ml, 14 mmol) in dry THF (28 ml) was cooled to -15°C under argon and a solution of isobutyl chloroformate (1.92 g, 14 mmol) in THF (1 1 ml) was added during 5 minutes. After a further 10 minutes at -15°C gaseous ammonia was bubbled through the mixture for 30 minutes, during which the temperature was kept at -5 to +5°C. The mixture was then allowed to warm to room temperature. The precipitate was removed by filtration and the filtrate evaporated. The residue was dissolved in ethyl acetate (150 ml) and the solution was washed successively with saturated aqueous sodium hydrogen carbonate (2 x 35 ml), water (35 ml), 10% citric acid solution (35 ml), and water (2 x 35 ml), then dried (Na2SU4) and evaporated. The residue was dissolved in the minimum volume of dichloromethane and the solution added dropwise to hexane (300 ml) with stirring. The precipitate was collected, washed with hexane and dried to give tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-carbamoylbutyrate (3.638 g, 77%), m.p. 138-140°C.
NMR Spectrum: (CD3SOCD3) 1.38 (s, 9H, C(CH3)3), 1.70 (m, IH, β-CH2), 1.85 (m, IH, β-CH2), 2.22 (t, J = 7.8 Hz, 2H, γ-CH2), 3.92 (m, IH, α-CH), 5.02 (m, 2H, PhCH2), 7.07 (s, IH, α-NH), 7.35 (m, 5H, Ph). Mass Spectrum: (FAB) m/e 359 [(M+Na)+], 337 [(M+H)+]. Elemental Analysis: Found C, 60.51; H, 7.15; N, 8.24%; C17 24N2°5 requires C, 60.70; H. 7.19; N, 8.33%. Optical Rotation: fCHCl31 [a]^° A R° (r=1)
(2) tert-Butyl (4R)-4-(benzyloxycarbonylamino)-4-cyanobutyrate
A solution of phosphorus oxy chloride (2.05 g, 13.4 mmol) in dichloromethane
(5.5 ml) was added during 20 minutes to a stirred solution of tert-butyl (4R)-4- (benzyloxycarbonylamino)-4-carbamoylbutyrate (3.0 g, 8.9 mmol) in dry pyridine
(16 ml) at -5°C under argon. The mixture was allowed to warm to room temperature and after 25 hours was poured into cold water (110 ml). The products were extracted with ethyl acetate (4 x 40 ml) and the combined ethyl acetate solution was washed successively with 10% aqueous citric acid solution (4 x 15 ml) and water (25 ml), then dried (Na2Sθ4) and evaporated. Toluene (4 x 25 ml) was added and evaporated and the residue was chromatographed with increasingly polar mixtures of hexane and ethyl acetate (100:0 to 2:1) as eluant to give tert-butyl (4R)-4-(benzyloxycarbonylamino)-4- cyanobutyrate (2.433 g, 86%) as a pale yellow oil.
NMR Spectrum: (CD3SOCD3) 1.39 (s, 9H, C(CH3)3), 1.95 (m, 2H, β-CH2), 2.34 (t, J = 7.4 Hz, 2H, γ-CH2), 4.61 (q, IH, α-CH),
5.08 (s, 2H, PhCH2), 7.37 (m, 5H, Ph), 8.21 (d, J = 8.0 Hz, IH, NH).
Mass Spectrum: (FAB) m/e 341 [(M+Na)+], 319 [(M+H)+].
Elemental Analysis: Found C, 63.93; H, 7.03; N, 8.77%;
C17H22N2°4 requires C, 64.13; H, 6.97; N, 8.80%. Optical Rotation: (CHCI3) [α]JJ° 40.5β (c=l). (3) tert-Butvl (4R)-4-(benzyloxycarbonylamino)-4-(tetrazol-5-yl)butyrate
A mixture of tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-cyanobutyrate (1.53 g, 4.8 mmol), ammonium chloride (0.28 g, 5.2 mmol), sodium azide (0.345 g, 5.3 mmol) and dry DMF (6 ml) was stirred and heated at 90-95°C under argon for 20 hours. The mixture was cooled and concentrated and the residue partitioned between ice-cooled water (40 ml) and ethyl acetate (30 ml) with the pH of the aqueous phase being adjusted to 3 by the addition of 10% aqueous citric acid solution (ca. 10 ml). The aqueous layer was extracted with further ethyl acetate (3 x 30 ml) and the combined organic solution washed with water (4 x 25 ml), dried (MgSO4) and evaporated. A solution of the residue in dichloromethane (3 ml) was added dropwise to stirred hexane (20 ml) and the precipitate was collected, washed with hexane and dried to give tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-(tetrazol-5-yl)butyrate (1.462 g, 84%), m.p. 99-101 °C. NMR Spectrum: (CD3SOCD3) 1.39 (s, 9H, C(CH3)3C), 2.03, 2.15 (2 x m, 2H, β-CH2), 2.31 (m, 2H, γ-CH2), 5.04 (m, 3H, α-CH, PhCH2), 7.36 (m, 5H, Ph), 7.97 (d, J = 8.0 Hz, 1H, NH).
Mass Spectrum: (FAB) m/e 384 [(M+Na)+], 362 [(M+H)+]. Elemental Analysis: Found C, 56.44; H, 6.44; N, 19.38%; C17H23N5°4 requires C, 56.50; H, 6.42; N, 19.38%. Optical Rotation: (CHCI3)
Figure imgf000091_0001
(c=l).
(4) tert-Butyl (4R)-4-amino-4-(tetrazol-5-yl)butyrate
A solution of tert-butyl (4R)-4-(benzyloxycarbonylamino)-4-(tetrazol-5-yl)- butyrate (1.2 g, 3.32 mmol) in ethanol (77 ml) was stirred with 10% Pd-C (0.166 g) under a hydrogen atmosphere at ambient temperature for 16 hours. The catalyst was removed by filtration and the filtrate evaporated. Dichloromethane was added to the residue and evaporated and the resulting solid was triturated with hexane and dried to give tert-butyl (4R)-4-amino-4-(tetrazol-5-yl)butyrate (0.687 g, 91%), m.p. 175°C (decomp.). NMR Spectrum: (CD3SOCD3) 1.38 (s, 9H, C(CH3)3C), 2.07 (m, 2H, β-CH2), 2.26 (m, 2H, γ-CH2), 4.44 (dd, J = 6.2, 7.7 Hz, IH, α-CH), 8.28 (br. s, 3H, NH3+). Mass Spectrum: (FAB) 250 [(M+Na)+], 228 [(M+H)+].
(5) Isrl-Butyl (4R)-4-{H-[N-(benzyloxycarbonyl)-α-t__rl-butyl-(S)-γ- glutamyl]amino } -4-(tetrazol-5-yl)butyrate
A stirred solution of N-(benzyloxycarbonyl)-L-glutamic acid α-tert-butyl ester (0.891 g, 2.64 mmol) in dry THF (10 ml) was cooled to -20°C under argon and 4-methylmorpholine (0.27 g, 2.64 mmol) and isobutyl chloroformate (0.36 g, 2.64 mmol) were added successively. After 10 minutes at -20°C, solid tert-butyl (4R)-4-amino-4-(tetrazol-5-yl)butyrate (0.60 g, 2.64 mmol) and further THF (5 ml) were- added. After a further 15 minutes at -20 °C, the mixture was stirred at room temperature for 4.5 hours. It was then filtered and the filtrate was concentrated. A solution of the residual syrup in ethyl acetate (100 ml) was washed successively with 10% aqueous citric acid solution (50 ml) and half-saturated brine (3 x 20 ml), then dried (MgSU4) and evaporated. Column chromatography of the residue with increasingly polar mixtures of dichloromethane and ethanol (100:0 to 90:10 v/v), followed by trituration with hexane, gave tert-butyl (4R)-4-{N-rN-(benzyloxycarbonyl)-α-tert-butyl-fS)-γ-glutamyl]amino}- 4-(tetrazol-5-yl)butyrate (0.948 g, 66%), m.p. 143-145°C. NMR Spectrum: (CD3SOCD3) 1.38, 1.39 (2 x s, 18H, C(CH3)3C), 1.81, 1.99, 2.13, 2.28 (4 x m, 8H, L-glu β-CH2, L-glu γ-CH2, β'-CH2, γ'-CH2), 3.90 (m, IH, L-glu α-CH), 5.03 (m, 2H, PhCH2), 5.17 (m, IH, α'-CH), 7.35 (m, 5H, Ph), 7.58 (d, J = 7.7 Hz, IH, L-glu NH), 8.43 (d, J = 7.9 Hz, IH, α'-NH), 13.6 (br., tetrazole NH). Mass Spectrum: (FAB) m/e 569 [(M+Na)+], 547 [(M+H)+]. Elemental Analysis: Found C, 57.07; H, 6.99; N, 15.18%; C26H38N6°7 requires C, 57.13; H, 7.01; N, 15.37%. (6) tert-Butyl (4R)-4-[N-(α-tert-butyl-(S)-γ-glutamyl)amino]-4-(tetrazol-5- yl)butyrate
A solution of tert-butyl (4R)-4-{N-[N-(benzyloxycarbonyl)-α-tert-butyl-(S)-γ- glutamyl]amino}-4-(tetrazol-5-yl)butyrate (0.320 g, 0.585 mmol) in ethanol (35 ml) was stirred with 10% Pd-C (0.12 g) under a hydrogen atmosphere at ambient temperature. After 16 hours further 10% Pd-C (0.09 g) was added and the mixture was stirred under hydrogen for a further 6 hours. It was then filtered through Celite and the filtrate was evaporated. Several portions of dichloromethane were added and evaporated to leave lert-butyl (4R)-4-[N-(α-ϊert-butyl-(S)-γ-glutamyl)amino]-4-(tetrazol-5-yl)butyrate as a crisp, colourless glass which was dried over phosphorus pentoxide and used without further purification. Yield 0.24 g; m.p. 92-94°C.
NMR Spectrum: (CD3SOCD3) 1.38, 1.43, 1.45 (3 x s, 18H, C(CH3)3C), 1.91, 2.03, 2.19, 2.28 (4 x m, 8H, L-glu β-CH2, L-glu γ-CH2, β'-CH2, γ'-CH2), 3.76 (t, J = 6.4 Hz, IH, L-glu α-CH), 5.08 (m, IH, α'-CH), 6.1 (br., 3H, NH3+), 8.29 (d, J = 8.4 Hz, IH, CONH). Additional minor signals (e.g. 8.21, equivalent to ca. 0.2H) suggest impurities were present. Mass Spectrum: (FAB) m/e 413 [(M+Na)+].
(T) tert-Butyl (4R)-4-{N-{N- {E-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-α-tert-butyl-L-γ- glutamyl} amino }-4-(tetrazol-5-yl)butyrate
( 1 H- 1 ,2,3-Benzotriazol- 1 -yloxy)-tris(pyrrolidino)phosphonium hexafluorophosphate (0.30 g, 0.578 mmol) and N,N-diisopropylethylamine (0.30 ml, 1.7 mmol) were added successively to a stirred, cooled (ice-water bath) mixture of p.-[N-((6RS)-2-methyl-4-oxo-3 ,4,7,8-tetrahydro-6J__-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoic acid (0.190 g, 0.50 mmol), prepared as described in Example 4(4), tert-butyl (4R)-4-[H-(o-tert-butyl-(S)-γ-glutamyl)amino]-4- (tetrazol-5-yl)butyrate (0.23 g, 0.57 mmol) and dry DMF (3 ml) under argon. After 5 minutes the mixture was allowed to come to room temperature, and after a further 2.5 hours it was partitioned between ethyl acetate (75 ml) and 10% aqueous citric acid solution (75 ml). The aqueous layer was extracted with ethyl acetate (2 x 50 ml) and the combined ethyl acetate solution washed successively with 10% citric acid (75 ml) and half-saturated brine (4 x 25 ml), then dried (N 2Sθ4) and evaporated. The residue was chromatographed twice with increasingly polar mixtures of dichloromethane and ethanol. The more polar product was isolated as a glass which was triturated with hexane, then dissolved in dichloromethane (5 ml). The solution was added to stirred hexane (30 ml) and the resulting precipitate collected, washed with hexane and dried. There was thus obtained ___r£-butyl (4R)-4-{N-{ -{β-[N-((6RS)-2-methyl-4-oxo-3,4,7,8- tefrahydro-6H-cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoyl}-α-tgrt- butyl-L-γ-glutamyl}amino}-4-(tetrazol-5-yl)butyrate (0.213 g, 55%), m.p. 154-156°C. NMR Spectrum: (CD3SOCD3) 1.37, 1.38, 1.41 (3 x s, 18H, (CH3)3C), 1.94, 2.08, 2.24 (3 x m, 9H, L-glu β-CH2, L-glu γ-CH2, β'-CH2, γ'-CH2, cyclopenta[g]quinazoline C7-H), 2.33 (s, 3H, C2-CH3), 2.5 (m, presumed IH, coincides with solvent signal, cyclopenta[g]quinazoline C7-H), 3.02 (m, IH, cyclopenta[g[quinazoline C8-H), 3.13 (m, 2H, C≡CH., cyclopenta[g]quinazoline C8-H), 3.84 (m, IH, CH2C--C), 4.10 (m, IH, CH2CHC), 4.28 (m, IH, L-glu α-CH), 5.15 (m, IH, α'-CH), 5.76 (t, J = 8 Hz, IH, cyclopenta[g]quinazoline C6-H), 7.02 (d, J = 9.0 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline C9-H), 7.81 (m, 3H, 2',6'-ArH, cyclopenta[g]quinazoline C5-H), 8.40 (m, 2H, L-glu NH, α'-NH), 12.14 (s, IH, cyclopenta[g]quinazoline N3-H).
Mass Spectrum: (FAB) m/e 790 [(M+Na)+]
Elemental Analysis: Found C, 59.67; H, 6.43; N, 16.36;
C4oH49N9O7 requires C, 60.03; H, 6.62; N, 15.75%.
(8) (4R)-4-{N-{N-{p.-[N-((6RS)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-M-(prop-2-ynyl)amino]benzoyl}-L-γ-glutamyl}amino}- 4-(tetrazol-5-yl)butyric acid l -Butyl (4R)-4-{N-{N-{E-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-α-tert-butyl-L-γ- glutamyl}amino}-4-(tetrazol-5-yl)butyrate (0.100 g, 0.130 mmol) was added to a stirred, cooled (ice-water bath) mixture of trifluoroacetic acid (7.9 ml), thioanisole (0.44 ml, 3.7 mmol), ethanedithiol (0.22 ml, 2.6 mmol) and water (0.22 ml). After 15 minutes the mixture was brought to room temperature and stirred in the dark for a further 1 hour. It was then evaporated and the residue triturated with diethyl ether. The resulting solid was dissolved in 0.5M aqueous sodium hydrogen carbonate (12 ml) and the solution was washed with dichloromethane (5 x 5 ml), using a centrifuge to assist separation into two layers. The aqueous solution was filtered through a cellulose nitrate membrane filter (0.65 μm pore size) and acidified to pH 3.5 by addition of 1M hydrochloric acid, whilst stirring and cooling in ice. The resulting suspension was centrifuged and the precipitate washed once by resuspension and centrifugation, then collected by filtration further washed with water, diethyl ether and dichloromethane in succession, then dried. There was thus obtained (4R)-4-{H-{N-{β-[N-((6RS)-2-methyl- 4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]- benzoyl} -L-γ-glutamyl} amino }-4-(tetrazol-5-yl)butyric acid (0.045 g, 53%), m.p. 175-177°C.
NMR Spectrum: 1.95, 2.1-2.4 (2 x m), 2.33 (s) (total 12H, L-glu β-CH2, L-glu γ-CH2, β'-CH2, γ'-CH2, cyclopenta[g]quinazoline C7-H, C2-CH3), 2.5 (m, presumed IH, coincides with solvent signal, cyclopenta[g]quinazoline C7-H), 3.02 (m, IH, cyclopenta[g[quinazoline C8-H), 3.14 (m, 2H, C≡CH, cyclopenta[g]quinazoline C8-H), 3.84 (m, IH, CH2C=C), 4.10 (m, IH, CH2C--C), 4.41 (m, IH, L-glu α-CH), 5.19 (m, IH, α'-CH), 5.77 (t, J = 8 Hz, IH, cyclopenta[g]quinazoline C6-H), 7.03 (d, J = 9.0 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline C9-H), 7.81 (m, 3H, 2',6'-ArH, cyclopenta[g]quinazoline C5-H), 8.44 (d, J = 7.8 Hz, IH), 8.55 (d, J = 7.7 Hz, IH) (L-glu NH, α'-NH), 12.15 (s, IH, cyclopenta[g]quinazoline N3-H); impurity signals: 1.23 (s), 1.38 (s), 1.42 (s), 1.65 (s), 1.69 (s) (total equivalent to ca. 1.7H), 8.35 (ca. 0.2H). Mass Spectrum: (FAB) m/e 678 [(M+Na)+] Elemental Analysis: Found C, 56.71; H, 5.42; N, 18.28; C32H33N9O7 1.4 H2O requires C, 56.45; H, 5.30; N, 18.51%. Example 19 : H-{N-{β-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoyl } -L-γ-glutamyl } - D-alanine
(1) Di-JsH-butyl N-{N-{E-_H-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-61i- cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoyl } -L-γ-glutamyl } - D-alaninate
To a stirred solution ofdi-tert-butyl L-γ-glutamyl-D-alaninate (0.171 g, 0.52 mmol), prepared as described in U.K. Patent Application GB 2,253,849A, in anhydrous DMF (3.5 ml) cooled to 0°C was added r)-[N-((6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-H-(prop-2-ynyl)amino]benzoic acid (0.150 g, 0.40 mmol), prepared as described in Example 13(5), followed by diethyl phosphorocyanidate (0.143 g, 0.88 mmol) and triethylamine (0.089 g, 0.88 mmol) (a clear solution was obtained after a few seconds). Stirring was continued at 0°C for 10 minutes under argon; the ice-bath was then removed and the reaction mixture was stirred for a further 2 hours before being partitioned between ethyl acetate (100 ml) and water (100 ml). The two layers were separated and the aqueous layer was extracted with ethyl acetate (150 ml) and dichloromethane (70 ml). The organic extracts were combined and washed with 10% aqueous citric acid (100 ml), saturated aqueous bicarbonate (100 ml) and dilute brine (100 ml), dried (Na2SO4) and concentrated in vacuo to a gummy residue. Purification by column chromatography, on elution with ethyl acetate (-200 ml) and then 2% methanol in chloroform afforded a pale yellow solid. This was rechromatographed using a gradient of methanol in ethyl acetate (0 to 4%) as eluant. The product, a white solid, was reprecipiated from dichloromethane (-5 ml)/hexanes. There was thus obtained di-tert-butyl N-{N-{r [N-((6RS)-2-methyl-4- oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N.-(prop-2-ynyl)amino]- benzoyl}-L-γ-glutamyl}-D-alaninate as a white solid (0.195 g, 71%), m.p. 145-148°C (softens); NMR Spectrum: (CD3SOCD3) 1.20 (d, J = 7.3 Hz, 3H, ala-CH3), 1.38, 1.41 (2 x s, 18H, 2 x C(CH3)3), 1.80-2.28 (m, 6H, glu β-CH2, glu γ-CH2 and cyclopenta[g]quinazoline 7-CH2), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2-97 » 3.13 (2 x m, 3H, cyclopenta[g]quinazoline 8-CH2 and C--CH), 3.95 (ABq, J = 19.3 Hz, 2H, CH2C--C), 4.09 (m(obscured), IH, ala α-CH), 4.26 (m, IH, glu α-CH), 5.75 (t, J = 8.1 Hz, IH, cyclopenta[g]quinazoline 6-CH), 7.01 (d, J = 8.9 Hz, 2H, 3*,5*-ArH), 7.48 (s, IH, cycloρenta[g]quinazoline 9-H), 7.79 (d, J = 8.4 Hz, 3H, 2',6'-ArH and cyclopenta[g]quinazoline 5-H), 8.21 (d,* J = 7.0 Hz, IH, ala NH), 8.35 (d, J = 7.3 Hz, IH, glu NH), 12.10 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 708 [(M+Na)+].
Elemental Analysis: Found C, 65.76; H, 6.99; N, 9.80; C38H47N507 0.5 H20 requires C, 65.69; H, 6.96; N, 10.07%.
(2) N- {N- {r)-[H-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-γ-glutamyl}- D-alanine
A solution of di-tert-butyl N-{M-{ [N-((6RS)-2-methyl-4-oxo-3 ,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-γ- glutamyl}-D-alaninate (0.138 g, 0.2 mmol), in trifluoroacetic acid (7 ml) was stirred at room temperature for 1.25 hours with protection from the light. The trifluoroacetic acid was then removed in vacuo to give a yellowish residue which triturated with ether. The precipitated white solid was collected by filtration, washed with ether, dried in vacuo over phosphorous pentoxide and then suspended in water (6.5 ml). To this suspension IN aqueous sodium hydroxide (1 ml) was added to give a clear solution which was stirred at room temperature for 10 minutes and then acidified to pH -4 with IN hydrochloric acid. The precipitated white solid was collected by filtration, washed with water (-5 ml) and dried in vacuo over phosphorous pentoxide. There was thus obtained -{N-{β-[N-((6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin- 6-yl)-N-(prop-2-ynyl)amino]benzoyl}-L-γ-glutamyl}-D-alanine (0.083 g, 73%) as a white solid, m.p. 185°C (dec); NMR Spectrum: (CD3SOCD3) 1.23 (d, J = 7.3 Hz, 3H, ala-CH3), 1.83-2.28 (m, 6H, glu β-CH2, glu γ-CH2 and cyclopenta[g]quinazoline 7-CH2), 2.33 (s, 3H, cyclopenta[g]quinazoline 2-CH3), 2.97, 3.15 (2 x m, 3H, cyclopenta[g]quinazoline 8-CH2 and C--CH), 3.96 (ABq, J = 19.0 Hz, 2H, CH2C=C), 4.18 (m(obscured), IH, ala α-CH), 4.35 (m, IH, glu α-CH), 5.76 (t, J = 8.1 Hz, IH, cyclopenta[g]quinazoline 6-CH), 7.02 (d, J = 8.9 Hz, 2H, 3',5'-ArH), 7.49 (s, IH, cyclopenta[g]quinazoline 9-H), 7.81 (d, J = 8.5 Hz, 3H, 2',6'-ArH and cyclopenta[g]quinazoline 5-H), 8.17 (d, J = 7.0 Hz, IH, ala NH), 8.33 (d, J = 7.4 Hz, IH, glu NH), 12.10 (s, IH, cyclopenta[g]quinazoline N3-H). Mass Spectrum: (FAB) m/e 574 [(M+H)+].
Elemental Analysis: Found C, 59.93; H, 5.72; N, 11.68; C3oH31N5O7 1.5 H2O requires C, 59.99; H, 5.71; N, 11.66%.
Example 20 : Formulation The following illustrate representative pharmaceutical dosage forms containing a cyclopentaquinazoline of formula (I), particularly in pharmaceutically acceptable salt form, for therapeutic or prophylactic use in humans:-
(a) Tablet I mg/tablet
Cyclopentaquinazoline salt 100 Lactose Ph.Eur 182.75
Croscarmellose sodium 12.0
Maize starch paste (5% w/v paste) 2.25
Magnesium stearate 3.0 (b) Tablet II me/tablet Cyclopentaquinazoline salt 50 Lactose Ph.Eur 223.75 Croscarmellose sodium 6.0 Maize starch 15.0
Polyvinylpyrrolidone (5% w/v paste) 2.25
Magnesium stearate 3.0
(c) Tablet III mg/tablet Cyclopentaquinazoline salt 1.0 Lactose Ph.Eur 93.25
Croscarmellose sodium 4.0
Maize starch paste (5% w/v paste) 0.75
Magnesium stearate 1.0
(d) Capsule mg/capsule
Cyclopentaquinazoline salt 10.0
Lactose Ph.Eur 488.5
Magnesium stearate 1.5
(e) Injection I (50 me/mll
Cyclopentaquinazoline salt 5.0% w/v
1M Sodium hydroxide solution 15.0% v/v
0.1M Hydrochloric acid (to adjust pH to 7.6)
Polyethylene glycol 400 4.5% w/v
Water for injection to 100% (f) Injection II flO mg/mH Cyclopentaquinazoline salt 1.0% w/v Sodium phosphate BP 3.6% w/v 0.1M Sodium hydroxide solution 15.0% v/v Water for injection to 100%
(g) Injection m π mg/ml. buffered to pH 6) Cyclopentaquinazoline salt 0.1% w/v Sodium phosphate BP 2.26% w/v Citric acid 0.38% w/v Polyethylene glycol 400 3.5% w/v Water for injection to 100%
The above formulations may be prepared by conventional procedures well known in the pharmaceutical art. The tablets (a) to (c) may be enteric coated by conventional means, for example with a coating of cellulose acetate phthalate.

Claims

CLAIMS 1. A cyclopentaquinazoline of the formula (I):
Ar1- CONHCH(C02H) — R3
Figure imgf000101_0001
(I) wherein R* is hydrogen, amino, Cι _4 alkyl, C\_A alkoxy, Cj_4 hydroxyalkyl or C2_4 fluoroalkyl; wherein R2 is hydrogen, C\_4 alkyl, C3.4 alkenyl, C3_4 alkynyl, C2_4 hydroxyalkyl,
C2_4 halogenoalkyl or C 1.4 cyanoalkyl;
Ar^ is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear one or two substituents selected from halogeno, hydroxy, amino, nitro, cyano, trifluoromethyl, Cj.4 alkyl and C1.4 alkoxy; and wherein R3 is a group of the formula:-
-A!-Ar2-A2-Y! in which A* is a bond between the α-carbon atom of the group -CONHCH(C02H)- and
Ar2 or is a Cι _2 alkylene group; Ar2 is phenylene, tetrazoldiyl, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, C\ .4 alkyl and C\ .4 alkoxy;
A2 is a Cj_3 alkylene or C2_3 alkenylene group; and γ is carboxy, tetrazol-5-yl, N-(Cj_4 alkylsulphonyl)carbamoyl, N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, Cj.4 alkyl and
Cj_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or Y* is a group of the formula:-
-CON(R)CH(Y2)Y3 in which R is hydrogen, Cj_4 alkyl, C3.4 alkenyl or C3.4 alkynyl;
Y2 is carboxy, tetrazol-5-yl, N-(Cj_4 alkylsulphonyl)carbamoyl, N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, Cj^ alkyl and
Cj_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; and
Y3 is the residue of a naturally occurring amino acid NH CH(CO H)Y3; or
Y3 is a group of the formula:- -A4-CO2H in which A4 is a C2_g alkylene group other than ethylene; wherein R3 is a group of the formula:-
-A5-CON(R)CH(Y4)Y5 in which A^ is a Cj.g alkylene group and R is as defined above; Y4 is carboxy, tetrazol-5-yl, N-(Cι .4 alkylsulphonyl)carbamoyl,
N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, Cj_4 alkyl and
C]_4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; and γ is the residue of a naturally occurring amino acid NH2CH(CO2H)Y^ provided that when R is hydrogen and Y4 is carboxy it is not the residue of glutamic acid; or
Y^ is a group of the formula:-
-A4-CO2H in which A4 is as defined above; or γ is a group of the formula:- -A6-Ar3-A7-Y6 in which A^ is a bond between the α-carbon atom of the group -A*-CON(R)CH(Y4)- and Ar3 or is a Cι _2 alkylene group;
Ar3 is phenylene, tetrazoldiyl, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which in the case of phenylene may optionally bear one or two substituents on the ring selected from halogeno, nitro, Cj_4 alkyl and Cj_4 alkoxy; A7 is a Cj_3 alkylene or C2.3 alkenylene group; and Y° is carboxy, tetrazol-5-yl, N-(C].4 alkylsulphonyl)carbamoyl, N-(phenylsulphonyl)carbamoyl which may optionally bear one or two substituents on the phenyl ring selected from the group consisting of halogeno, nitro, C _ alkyl and C j .4 alkoxy, tetrazol-5-ylthio, tetrazol-5-ylsulphinyl or tetrazol-5-ylsulphonyl; or wherein R3 is a group of the formula:-
-A8-X-Ar4 in which A° is a C1.4 alkylene group; X is sulphinyl, sulphonyl or methylene; and Ar4 is 1 ,2,3-triazol-4-yl, 1 ,2,4-triazol-3-yl or, except when X is methylene, tetrazol-5-yl; the compound (I) optionally being in the form of a pharmaceutically acceptable salt or ester.
2. A cyclopentaquinazoline according to Claim 1, wherein R3 is a group of the formula -A ' -Ar -A2-Y* in which A ' is a bond or is methylene or ethylene, Ar2 is phenylene, thiophenediyl or tetrazoldiyl, A2 is methylene, ethylene or trimethylene and Y* is carboxy or tetrazol-5-yl.
3. A cyclopentaquinazoline according to Claim 1, wherein R3 is a group of the formula -A5-CON(R)CH(Y4)-A6-Ar3-A7-Y6 in which A5 is methylene or ethylene, R is hydrogen or methyl, Y4 is carboxy or tetrazol-5-yl, A° is a bond or is methylene or ethylene, Ar3 is phenylene, thiophenediyl or tetrazoldiyl, A7 is methylene, ethylene or trimethylene and Y" is carboxy or tetrazol-5-yl.
4. A cyclopentaquinazoline according to any of Claims 1 to 3, wherein R' is hydrogen, amino, hydroxymethyl or methyl; wherein R2 is hydrogen, methyl, ethyl, propyl, prop-2-enyl, prop-2-ynyl, 2-hydroxyethyl, 2-fluoroethyl, 2-bromoethyl or 2-cyanoethyl; and wherein Ar^ is 1 ,4-phenylene which may optionally bear one or two substituents selected from the group consisting of fluoro and chloro or Ar is thiophene-2,5-diyl, thiazole-2,5-diyl or pyridine-2,5-diyl. 5. A cyclopentaquinazoline according to Claim 1, wherein R* is amino, hydroxymethyl or methyl; wherein R2 is methyl, ethyl or prop-2-ynyl; and wherein Ar is 1,4-phenylene, 2-fluoro-l,4-phenylene, 2,6-difluoro-l,4-phenylene or pyridine 2,
5-diyl.
6. A cyclopentaquinazoline according to Claim 1 , wherein R' is methyl; wherein R2 is methyl or prop-2-ynyl; wherein Ar* is l,4-phenylene or 2-fluoro-l,4-phenylene; and wherein R3 is p-carboxymethylphenyl, 2-( 1 -carboxymethyltetrazol-5-yl)ethyl,
2-(2-carboxymethyltetrazol-5-yl)ethyl or 2-(N-[p-carboxymethyl-α-carboxybenzyl]- carbamoyl)ethyl.
7. A cyclopentaquinazoline being: 2-{r2-[N-methyl-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)quinazolin- 6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid,
2-{E-[N-ethyl-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)quinazolin-6-yl)- amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{β;-[N-(prop-2-ynyl)-H-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H.-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{p.-[__I-methyl-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{β-[M-ethyl-N_-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{β-[N-prop-2-ynyl)-N-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l - or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{β-[N-methyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)quinazolin- 6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{p.-[N-ethyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)quinazolin- 6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{E-π__-(prop-2-ynyl)-H-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{2-fluoro-rj-[H-memyl-N-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{_2-fluoro-ri-[N.-ethyl-H-(2-amino-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{2-fl oro-r2-[N-(prop-2-ynyl)-N-(2-amino-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta(g)quinazolin-6-yl)amino]benzamido}-4-(l- or 2- carboxymethyltetrazol-5-yl)butyric acid, 2-{__,-fluoro-rj-[ I-methyl-N-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta(g)quinazolin-6-yl)amino]benzamido } -4-( 1 - or 2-carboxymethyltetrazol-5-yl)butyric acid,
2-{__-fluoro-rj-[N-ethyl-H-(2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro- 6H-cyclopenta(g)quinazolin-6-yl)amino]benzamido } -4-( 1 - or 2-carboxymethyltetrazol-5-yl)butyric acid,
2-{o-fluoro-g-[N-(prop-2-ynyl)-N-(2-hydroxymethyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta(g)quinazolin-6-yI)amino]benzamido } -4-( 1 - or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{__-fluoro-ri-[N-methyl-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{o-fluoro-r2-[N-ethyl-N_-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta(g)- quinazolin-6-yl)amino]benzamido}-4-(l- or 2-carboxymethyltetrazol-5-yl)butyric acid, 2-{Q-fluoro-r2-[N-(prop-2-ynyl)-N-(2-methyl-4-oxo-3,4,7,8-tetrahydro-6H- cyclopenta(g)quinazolin-6-yl)amino]benzamido } -4-( 1 - or 2-carboxymethyltetrazol-5-yl)butyric acid; or a pharmaceutically acceptable salt or ester thereof.
8. A cyclopentaquinazoline according to any of the preceding claims for use in therapy.
9. A process for the manufacture of a cyclopentaquinazoline of the formula (I) according to Claim 1 which comprises:
(a) the reaction of an acid of the formula (II):-
Figure imgf000106_0001
(II) or a reactive derivative thereof with the terminal amino group of a compound of the formula:-
NH2CH(CO2H)-R3 wherein R , R2, R3 and Ar' have the meanings stated in Claim 1 and any amino group in R3 and Ar is protected by a conventional protecting group, any amino group in R' , any hydroxy group in R\ R2, R3 and Ar^ and the carboxy group or groups in NH2CH(CO2H)-R3 may be protected by a conventional protecting group or alternatively such an amino, hydroxy or carboxy group need not be protected; and wherein R4 is hydrogen or a protecting group; (b) the reaction of a compound of the formula (III):-
Figure imgf000106_0002
(III) or the reductive amination of a compound of the formula (IIIA):-
Figure imgf000107_0001
Figure imgf000107_0002
with a compound of the formula:-
NH(R2)-Ar! -CONHCH(CO2H)-R3 wherein R' , R2, R3, R4 and Ar nave me meanings stated under (a) above and any amino group in R3 and Ar* is protected by a conventional protecting group, the carboxy group or groups in NH(R2)-Ar -CONHCH(CO2H)-R3 are protected by a conventional protecting group and any amino group in R' and any hydroxy group in R' , R2, R3 and Arl may be protected by a conventional protecting group or alternatively such an amino or hydroxy group need not be protected; and wherein Z is a displaceable group; (c) the alkylation of an amine of the formula (IV):-
— Ar1— C0NHCH(C02H) — R3
Figure imgf000107_0003
(IV) with an alkylating agent of the formula:
R2-Z wherein R , R2, R3, R4 and Ar^ have the meanings stated under (a) above and any amino group in Ri, R3 and Ar* is protected by a conventional protecting group; and wherein Z is a displaceable group; or (d) when the cyclopentaquinazoline has a group R2 whose attachment to the nitrogen atom to which it is bonded is through a methylene group, the reductive amination with an amine of the formula (IV) as described under (c) above of a compound of the formula:- R8-CHO wherein R8 is a group such that R8-CH2 corresponds to R2; and thereafter, where appropriate, in any of (a) to (d), any undesired protecting group, including any protecting group R4, is removed by conventional means and/or in any of (a) to (d) the compound of formula (I) is converted to a pharmaceutcially acceptable salt or ester form thereof.
10. A cyclopentaquinazoline of the formula (IIIA):-
Figure imgf000108_0001
(IIIA) wherein R is hydrogen, amino, Cj.4 alkyl, Cι _4 alkoxy, C1.4 hydroxyalkyl or C2_4 fluoroalkyl; and wherein R4 is hydrogen or a protecting group.
11. A cyclopentaquinazoline according to Claim 10, wherein R* is hydrogen, amino, hydroxymethyl or methyl.
12. A cyclopentaquinazoline according to Claim 10 or 11, wherein R4 is a pivaloyloxymethyl group.
13. A pharmaceutical composition comprising a cyclopentaquinazoline according to any of Claims 1 to 7 together with a pharmaceutically acceptable diluent or carrier.
14. The use of a cyclopentaquinazoline according to any of Claims 1 to 7 for the manufacture of a medicament for use in the treatment of cancer, an allergic disease or an inflammatory disease.
15. A method for aiding regression and palliation of cancer in a patient in need of such treatment which comprises administering to said patient an effective amount of a cyclopentaquinazoline according to any of Claims 1 to 7.
PCT/GB1995/001016 1994-05-05 1995-05-04 Anti-cancer compounds containing cyclopentaquinazoline ring WO1995030673A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US08/732,273 US5747499A (en) 1994-05-05 1995-05-04 Anti-cancer compounds
CA002187449A CA2187449C (en) 1994-05-05 1995-05-04 Anti-cancer compounds containing cyclopentaquinazoline ring
JP52877095A JP4173911B2 (en) 1994-05-05 1995-05-04 Anticancer compounds containing a cyclopentaquinazoline ring
DK95917433T DK0758328T3 (en) 1994-05-05 1995-05-04 Anticancer compounds containing cyclopentaquinazoline ring
DE69531296T DE69531296T2 (en) 1994-05-05 1995-05-04 ANTI-TUMOR COMPOUNDS CONTAINING A CYCLOPENTAQUINAZOLINE CYCLE
EP95917433A EP0758328B1 (en) 1994-05-05 1995-05-04 Anti-cancer compounds containing cyclopentaquinazoline ring
AT95917433T ATE245154T1 (en) 1994-05-05 1995-05-04 ANTI-TUMOR COMPOUNDS CONTAINING A CYCLOPENTAQUINAZOLINE CYCLE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408936A GB9408936D0 (en) 1994-05-05 1994-05-05 Anti-cancer compounds
GB9408936.4 1994-05-05

Publications (1)

Publication Number Publication Date
WO1995030673A1 true WO1995030673A1 (en) 1995-11-16

Family

ID=10754612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001016 WO1995030673A1 (en) 1994-05-05 1995-05-04 Anti-cancer compounds containing cyclopentaquinazoline ring

Country Status (11)

Country Link
US (1) US5747499A (en)
EP (1) EP0758328B1 (en)
JP (1) JP4173911B2 (en)
AT (1) ATE245154T1 (en)
CA (1) CA2187449C (en)
DE (1) DE69531296T2 (en)
DK (1) DK0758328T3 (en)
ES (1) ES2203639T3 (en)
GB (2) GB9408936D0 (en)
PT (1) PT758328E (en)
WO (1) WO1995030673A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053534A1 (en) * 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2003020300A1 (en) 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
WO2003020748A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Anti-cancer cyclopenta[g]quinazoline compounds
WO2003020706A1 (en) * 2001-08-31 2003-03-13 Btg International Limited PROCESS FOR THE PREPARATION OF CYCLOPENTA[g]QUINAZOLINE DERIVATIVES
US7271280B2 (en) 2002-03-05 2007-09-18 Sumitomo Chemical Company, Limited Process for preparing a biaryl compound
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US8809526B2 (en) 2010-07-19 2014-08-19 Onyx Pharmaceuticals, Inc. Synthesis of cyclopentaquinazolines

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5599773B2 (en) * 2008-03-18 2014-10-01 ビーティージー・インターナショナル・リミテッド Cyclopenta [G] quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukemia
CA2819510A1 (en) * 2010-12-22 2012-06-28 Onyx Pharmaceuticals, Inc. Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta(g)quinazoline trisodium salt
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
MX2020002010A (en) 2017-08-21 2020-07-13 Celgene Corp Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopent anoate.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562734A1 (en) * 1992-03-11 1993-09-29 Zeneca Limited Anti-tumour compounds containing quinazoline and tetrazole rings
GB2272217A (en) * 1992-11-06 1994-05-11 Zeneca Ltd Anti-cancer cyclopentaquinazolines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925939A (en) * 1989-01-05 1990-05-15 Sloan-Kettering Institute For Cancer Research 6,7-dihydropyrrol[3,4-c]pyrido[2,3-d]pyrimidine derivatives
CA2021042A1 (en) * 1989-07-21 1991-01-22 Fabrizio Marazza Salts of n ,n -methylene-5,6,7,8-tetrahydrofolic acid
US5077404A (en) * 1989-08-29 1991-12-31 Piper James R Cyclized 5,10-dideazaaminopterin compounds
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
FR2659330B1 (en) * 1990-03-09 1994-02-11 Sapec Sa DIASTEREOISOMERIC COMPOUNDS DERIVED FROM TETRAHYDROFOLIC ACID, PROCESS FOR THEIR PREPARATION AND USE IN THE SYNTHESIS OF 6S AND 6R DIASTEREOMERS OF REDUCED FOLATES.
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
ZA917355B (en) * 1990-09-17 1992-08-26 Agouron Pharma Antiproliferative substituted naphthalene compounds
YU155791A (en) * 1990-09-25 1994-01-20 Agouron Pharmaceuticals Inc. ANTIPROLIFERATIVE SUBSTITUTED TRICYCLIC COMPOUNDS
GB9105771D0 (en) * 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
AU4632893A (en) * 1992-07-29 1994-03-03 Agouron Pharmaceuticals, Inc. Antiproliferative tricyclic compounds
GB9220571D0 (en) * 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
GB9320113D0 (en) * 1993-09-29 1993-11-17 Zeneca Ltd Tricyclic derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562734A1 (en) * 1992-03-11 1993-09-29 Zeneca Limited Anti-tumour compounds containing quinazoline and tetrazole rings
GB2272217A (en) * 1992-11-06 1994-05-11 Zeneca Ltd Anti-cancer cyclopentaquinazolines

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2002053534A1 (en) * 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
CN100471838C (en) * 2000-12-28 2009-03-25 第一制药株式会社 VLA-4 inhibitors
US7863284B2 (en) 2001-08-31 2011-01-04 Btg International Limited Anti-cancer cyclopenta[G]quinazoline compounds
US8486955B2 (en) 2001-08-31 2013-07-16 Btg International Limited Anti-cancer cyclopenta [g] quinazoline compounds
US7250511B2 (en) 2001-08-31 2007-07-31 Btg International Limited Process for the preparation of cyclopenta[g]quinazoline derivatives
US8552016B2 (en) 2001-08-31 2013-10-08 Btg International Limited Anti-cancer cyclopenta(g)quinazoline compounds
US7297701B2 (en) 2001-08-31 2007-11-20 Btg International Limited Anti-cancer cyclopenta [G]quinazoline compounds
AU2002321576B2 (en) * 2001-08-31 2008-09-11 Btg International Limited Anti-cancer cyclopenta[G]quinazoline compounds
WO2003020748A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Anti-cancer cyclopenta[g]quinazoline compounds
EP2332962A1 (en) 2001-08-31 2011-06-15 BTG International Limited Cyclopenta[g]quinazoline compounds for use in the treatment of inflammatory or allergic conditions
US7705006B2 (en) 2001-08-31 2010-04-27 Btg International Limited Anti-cancer cyclopenta[g]quinazoline compounds
WO2003020706A1 (en) * 2001-08-31 2003-03-13 Btg International Limited PROCESS FOR THE PREPARATION OF CYCLOPENTA[g]QUINAZOLINE DERIVATIVES
EP2213664A1 (en) 2001-08-31 2010-08-04 BTG International Limited Process for the preparation of cyclopenta[g]quinazoline derivatives
KR100983962B1 (en) * 2001-08-31 2010-09-27 비티지 인터내셔널 리미티드 Anti-cancer cyclopenta[g]quinazoline compounds
WO2003020300A1 (en) 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
US8063056B2 (en) 2001-08-31 2011-11-22 Btg International Limited Anti-cancer cyclopenta [g]quinazonline compounds
EP2311850A1 (en) 2001-08-31 2011-04-20 BTG International Limited Anti-cancer cyclopenta[g]quinazoline compounds
US7714157B2 (en) 2002-03-05 2010-05-11 Sumitomo Chemical Company, Limited Process for preparing a biaryl compound
US7271280B2 (en) 2002-03-05 2007-09-18 Sumitomo Chemical Company, Limited Process for preparing a biaryl compound
US7893279B2 (en) 2003-07-24 2011-02-22 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US8809526B2 (en) 2010-07-19 2014-08-19 Onyx Pharmaceuticals, Inc. Synthesis of cyclopentaquinazolines

Also Published As

Publication number Publication date
US5747499A (en) 1998-05-05
JP4173911B2 (en) 2008-10-29
CA2187449A1 (en) 1995-11-16
GB9509261D0 (en) 1995-06-28
GB9408936D0 (en) 1994-06-22
DK0758328T3 (en) 2003-11-03
JPH09512812A (en) 1997-12-22
EP0758328A1 (en) 1997-02-19
CA2187449C (en) 2006-01-03
DE69531296D1 (en) 2003-08-21
GB2290082B (en) 1997-10-29
DE69531296T2 (en) 2004-04-22
PT758328E (en) 2003-11-28
EP0758328B1 (en) 2003-07-16
ATE245154T1 (en) 2003-08-15
GB2290082A (en) 1995-12-13
ES2203639T3 (en) 2004-04-16

Similar Documents

Publication Publication Date Title
CA1285943C (en) Anti-tumour agents
DE69322605T2 (en) Imidazo (1,2-a) pyridines as bradykinin antagonists
KR100221011B1 (en) Anti-tumor compounds, method for their preparation and pharmaceutical composition containing the same
US5932567A (en) Thrombin inhibitors
US5444061A (en) Anti-cancer compounds
US5561133A (en) Thymidylate synthase inhibiting quinazolinones
NZ260736A (en) Fused n-bicyclic ring containing compounds, preparation and pharmaceutical compositions thereof
CZ20031715A3 (en) Novel N-(phenylsulfonyl)glycine derivatives and their therapeutic use
US5747499A (en) Anti-cancer compounds
EP0228845B1 (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
US5789417A (en) Tricyclic compounds with pharmaceutical activity
EP0281316A2 (en) Renin inhibitors
WO1995009158A1 (en) Tricyclic derivatives
GB2272217A (en) Anti-cancer cyclopentaquinazolines
DD298410A5 (en) RENININHIBITIC PEPTIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995917433

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2187449

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08732273

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995917433

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995917433

Country of ref document: EP